To,
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Fort,
Mumbai 400 001.

Date: 08.09.2026

Dear Sir/ Madam,

Sub: Submission of 32nd AGM notice which is dispatched to shareholders of the Company-reg.

Unit: Sangam Health Care Products Limited (BSE Scrip Code: 531625)

In terms of Regulations of SEBI (Listing obligations and Disclosure Requirements) Regulations, 2015 as amended we are forwarding the notice of 32nd Annual General Meeting of the Company, which is being dispatched to our Shareholders on 08th September, 2026. The 32nd Annual General Meeting of the company is scheduled to be held on Wednesday, the 30th Day of September 2026 at 09.00 A.M at registered office.

Please find the enclosed the Notice of the 32nd AGM for the financial year 2025. Same will be made available on the company's website, https://www.sangamhealthcare.co.in.

This is for the information and records of the Exchange, please.

Yours faithfully,
For Sangam Health Care Products Limited

SANGAM HEALTH CARE PRODUCTS LTD. Hyderabad

DUNDUMULLA BHAGATREDDY
Digitally signed by DUNDUMULLA BHAGATREDDY
Date: 2026.09.08 18:15:51 +05'30'

Bhagt Reddy Dundumulla
Managing Director
DIN: (07087331)

SANGAM HEALTH CARE PRODUCTS LIMITED

32nd ANNUAL REPORT

2025-26

Corporate Information

Board of Directors:

Mr. D. Bhagat Reddy	-	Managing Director (DIN: 07087331)
Mrs. Padma Ghanakota	-	Non-Executive Director (DIN: 07078176)
Mr. A. Sai Balaji Krishna Teja	-	Non-Executive Director (DIN: 07003946)
Mr. Rajesh Kakkera	-	Independent Director (DIN: 07931218)
Mr. M. Madhavarao	-	Independent Director (DIN: 07931672)
Mr. Addagarla Tarun	-	Independent Director (DIN: 07003887)

Chief financial officer: Mrs. S Vijayagowri Satyabhavani

Chief executive officer: Mr. A. Bala Gopal

Company Secretary & Compliance Officer: T. Abhilash

Registered Office:

Survey No.182, Yellampet Village,
Medchal Mandal, Medchal District, Telangana-501401

Factory- I:
Survey No.182, Yellampet Village,
Medchal Mandal, Medchal District, Telangana-501401

Factory -II:
Survey No.189/A, Durshed Village,
Karimanagar District-505001

Statutory auditors:

M/s M.M. Reddy & Co.,
Chartered Accountants,
Hyderabad.

Secretarial Auditor:
M/s. Chakravarthy & Associates,
Practicing Company Secretary,
Hyderabad

Bankers:

State Bank of Hyderabad

Audit committee:

Mr. Rajesh Kakkera	-	Chairman
Mr. M. Madhavarao	-	Member
Mr. Addagarla Tarun	-	Member

Nomination & Remuneration Committee:

Mr. Rajesh Kakkera	-	Chairman
Mr. M. Madhavarao	-	Member
Mr. Addagarla Tarun	-	Member

Stakeholders Relationship Committee:

Mr. Rajesh Kakkera	-	Chairman
Mr. M. Madhavarao	-	Member
Mr. Addagarla Tarun	-	Member

Registrar & Share Transfer Agents:
M/s. XL Softech Systems Limited
3, Sagar Society, Road No.2,
Banjara Hills, Hyderabad
Phone # 040-23545913/14/15
Email: xlfield@gmail.com

Listed at: BSE Limited

ISIN: INE431E01011

website: www.sangamhealthcare.co.in

Investor E-Mail Id: cssangamltd2024@gmail.com

Corporate Identity Number: L24230TG1993PLC016731

NOTICE

Notice is hereby given that the 32nd Annual General Meeting of the Members of Sangam Health Care Products Limited will be held on Wednesday, the 30th day of September, 2026 at 9.00 a.m. at Survey No.182, Yellampet Village, Medchal Mandal, Medchal District, Telangana - 501401, to transact the following business:

Ordinary Business:

1. To receive, consider and adopt the Audited Balance Sheet as at 31st March 2026, the Statement of Profit & Loss and Cash Flow Statement for the year ended on that date together with the Notes attached thereto, along with the Reports of Auditors and Directors thereon.

2. To appoint a director in place of Mr. A. Sai Balaji Krishna Teja (DIN: 07003946), Non-Executive Director who retires by rotation and, being eligible, offers himself for re-appointment."

Special Business:

3. **Continuation of Directorship of Mrs. Padma Ghanakota (DIN: 07078176) as a Non-Executive and Non-Independent Director of the Company.**

To consider and, if thought fit, to pass with or without modification(s), the following Resolution as an **Ordinary Resolution**:

"**RESOLVED THAT** pursuant to the provisions of Section 152 and other applicable provisions, if any, of the Companies Act, 2013, read with Regulation 17(1D) and other applicable provisions of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and in accordance with the recommendation of the Nomination and Remuneration Committee and the approval of the Board of Directors of the Company, consent of the Members of the Company be and is hereby accorded for the continuation of directorship of Mrs. Padma Ghanakota (DIN: 07078176) as a Non-Executive and Non-Independent Director of the Company, on the existing terms and conditions of her appointment, notwithstanding the provisions relating to retirement by rotation, to the extent applicable.

RESOLVED FURTHER THAT the Board of Directors ('the Board'), which term shall be deemed to mean and include any Committee constituted by the Board be and is hereby authorised to take such steps as may be necessary, proper and expedient to give effect to this Resolution."

4. Re appointment of Mr. Bhagat Reddy Dundumulla as Managing Director of the Company:

To consider and, if thought fit, to pass with or without modification(s), the following Resolution as a **Special Resolution**:

“**RESOLVED THAT** pursuant to the provisions of Sections 178, 196, 197 and 203 read with Schedule V and other applicable provisions, if any, of the Companies Act, 2013 and the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014 and Regulation 17 of SEBI (LODR) Regulations, 2015 (including any statutory modification(s) or re-enactment thereof for the time being in force), and Articles of Association of the Company), the consent of the members of the company be and is hereby accorded for the re-appointment of Mr. Bhagat Reddy Dundumulla (DIN: 07087331) as Managing Director of the Company for a period of five (5) years with effect from 7 September 2026, whose present term of office expires on 6 September 2026 at a remuneration as may be decided by the Board from time to time and the Board of Directors be and is hereby authorized to vary or increase the remuneration, perquisites, and allowances etc., within such prescribed limits in terms of Schedule V of the Companies Act, 2013, as amended from time to time.”

“**RESOLVED FURTHER THAT**, in the event of losses or inadequacy of profits in any financial year during his tenure the Company shall pay to Mr. Bhagat Reddy Dundumulla, remuneration by way of salaries and allowances as specified above as minimum remuneration and in accordance with the limits specified under the Companies Act, 2013 read with Schedule V to the Companies Act 2013, or such other limit as may be prescribed by the Government from time to time.”

“RESOLVED FURTHER THAT the Board be and is hereby authorized to approve the terms and conditions including any changes in remuneration and to do all such acts, deeds, matters and things as may be considered necessary, appropriate and desirable to give effect to the resolution.”

For and on behalf of the Board of Directors
Sangam Health Care Products Limited

Sd/-
D. Bhagat Reddy
Managing Director
DIN: 07087331

Place: Secunderabad
Date: 13.08.2026

Notes:

1. **A MEMBER ENTITLED TO ATTEND AND VOTE IS ENTITLED TO APPOINT A PROXY TO ATTEND AND VOTE INSTEAD OF HIMSELF/HERSELF AND A PROXY NEED NOT BE A MEMBER OF THE COMPANY.** The instrument of Proxy in order to be effective shall be deposited at the Corporate Office of the Company by not less than 48 hours before the commencement of the Meeting.

   Pursuant to the provisions of Section 105 of the Companies Act, 2013, a person can act as a proxy on behalf of not more than fifty (50) members and holding in aggregate not more than 10% of the total share capital of the Company carrying voting rights. A member holding more than 10% of the total share capital of the Company carrying voting rights may appoint a single person as proxy, who shall not act as a proxy for any other person or shareholder. The appointment of proxy shall be in the Form No. MGT.11 annexed herewith.

2. Members holding shares in the electronic form are requested to inform any changes in address/ bank mandate directly to their respective Depository Participants.

3. Pursuant to Section 91 of the Companies Act, 2013, the Register of Members and Share Transfer Books of the Company will remain closed from 24.09.2026 to 30.09.2026 (Both days inclusive).

4. Members are requested to hand over the enclosed Attendance Slip, duly signed in accordance with their specimen signature(s) registered with the Company for admission to the meeting hall. Members who hold shares in dematerialized form are requested to bring their Client ID and DP ID Numbers for identification.

5. Corporate Members are requested to send to the Company's Registrar & Transfer Agent; a duly certified copy of the Board Resolution authorizing their representative to attend and vote at the Annual General Meeting.

6. In case of joint holders attending the Meeting, only such joint holders who are higher in the order of names will be entitled to vote.

7. The Securities and Exchange Board of India has mandated submission of Permanent Account Number (PAN) by every participant in securities market. Members holding shares in demat form are, therefore, requested to submit PAN details to the Depository Participants with whom they have demat accounts. Members holding shares in physical form can submit their PAN details to the Company/Registrar and Share Transfer Agents (M/s. XL Softech Systems Limited)

8. Members are requested to send their queries at least 10 days before the date of meeting so that information can be made available at the meeting.

9. As a measure of austerity, copies of the annual report will not be distributed at the Annual General Meeting. Members are therefore, requested to bring their copies of the Annual Report to the Meeting.

10. With a view to using natural resources responsibly, we request shareholders to update their email address with their Depository Participants to enable the Company to send communications electronically.

11. Members holding shares in the same name under different ledger folios are requested to apply for consolidation of such folios and send the relevant share certificates to M/s. XL Softech Systems Limited Share Transfer Agents of the Company for their doing the needful.

12. In respect of shares held in physical mode, all shareholders are requested to intimate changes, if any, in their registered address immediately to the registrar and share transfer agent of the company and correspond with them directly regarding share transfer/transmission/ transposition, Demat /Remat, change of address, issue of duplicate shares certificates, ECS and nomination facility.

13. In terms of Section 72 of the Companies Act, 2013, a member of the company may nominate a person on whom the shares held by him/her shall vest in the event of his/her death. Members desirous of availing this facility may submit nomination in prescribed Form SH-13 to the company/ RTA in case shares are held in physical form, and to their respective depository participant, if held in electronic form.

14. The Register of Directors and Key Managerial Personnel and their Shareholding maintained under Section 170 of the Companies Act, 2013, the Register of Contracts or arrangements in which Directors are interested under Section 189 of Companies Act, 2013 will be available for inspection at the Annual General Meeting.

15. Electronic copy of the Annual Report for 2025-26 is being sent to all the members whose email IDs are registered with the Company/Depository Participants(s) for communication purposes unless any member has requested for a hard copy of the same.

16. Members may also note that the Notice of the 32nd Annual General Meeting and the Annual Report for 2025-26 will also be available on the Company's website for download. The physical copies of the aforesaid documents will also be available at the Company's Registered Office for inspection during normal business hours on working days. Even after registering for e-communication, members are entitled to receive such communication in physical form, upon making a request for the same,

by post free of cost. For any communication, the shareholders may also send requests to the Company's investor email id: sangamlisting@gmail.com.

17. In terms of Regulation 40 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, securities of listed companies can be transferred only in dematerialized form with effect from 1st April, 2019 except in case of requests received for transmission or transposition of securities.

18. **Voting through electronic means:**

    a. In compliance with provisions of Section 108 of the Companies Act, 2013, Rule 20 of the Companies (Management and Administration) Rules, 2014 as amended by the Companies (Management and Administration) Amendment Rules, 2015 and Regulation 44 of SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015, and Secretarial Standard on General Meetings (SS2) issued by the Institute of Company Secretaries of India, the Company is pleased to provide members facility to exercise their right to vote on resolutions proposed to be considered at the Annual General Meeting (AGM) by electronic means and the business may be transacted through e-Voting Services. The facility of casting the votes by the members using an electronic voting system from a place other than venue of the AGM ("remote e- voting") will be provided by Central Depository Services (India) Limited.

    b. The facility for voting through ballot paper shall be made available at the AGM and the members attending the meeting who have not cast their vote by remote e-voting shall be able to exercise their right at the meeting through ballot paper. The members who have cast their vote by remote e-voting prior to the AGM may also attend the AGM but shall not be entitled to cast their vote again.

    c. The remote e-voting period commences on 27th September, 2026 (9:00 AM) to 29th September, 2026 (5:00 PM). During this period shareholders of the Company, holding shares either in physical form or in dematerialized form, as on the cut-off date of 23rd September, 2026, may cast their vote electronically. The e-voting module shall be disabled by CDSL for voting thereafter. Once the vote on a resolution is casted by the shareholder, the shareholder shall not be allowed to change it subsequently.

    d. A person who has acquired shares & become a member of the company after the dispatch of notice of AGM & holding shares as of cut-off date, may obtain the login ID & password by sending a request at sangamlisting@gmail.com. However, if the person is already registered with the CDSL for remote e-voting then the existing user ID & password can be used for casting vote.

e. **<u>Login method for e-Voting and voting during the meeting for Individual Shareholders holding securities in demat mode.</u>**

In terms of the SEBI circular dated December 9, 2020 on the e-Voting facility provided by listed companies and as part of increasing the efficiency of the voting process, e-Voting process has been enabled to all individual Shareholders holding securities in demat mode to vote through their demat account maintained with depositories / websites of depositories / depository participants. Shareholders are advised to update their mobile number and email ID in their demat accounts in order to access e-Voting facility. Login method for Individual Shareholders holding securities in demat mode is given below:

Type of Shareholders	**Login Method**
Individual Shareholders holding securities in Demat mode with **<u>CDSL</u>**	a. Users who have opted for Easi / Easiest facility, can login through their existing user id and password. Option will be made available to reach e-Voting page without any further authentication. The URL for users to login to Easi / Easiest is https://web.cdslindia.com/ myeasi/home/login or www.cdslindia.com and click on Login icon and select New System Myeasi. b. After successful login the Easi / Easiest user will be able to see the e-Voting option for eligible companies where the e-Voting is in progress as per the information provided by company. On clicking the e-Voting option, the user will be able to see e-Voting page of the e-Voting service provider ("ESP") i.e. CDSL, for casting your vote during the remote e-Voting period or joining virtual meeting & voting during the meeting. Additionally, there are also links provided to access the system of all ESP i.e. CDSL/NSDL, so that the user can visit the ESP website directly. c. If the user is not registered for Easi/Easiest, option to register is available at https://web. cdslindia.com/myeasi/ Registration/ EasiRegistration. Alternatively, the user can directly access e-Voting page by providing demat Account Number and PAN No. from a link in www.cdslindia.com home page or click on https://evoting.cdslindia.com/Evoting/ EvotingLogin. The system will authenticate the user by sending OTP on registered Mobile & Email as recorded in the Demat Account. After successful authentication, user will be provided links for the respective ESP i.e. CDSL where the e-Voting is in progress.

Individual Shareholders holding securities in Demat mode with **NSDL**	a. If you are already registered for NSDL IDeAS facility, please visit the e-Services website of NSDL. Open web browser by typing the following URL: https://eservices.nsdl.com. b. Once the home page of e-Services is launched, click on the "Beneficial Owner" icon under "Login" which is available under 'IDeAS' section. A new screen will open. You will have to enter your User ID and Password. After successful authentication, you will be able to see e-Voting services. c. Click on "Access to e-Voting" under e-Voting services and you will be able to see e-Voting page. Click on company name or e-Voting service provider- CDSL and you will be re-directed to the CDSL e-Voting website for casting your vote during the remote e-Voting period or joining virtual meeting & voting during the meeting. d. If the user is not registered for IDeAS e-Services, option to register is available at https://eservices.nsdl.com. Select "Register Online for IDeAS "Portal or click at https://eservices.nsdl.com/SecureWeb/IdeasDirectReg.jsp. e. Visit the e-Voting website of NSDL. Open web browser by typing the following URL: https://www.evoting.nsdl.com/. Once the home page of e-Voting system is launched, click on the icon "Login" which is available under 'Shareholder/Member' section. f. A new screen will open. You will have to enter your User ID (i.e. your 16 digit demat account number held with NSDL), Password/OTP and a Verification Code as shown on the screen. g. After successful authentication, you will be redirected to NSDL Depository site wherein you can see e-Voting page. Click on Company name or e-Voting service provider-CDSL and you will be redirected to e-Voting website of CDSL for casting your vote during the remote e-Voting period or joining virtual meeting & voting during the meeting.
Individual Shareholders	d. You can also login using the login credentials of your Demat account through your Depository Participant registered with

(holding securities in Demat mode) login through their **<u>Depository Participants</u>**	NSDL/CDSL for e-Voting facility. e. After successful login, you will be able to see e-Voting option. Once you click on e-Voting option, you will be redirected to NSDL/CDSL Depository site after successful authentication, wherein you can see e-Voting feature. f. Click on Company name or e-Voting service provider name - CDSL and you will be redirected to e-Voting website of CDSL for casting your vote during the remote e-Voting period or joining virtual meeting & voting during the meeting.

<u>Important note:</u> Members who are unable to retrieve User ID/ Password are advised to use "Forget User ID" and "Forget Password" option available at abovementioned website.

Helpdesk for Individual Shareholders holding securities in demat mode for any technical issues related to login through Depository i.e. CDSL and NSDL

Login type	**Helpdesk details**
Individual Shareholders holding securities in Demat mode with **CDSL**	Members facing any technical issue in login can contact CDSL helpdesk by sending a request at helpdesk.evoting@cdslindia.com or contact at 022-23058738 and 22-23058542-43.
Individual Shareholders holding securities in Demat mode with **NSDL**	Members facing any technical issue in login can contact NSDL helpdesk by sending a request at evoting@nsdl.co.in or call at toll free no.: 1800 1020 990 and 1800 22 44 30

f. Login method for e-Voting and voting during the meeting for Shareholders holding securities in physical mode and Shareholders other than Individual Shareholders holding securities in demat mode.

a) The shareholders should log on to the e-voting website <u>www.evotingindia.com</u>.

b) Click on Shareholders tab/ module.

c) Now Enter your User ID
   - For CDSL: 16 digits beneficiary ID,
   - For NSDL: 8 Character DP ID followed by 8 Digits Client ID,
   - Members holding shares in Physical Form should enter Folio Number registered with the Company.

d) Next enter the Image Verification as displayed and Click on Login.

e) If you are holding shares in demat form and had logged on to www.evotingindia.com and voted on an earlier voting of any company, then your existing password is to be used.

f) If you are a first-time user follow the steps given below:

Login type	**For Shareholders holding securities in physical mode and Shareholders other than Individual Shareholders holding securities in demat mode.**
PAN	Enter your 10-digit alpha-numeric "PAN" issued by Income Tax Department. Shareholders who have not updated their PAN with the Company/Depository Participant are requested to use the sequence number sent by RTA or contact RTA.
Dividend Bank Details **OR** Date of Birth (DOB)	Enter the Dividend Bank Details or Date of Birth (in dd/mm/yyyy format) as recorded in your demat account or in the company records in order to login. If both the details are not recorded with the depository or company please enter the member id / folio number in the Dividend Bank details field as mentioned in instruction (iii).

g) After entering these details appropriately, click on "SUBMIT" tab.

h) Shareholders holding shares in physical mode will then directly reach the Company selection screen. However, Shareholders holding shares in Demat mode will now reach 'Password Creation' menu wherein they are required to mandatorily enter their login password in the new password field. Kindly note that this password is to be also used by the Demat account holders for voting for resolutions of any other Company on which they are eligible to vote, provided that Company opts for e-Voting through CDSL platform. It is strongly recommended not to share your password with any other person and take utmost care to keep your password confidential.

i) For Members holding shares in physical form, the details can be used only for e-voting on the resolutions contained in this Notice.

j) Click on the EVSN for the relevant <Company Name> on which you choose to vote.

k) On the voting page, you will see “RESOLUTION DESCRIPTION” and against the same the option “YES/NO” for voting. Select the option YES or NO as desired. The option YES implies that you assent to the Resolution and option NO implies that you dissent to the Resolution.

l) Click on the “RESOLUTIONS FILE LINK” if you wish to view the entire Resolution details.

m) After selecting the resolution, you have decided to vote on, click on “SUBMIT”. A confirmation box will be displayed. If you wish to confirm your vote, click on “OK”, else to change your vote, click on “CANCEL” and accordingly modify your vote.

n) Once you “CONFIRM” your vote on the resolution, you will not be allowed to modify your vote.

o) You can also take a print of the votes cast by clicking on “Click here to print” option on the Voting page.

p) You can also take a print of the votes cast by clicking on “Click here to print” option on the Voting page.

q) If a Demat account holder has forgotten the login password, then Enter the User ID and the image verification code and click on Forgot password and enter the details as prompted by the system.

r) **Additional Facility for Non – Individual Shareholders and Custodians –For Remote e-Voting only.**

- Non-Individual Shareholders (i.e. other than Individuals, HUF, NRI etc.) and Custodians are required to log on to www.evotingindia.com and register themselves in the “Corporates” module.

- A scanned copy of the Registration Form bearing the stamp and sign of the entity should be emailed to helpdesk.evoting@cdslindia.com.

- After receiving the login details a Compliance User should be created using the admin login and password. The Compliance User would be able to link the account(s) for which they wish to vote on.

- The list of accounts linked in the login should be mailed to helpdesk.evoting@cdslindia.com and on approval of the accounts they would be able to cast their vote.

- A scanned copy of the Board Resolution and Power of Attorney (“POA”) which they have issued in favour of the Custodian, if any, should be uploaded in PDF format in the system for the scrutinizer to verify the same.

- Alternatively, Non-Individual Shareholders are required to send the relevant Board Resolution/ Authority letter etc. together with attested specimen signature of the duly authorized signatory who are authorized to vote, to the Scrutinizer at the email address viz; sangamlisting@gmail.com, if they have voted from individual tab & not uploaded same in the CDSL e-Voting system for the scrutinizer to verify the same.

19. The voting rights of shareholders shall be in proportion to their shares of the paid up equity share capital of the Company as on the cut-off date (record date) of 23rd September, 2026.

20. M/s Chakravarthy & Associates, Practicing Company Secretary, has been appointed as the Scrutinizer to scrutinize the e-voting process.

21. The Results shall be declared on or after the AGM of the Company. The Results declared along with the Scrutinizer's Report shall be placed on the Company's website and on the website of CDSL within two (2) days of passing of the resolutions at the AGM of the Company and communicated to the BSE Limited.

22. The Ministry of Corporate Affairs (vide circular nos. 17/2011 and 18/2011 dated April 21 and April 29, 2011 respectively), has undertaken a 'Green Initiative in Corporate Governance' and allowed companies to share documents with its shareholders through an electronic mode. Members are requested to support this green initiative by registering/uploading their email addresses, in respect of shares held in dematerialized form with their respective Depository Participant and in respect of shares held in physical form with the Company's Registrar and Share Transfer Agents

For and on behalf of the Board of Directors
Sangam Health Care Products Limited

Sd/-

Place: Secunderabad
Date: 14.08.2026

D. Bhagat Reddy
Managing Director
DIN: 07087331

EXPLANATORY STATEMENT
[Pursuant to Section 102 of the Companies Act, 2013]

Item No: 3 Continuation of Directorship of Mrs. Padma Ghanakota (DIN: 07078176) as a Non-Executive and Non-Independent Director of the Company

Pursuant to the Securities and Exchange Board of India ("SEBI") notification dated 14 June 2023, Regulation 17(1D) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("SEBI Listing Regulations"), became applicable with effect from 1 April 2024. Regulation 17(1D) provides that the continuation of a director serving on the board of a listed entity shall be subject to the approval of the shareholders in a general meeting at least once in every five years from the date of appointment or re-appointment, as applicable.

Mrs. Padma Ghanakota (DIN: 07078176) is a Non-Executive and Non-Independent Director of the Company. She was appointed as a director not liable to retire by rotation by the Members of the Company at the Annual General Meeting held on 25 March 2015. Accordingly, her continuation as a director was not subject to approval of the Members by way of retirement by rotation.

In view of the aforesaid provisions of Regulation 17(1D) of the SEBI Listing Regulations, the Company is required to obtain the approval of the Members for the continuation of Mrs. Padma Ghanakota on the Board of the Company.

The Board of Directors, based on the recommendation of the Nomination and Remuneration Committee, has considered and approved the continuation of Mrs. Padma Ghanakota (DIN: 07078176) as a Non-Executive and Non-Independent Director of the Company and recommends the same for approval of the Members.

Accordingly, approval of the Members is sought for the continuation of directorship of Mrs. Padma Ghanakota (DIN: 07078176) as a Non-Executive and Non-Independent Director of the Company for a period of five (5) years with effect from 1 April 2026, on the existing terms and conditions of her appointment.

Mrs. Padma Ghanakota has given her consent to continue to act as a Director of the Company and has confirmed that she is not disqualified from being appointed or continuing as a director under the provisions of the Companies Act, 2013 and the SEBI Listing Regulations.

The Board is of the opinion that the continued association of Mrs. Padma Ghanakota with the Company would be beneficial to the Company, considering her experience, knowledge and contribution to the affairs of the Company.

The Board recommends the passing of the resolution set out at Item No. 3 of the accompanying Notice as an Ordinary Resolution.

Mrs. Padma Ghanakota, to the extent of his shareholding and directorship in the Company, is deemed to be interested in this item of business

Save and except above, no other Director/Key Managerial Personnel and/or their relatives, are directly or indirectly concerned or interested, financially or otherwise, in this item of business except to the extent of shareholding, if any, in the Company.

Item No: 4 Re appointment of Mr. Bhagat Reddy Dundumulla as Managing Director of the Company:

Pursuant to the provisions of Sections 196, 197, 203 and 178 read with Schedule V and other applicable provisions, if any, of the Companies Act, 2013 and the Rules made thereunder, and the applicable provisions of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, including any statutory modification(s) or re-enactment(s) thereof for the time being in force, Mr. Bhagat Reddy Dundumulla was appointed as the Managing Director of the Company with effect from 06 September 2021 at the 27th Annual General Meeting, for a period of 5 (Five) consecutive years, which expires on 05 September 2026.

Pursuant to the recommendation of the Nomination and Remuneration Committee, evaluation of his performance by the Board and approval of the Board of Directors at their respective meetings held on 13 August 2026, and pursuant to the provisions of Sections 196, 197, 203 and 178 read with Schedule V and other applicable provisions, if any, of the Companies Act, 2013, the Companies (Appointment and Qualification of Directors) Rules, 2014 and the applicable provisions of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, including any statutory modification(s) or re-enactment(s) thereof for the time being in force, the consent and approval of the Members of the Company by way of Special Resolution is sought for the re-appointment of Mr. Bhagat Reddy Dundumulla as Managing Director of the Company for a further term of 5 (Five) consecutive years with effect from 06 September 2026.

The information required under Section II of Part II of Schedule V to the Companies Act, 2013 is provided as an Annexure to this Notice. In addition, a brief profile and other disclosures, as required under Regulation 36 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and Secretarial Standard – 2 on General Meetings issued by the Institute of Company Secretaries of India, are also provided as an Annexure to this Notice.

Except Mr. Bhagat Reddy Dundumulla, none of the other Directors, Key Managerial Personnel of the Company or their respective relatives is, in any way, concerned or interested, financially or otherwise, in the proposed resolution.

The Board of Directors recommends the passing of the above resolution as a Special Resolution as set out in Item No. 4 of the Notice.

Information in accordance with Schedule V of Companies Act, 2013

I. General information:

<table>
<tr><td>1</td><td>Nature of Industry: Health care</td></tr>
<tr><td>2</td><td>Date or expected date of commencement of commercial: 13.12.1993</td></tr>
<tr><td>3</td><td>In case of new companies, expected date of commencement of business activities as per project approved by financial institutions appearing in the prospects: Not Applicable</td></tr>
<tr><td>4</td><td>Financial performance based on given indications
<table>
<tr><th>Particulars</th><th>2025-26
(Rs. in lakhs)</th><th>2024-25
(Rs. in lakhs)</th><th>2023-24
(Rs. in lakhs)</th></tr>
<tr><td>Turnover</td><td>1123.33</td><td>1,245.96</td><td>1210.84</td></tr>
<tr><td>Net profit after Tax</td><td>5.33</td><td>44.96</td><td>41.84</td></tr>
</table>
</td></tr>
<tr><td>5</td><td>Foreign investments or collaborations, if any: Not Applicable</td></tr>
</table>

II. Information about the appointee:

1.	**Background Details:** Mr. Bhagat Reddy Dundumulla is already acting as Managing Director of the Company. He has 12 Years of Experience in manufacturing IV sets and other Medical Disposables
2.	**Past Remuneration:** Nil
3.	**Recognition or awards:** Not Applicable
4.	**Job Profile and his suitability:** Keeping in mind the background details, past record and proficiency of Mr. Bhagat Reddy Dundumulla, the Board is of the view that he is the most suitable person for the job
5.	**Remuneration proposed:** At present Mr. D. Bhagat Reddy, Managing Director is not drawing any remuneration keeping in mind the interest of the company. Whenever any remuneration is drawn it should be within the limits

	prescribed in the Companies Act.
6.	**Comparative remuneration profile with respect to industry, size of the Company profile of the position and person (in case of expatriates the relevant details would be w.r.t. the country of his origin):** At present Mr. D. Bhagat Reddy, Managing Director is not drawing any remuneration keeping in mind the interest of the company. Whenever any remuneration is drawn it should be within the limits prescribed in the Companies Act.
7.	**Pecuniary relationship directly or indirectly with the Company, or relationship with the managerial personnel, if any:** Mr. D. Bhagat Reddy holds 2,00,000 Equity shares
8.	**Names of Listed entities in which the person also holds the Directorship and the membership of Committees of the board along with listed entities from which the person has resigned in the past three years:** None

III. Other information:

1.	**Reasons for inadequate profits:** The Company is in the mode of expansion of the business which generally requires spending lot of money upfront leading to minimal profits in the initial years. All this expenditure will result in to revenues over a period of next two to three years.
2.	**Steps taken or proposed to be taken for improvement:** Necessary efforts are being made to increase the clientele who in turn contribute for the growth of the business as well as the profitability. The company is planning to recruit new talent to meet the market demands of new technology solutions.
3.	**Expected increase in productivity and profit in measurable terms:** The Company is committed to build the business operations within budget and considering that the business operates on a going concern basis, it is believed that financial position of the Company will improve further in near future.

Details of Directors seeking appointment at the Extra Ordinary General Meeting [Pursuant to Regulation 36(3) of the SEBI (Listing Obligation and Disclosure Requirement) Regulations, 2015 and Secretarial Standard 2 on General Meetings]

Name of the Director	Mr. Bhagat Reddy Dundumulla	Mrs. Padma Ghanakota
DIN	07087331	07078176
Date of Birth	20.01.1984	17.08.1964
Date of first appointment	06.09.2021	25.03.2015

Board Meetings attended during the year	4	4
Brief Resume, Qualification and Experience	Mr. Bhagat Reddy Dundumulla is already acting as Managing Director of the Company. He has 12 Years of Experience in manufacturing IV sets and other Medical Disposables	She has extensive experience in the manufacturing of IV sets and pouches and has been involved in handling the operations relating to the manufacture of IV sets at the Company's Jeedimetla unit, Hyderabad. She has rich experience in the operational aspects of the Company's manufacturing activities and continues to contribute to the affairs of the Company in her capacity as a Non-Executive, Non-Independent Director.
Expertise in specific functional area	Business development, Administration and operations.	Business development, Administration and operations.
Terms and conditions of appointment	Appointment as Managing Director w.e.f. 07.09.2026 for a period of 5 years	Appointment as a Non-Executive Director w.e.f. 01.04.2026
Remuneration drawn, if any	Not Applicable	Not Applicable

For and on behalf of the Board of Directors
Sangam Health Care Products Limited

Sd/-
D. Bhagat Reddy
Managing Director
DIN: 07087331

Place: Secunderabad
Date: 13.08.2026

DIRECTORS' REPORT

To the Members,
Sangam Health Care Products Limited
Hyderabad, Telangana, India

The Directors have pleasure in presenting before you the 32nd Director's Report of the Company together with the Audited Statements of Accounts for the year ended 31st March, 2026. The Company's performance is summarized below:

1. Financial summary/highlights:

The performance during the period ended 31st March, 2026 has been as under:

(Rs. In Lakhs)

Particulars	**2025-26**	**2024-25**
Turnover/Income (Gross)	1123.33	1245.96
Other Income	2.10	2.11
Profit/loss before Depreciation, Finance Costs, Exceptional items and Tax Expense		148.8
Less: Depreciation/ Amortisation/ Impairment	5.64	121.84
Profit /loss before Finance Costs, Exceptional items and Tax Expense		26.96
Less: Finance Costs	0.91	1.49
Profit /loss before Exceptional items and Tax Expense	20.71	25.47
Add/(less): Exceptional items	0	0
Profit /loss before Tax Expense	20.71	25.47
Less: Tax Expense	5.38	3.82
Less: Deferred Tax	10	(23.32)
Less: MAT Credit	--	--
Less: Previous Year Tax	--	--
Profit /loss for the year (1)	5.33	44.97
Total Comprehensive Income/loss (2)	--	--
Total (1+2)	5.33	44.97
Balance of profit /loss for earlier years	--	--
Less: Transfer to Debenture Redemption Reserve	--	--
Less: Transfer to Reserves	--	--
Less: Dividend paid on Equity Shares	--	--
Less: Dividend paid on Preference Shares	--	--
Less: Dividend Distribution Tax	--	--
Balance carried forward	**5.33**	**44.97**

2. **Review of operations:**

During the year under review, the Company has recorded a total income of Rs. 1123.33 lakhs and profit of Rs. 5.33 lakhs for the financial year ending 31.03.2026 as against the total income of Rs. 1245.96 lakhs and profit of Rs. 44.97 lakhs in the previous financial year ending 31.03.2025.

3. **Business update and state of company's affairs:**

The information on Company's affairs and related aspects is provided under Management Discussion and Analysis report, which has been prepared, inter-alia, in compliance with Regulation 34 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and forms part of this Report.

4. **Change in the nature of business, if any:**

The Company has not undergone any change in the nature of business during the FY 2025-26.

5. **Transfer to reserves:**

Pursuant to provisions of Section 134 (3) (j) of the Companies Act, 2013, the company has not proposed to transfer any amount to general reserves account of the company during the year under review.

6. **Dividend:**

Keeping the Company's growth plans in mind, your directors have decided not to recommend dividend for the year.

7. **Revision of financial statements:**

There was no revision of the financial statements for the year under review.

8. **Material changes & commitment affecting the financial position of the company:**

There have been no material changes and commitments affecting the financial position of the Company which have occurred during the end of the Financial Year of the Company to which the financial statements relate and the date of the report.

9. **Dividend:**

Keeping the Company's growth plans in mind, your directors have decided not to recommend dividend for the year.

10. Significant & material orders passed by the regulators or courts or tribunals:

The details of significant and material orders passed by the Regulators /Courts and Appellate Tribunals, during the year under review and till the date of this report are mentioned hereunder:

The Company approached the Hon'ble Securities Appellate Tribunal, Mumbai, seeking restoration of its listing status on BSE Limited, which had been revoked pursuant to the order passed by the BSE Delisting Committee vide its order dated 28.11.2024. The Company submitted a detailed appeal, highlighting the grounds on which the delisting order was contested, and requested immediate reinstatement of its securities to the exchange.

After considering the submissions and the merits of the case, the Hon'ble Securities Appellate Tribunal, Mumbai, vide its order dated 17.04.2025, directed that the Company's listing on BSE Limited shall be restored forthwith.

11. Investor Relations:

The Company continuously strives for excellence in its Investor Relations engagement with International and Domestic investors through structured conference-calls and periodic investor/analyst interactions like individual meetings, participation in investor conferences, quarterly earnings calls and analyst meet from time to time. The Company ensures that critical information about the Company is available to all the investors, by uploading all such information on the Company's website.

12. Transfer of un-claimed dividend to Investor Education and Protection:

There is no such amount of Un-paid or Unclaimed Dividend be transferred to Investor and Education and Protection Fund for the financial year ended 31st March 2026.

13. Details of utilization of funds:

During the year under review, the Company has not raised any funds through Preferential Allotment or Qualified Institutions Placement as specified under Regulation 32(7A) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

14. Details of Nodal Officer:

The Company has designated Mr. Bala Gopal Addepalli as a Nodal Officer for the purpose of IEPF.

15. Investor Education and Protection Fund (IEPF):

Pursuant to the provisions of Section 124 of the Act, Investor Education and Protection Fund Authority (Accounting, Audit, Transfer and Refund) Rules, 2016 ("IEPF Rules") read with the relevant circulars and amendments thereto, the amount of dividend remaining unpaid or unclaimed for a period of seven years from the due date is required to be transferred to the Investor Education and Protection Fund (“IEPF”), constituted by the Central Government

During the Year, no amount of dividend was unpaid or unclaimed for a period of seven years and therefore no amount is required to be transferred to Investor Education and Provident Fund under the Section 125(1) and Section 125(2) of the Act.

16. Deposits from public:

The Company has not accepted any public deposits during the Financial Year ended March 31, 2026 and as such, no amount of principal or interest on public deposits was outstanding as on the date of the balance sheet.

Since the Company has not accepted any deposits during the Financial Year ended March 31, 2026, there has been no non-compliance with the requirements of the Act.

17. Independent director’s familiarization programmes:

Independent Directors are familiarized about the Company’s operations, businesses, financial performance and significant development so as to enable them to take well-informed decisions in timely manner. Interaction with the Business heads and key executives of the Company is also facilitated. Detailed presentations on important policies of the Company are also made to the directors. Direct meetings with the Chairperson are further facilitated to familiarize the incumbent Director about the Company/its businesses and the group practices.

The details of familiarisation programme held in FY 2025-26 are also disclosed on the Company’s website and its web link is http://www.sangamhealthcare.co.in.

18. Audit Committee Recommendations:

During the year, all recommendations of Audit Committee were approved by the Board of Directors.

19. Board Evaluation:

Performance of the Board and Board Committees was evaluated on various parameters such as structure, composition, diversity, experience, corporate governance competencies, performance of specific duties and obligations, quality of decision-making and overall Board effectiveness. Performance of individual Directors was evaluated on parameters such as meeting attendance, participation and contribution, engagement with colleagues on the Board, responsibility towards stakeholders and independent judgement. All the Directors were subjected to peer-evaluation.

All the Directors participated in the evaluation process. The results of evaluation were discussed in the Board meeting held in February 2026. The Board discussed the performance evaluation reports of the Board, Board Committees, Individual Directors, and Independent External Persons. The Board upon discussion noted the suggestions / inputs of the Directors. Recommendations arising from this entire process were deliberated upon by the Board to augment its effectiveness and optimize individual strengths of the Directors.

The detailed procedure followed for the performance evaluation of the Board, Committees and Individual Directors is enumerated in the Corporate Governance Report.

20. Meetings of the Board:

During the year, four (4) meetings of the Board of Directors of the Company were convened and held in accordance with the provisions of the Act. The date(s) of the Board Meeting, attendance by the directors is given in the Corporate Governance Report forming an integral part of this report.

21. Committees of the Board:

There are various Board constituted Committees as stipulated under the Act and Listing Regulations namely Audit Committee, Nomination and Remuneration Committee, Stakeholders Relationship and Risk Management Committee. Brief details pertaining to composition, terms of reference, meetings held and attendance thereat of these Committees during the year have been enumerated in Corporate Governance Report forming part of this Annual Report.

22. Directors and key managerial personnel:

As on date of this report, the Company has six Directors, out of which three are Independent Directors and one is executive directors and Two Non-Executive Directors.

a) Appointment/Re-appointment of Directors of the Company:

In accordance with the provisions of the companies Act, 2013 and Articles of Association of the company Mrs. Padma Ghanakota, non-executive director, retire by rotation and being eligible, offers himself for re-appointment.

Resignation of Mr. Vijay Rayapa Reddy Tumma as Chief Financial Officer of the company w.e.f. 24.02.2026

Appointment of Mrs. S Vijayagowri Satya Bhavani as Chief Financial Officer of the Company w.e.f. 24.02.2026

b) Key Managerial Personnel:

Key Managerial Personnel for the financial year 2025-26

- Mr. D. Bhagat Reddy, Managing Director of the company.
- Mrs. S Vijayagowri Satya Bhavani, CFO of the company.
- Mr. T. Abhilash Company Secretary & Compliance Officer of the Company.

23. Statutory audit and auditors report:

The members of the Company at their 26th Annual General Meeting have appointed M/s. M.M Reddy & Co., as statutory auditors of the Company to hold office until the conclusion of 31st Annual General meeting of the Company.

The existing Statutory Auditors M/s. M.M Reddy & Co., Chartered Accountants, Hyderabad will retire at the ensuing Annual General Meeting. Accordingly, pursuant to the provisions of sections 139 of the companies Act, 2013 read with rules made there under, and based on the recommendation of the Audit Committee, the Board in its meeting held on 14.08.2025 has appointed M/s. M.M Reddy & Co.,Chartered Accountants, Hyderabad as the statutory auditors of the company, from the conclusion of 31st Annual General Meeting for a period of five Years till the conclusion of this 36th Annual General Meeting subject to the approval of members in ensuing Annual General Meeting

The Auditors' Report for fiscal year 2025-2026 does not contain any qualification, reservation or adverse remark. The Auditors' Report is enclosed with the financial statements in this Annual Report. The Company has received audit report with unmodified opinion for both Audited Financial Results of the Company for the Financial Year ended March 31, 2026 from the statutory auditors of the Company.

The Auditors have confirmed that they have subjected themselves to the peer review process of Institute of Chartered Accountants of India (ICAI) and hold valid certificate issued by the Peer Review Board of the ICAI.

24. Internal auditors:

Pursuant to provisions of Section 138 read with Rule 13 of the Companies (Accounts) Rules, 2014 and Section 179 read with Rule 8(4) of the Companies (Meetings of Board and its Powers) Rules, 2014; during the year under review, the Internal Audit of the functions and activities of the Company was undertaken by M/s. K. R. Shekhar & Co., the Internal Auditor of the Company.

Deviations are reviewed periodically and due compliance was ensured. Summary of Significant Audit Observations along with recommendations and its implementations are reviewed by the Audit Committee and concerns, if any, are reported to the Board. There were no adverse remarks or qualification on accounts of the Company from the Internal Auditor.

The Board has re-appointed M/s. K. R. Shekhar & Co., Chartered Accountants, Hyderabad, as Internal Auditors for the Financial Year 2026-27.

25. **Secretarial Auditor & Audit Report:**

In terms of section 204 of the Companies Act, 2013 read with the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014, based upon the recommendations of the Audit Committee, the Board of Directors had appointed M/s. Chakravarthy & Associates, Practicing Company Secretary (CP No. 22563) as the Secretarial Auditor of the Company, for conducting the Secretarial Audit for financial year ended March 31, 2026.

The Secretarial Audit was carried out by M/s. Chakravarthy & Associates, Practicing Company Secretary (CP No. 22563) for the financial year ended March 31, 2025. The Report given by the Secretarial Auditor is annexed and forms integral part of this Report.

Secretarial Auditors Qualification:

The qualifying remarks, reported by the Secretarial Auditor in their report for the Financial Year ended 31st March, 2026 and the explanations of the management are tabulated below:

S. No.	**Observation/ Qualification**	**Explanation by the Management**
1.	The Company has not complied with Regulation 47(1) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as the approved financial results were not published in newspapers as mandated.	Due to financial constraints and oversight, the publication could not be made. However, the results were duly filed with the Stock Exchange and uploaded on the Company's website. The management will ensure strict compliance in the future.
2.	The Company has not furnished the declarations of independence from its Independent Directors, as required under Regulation 25 of SEBI (LODR) Regulations, 2015 read with Section 149(7) and Schedule IV of the Companies Act, 2013, for audit	The non-furnishing was due to procedural delay. Independent Directors have since confirmed their independence, and the Company will ensure timely collection and maintenance of declarations henceforth.

	verification.	
3.	The Company has not produced the records relating to Board Meeting and Committee Meeting Agendas, Minutes of the Board, Audit Committee, Nomination & Remuneration Committee, and Stakeholders' Relationship Committee for audit verification, in contravention of the provisions of the Act and applicable Secretarial Standards.	The records are maintained; however, due to administrative lapses, the same could not be produced for audit verification. The Company is taking corrective measures to maintain proper documentation and ensure its availability during audits.
4.	The Company has failed to intimate the stock exchange (BSE Limited) about the convening of Board Meetings for the financial year 2024-25, in violation of Regulation 29(1) of the SEBI (LODR) Regulations, 2015.	The non-intimation was due to inadvertence. The Company assures that all future intimations will be filed with the Stock Exchange within the prescribed timelines.
5.	The Company has failed to maintain the statutory registers as prescribed under the Companies Act, 2013 and allied rules.	Certain statutory registers were not updated owing to clerical lapses. The Company is in the process of updating and maintaining all registers in compliance with the Act.
6.	The Company has not provided the statutory disclosures in Form DIR-8 and MBP-1, as mandated under Sections 164 and 184 of the Companies Act, 2013, for audit verification.	The delay in obtaining the said disclosures was unintentional. The Company has since initiated the process to collect and maintain the disclosures in proper records.
7.	Independent Directors, namely Mr. Rajesh Kakkera, Mr. M. Madhavarao, and Mr. Addagarla Tarun, have failed to register/renew their names in the Independent Directors' Data Bank maintained by the Indian Institute of Corporate Affairs (IICA) within the stipulated period, thereby attracting non-compliance with the provisions of the Act and SEBI regulations.	The concerned Independent Directors are in the process of completing the renewal formalities. The Company is following up to ensure full compliance.
8.	The Company has failed to conduct the annual performance evaluation of the Board, its Committees, and individual Directors, as mandated	The performance evaluation could not be conducted during the period due to oversight. The same will be undertaken in the current financial

	under Regulation 17(10) of SEBI (LODR) Regulations, 2015 and Section 134(3)(p) of the Companies Act, 2013.	year as per statutory requirements.
9.	The Company has not maintained acknowledgments of dispatch/delivery of notices of Board and Committee Meetings, in violation of the Secretarial Standards issued by the ICSI.	Due to administrative lapses, acknowledgments were not maintained. The Company has taken corrective steps to ensure proper records are preserved in compliance with Secretarial Standards.
10.	The Company has failed to maintain the attendance registers for meetings of the Board of Directors and Committees, as mandated under the Act and Secretarial Standards.	The attendance records were inadvertently not updated. The Company is implementing stronger internal controls to ensure registers are maintained in the prescribed manner.

26. Annual Secretarial Compliance Report:

SEBI vide its Circular No. CIR/CFD/CMD1/27/2019 dated February 08, 2019 read with Regulation 24(A) of the Listing Regulations, directed listed entities to conduct Annual Secretarial compliance audit from a Practicing Company Secretary of all applicable SEBI Regulations and circulars/guidelines issued thereunder.

27. Information about The Financial Performance / Financial Position of The Subsidiaries / Associates:

The Company does not have any subsidiary. During the year neither any company became a subsidiary nor ceased as a subsidiary.

28. Cost records and cost audit:

Maintenance of cost records and requirement of cost audit as prescribed under the provisions of Section 148(1) of the Act, are not applicable for the business activities carried out by the Company.

29. No Frauds reported by statutory auditors:

During the Financial Year 2025-26, the Auditors have not reported any matter under section 143(12) of the Companies Act, 2013, therefore no detail is required to be disclosed under section 134(3) (ca) of the Companies Act, 2013.

30. Declaration by the Company:

None of the Directors of the Company are disqualified for being appointed as Directors as specified in Section 164 (2) of the Act read with Rule 14 of Companies (Appointment and Qualifications of Directors) Rules, 2014.

31. Conservation of energy, technology absorption and foreign exchange outgo:

The required information as per Sec.134 (3) (m) of the Companies Act 2013 is provided hereunder and Rule 8 of Companies (Accounts) Rules, 2014:

A. Conservation of Energy:

Your Company's operations are not energy intensive. Adequate measures have been taken to conserve energy wherever possible by using energy efficient computers and purchase of energy efficient equipment.

B. Technology Absorption:

1. Research and Development (R&D): NIL
2. Technology absorption, adoption and innovation: NIL

C. Foreign Exchange Earnings and Out Go:

1. Foreign Exchange Earnings: Nil
2. Foreign Exchange Outgo: Nil

32. Management discussion and analysis report:

Management discussion and analysis report for the year under review as stipulated under Regulation 34(2) (e) read with schedule V, Part B of SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015 with the stock exchange in India is annexed herewith as **Annexure- I** to this report.

33. Risk management policy:

The Board of Directors had constituted Risk Management Committee to identify elements of risk in different areas of operations and to develop policy for actions associated to mitigate the risks. The Committee is responsible for reviewing the risk management plan and ensuring its effectiveness. The major risks identified by the businesses and functions are systematically addressed through mitigating actions on a continual basis.

34. Corporate governance:

Your Company has taken adequate steps to ensure compliance with the provisions of Corporate Governance as prescribed under the Listing Regulations. A separate section on Corporate Governance, forming a part of this Report and the requisite certificate from the Company's Auditors confirming compliance with the conditions of Corporate Governance is attached to the report on Corporate Governance as **Annexure II.**

35. Annual Return:

Pursuant to Sections 92 & 134(3) of the Act and Rule 12 of the Companies (Management and Administration) Rules, 2014, the Annual Return in Form MGT-7 is also available on the Company's website www.sangamhealthcare.co.in

36. Authorised and paid-up capital of the company:

The authorized capital of the Company stands at Rs. 15,00,00,000/- divided into 1,50,00,000 equity shares of Rs. 10/- each. The Subscribed, Issued and Paid-up capital of the Company stands at Rs. 14,86,07,000/- divided into 1,48,60,700 equity shares of Rs. 10/- each.

37. Declaration of independence:

The Company has received declarations from all the Independent Directors of the Company confirming that they meet with both the criteria of independence as prescribed under sub-section (6) of Section 149 of the Companies Act, 2013 and under Regulation 16(1)(b) read with Regulation 25 of the Listing Regulations.

In compliance with Rule 6 of Companies (Appointment and Qualification of Directors) Rules, 2014, all the PIDs of the Company have registered themselves with the India Institute of Corporate Affairs (IICA), Manesar and have included their names in the databank of Independent Directors within the statutory timeline.

The Independent Directors have also confirmed that they have complied with Schedule IV of the Act and the Company's Code of Conduct.

In terms of Regulations 25(8) of the Listing Regulations, the Independent Directors have confirmed that they are not aware of any circumstance or situation, which exists or may be reasonably anticipated, that could impair or impact their ability to discharge their duties with an objective independent judgement and without any external influence.

During the year, Independent Directors of the Company had no pecuniary relationship or transactions with the Company, other than sitting fees, commission and reimbursement of expenses incurred by them for the purpose of attending meetings of the Board of Directors and Committee(s).

38. Director's Responsibility Statement:

Pursuant to Section 134(5) of the Companies Act, 2013, the Board of Directors, to the best of their knowledge and ability, confirm that for the financial year ended March 31, 2026:

a) in the preparation of the annual accounts for the financial year ended 31 March 2026, the applicable accounting standards and schedule III of the Companies Act, 2013 have been followed and there are no material departures from the same;

b) the Directors have selected such accounting policies and applied them consistently and made judgments and estimates that are reasonable and prudent so as to give a true and fair view of the state of affairs of your Company as on 31 March 2026 and of the profit and loss of the Company for the financial year ended 31 March 2026;

c) proper and sufficient care has been taken for the maintenance of adequate accounting records in accordance with the provisions of the Companies Act, 2013 for safeguarding the assets of the Company and for preventing and detecting fraud and other irregularities;

d) The annual accounts have been prepared on a going concern basis;

e) Proper internal financial controls laid down by the Directors were followed by the Company and that such internal financial controls are adequate and were operating effectively; and

f) Proper systems to ensure compliance with the provisions of all applicable laws were followed and that such systems were adequate and operating effectively.

39. Vigil Mechanism/Whistle Blower Policy:

The Company has formulated a Vigil Mechanism / Whistle Blower Policy pursuant to Regulation 22 of the Listing Regulations and Section 177(10) of the Act, enabling stakeholders to report any concern of unethical behaviour, suspected fraud or violation.

The said policy inter-alia provides safeguard against victimization of the Whistle Blower. Stakeholders including directors and employees have access to the Managing Director & CFO and Chairperson of the Audit Committee.

During the year under review, no stakeholder was denied access to the Chairperson of the Audit Committee.

The policy is available on the website of the Company at www.sangamhealthcare.co.in

40. Corporate social responsibility policy:

Since your Company does not have net worth of Rs. 500 Crore or more or turnover of Rs. 1000 Crore or more or a net profit of Rs. 5 Crore or more during the financial year, section 135 of the Companies Act, 2013 relating to Corporate Social Responsibility is not applicable and hence the Company need not adopt any Corporate Social Responsibility Policy.

41. Board Evaluation:

Performance of the Board and Board Committees was evaluated on various parameters such as structure, composition, diversity, experience, corporate governance competencies, performance of specific duties and obligations, quality of decision-making and overall Board effectiveness. Performance of individual Directors was evaluated on parameters, such as meeting attendance, participation and contribution, engagement with colleagues on the Board, responsibility towards stakeholders and independent judgement. All the Directors were subjected to peer-evaluation.

All the Directors participated in the evaluation process. The results of evaluation were discussed in the Board meeting held in Feb 2026. The Board discussed the performance evaluation reports of the Board, Board Committees, Individual Directors, Independent External Persons and noted the suggestions / inputs of the Directors. Recommendations arising from this entire process were deliberated upon by the Board to augment its effectiveness and optimize individual strengths of the Directors.

The detailed procedure followed for the performance evaluation of the Board, Committees and Individual Directors is enumerated in the Corporate Governance Report.

42. Audit Committee Recommendations:

During the year, all recommendations of Audit Committee were approved by the Board of Directors.

43. Companies which have become or ceased to be subsidiaries:

None of the companies have become or ceased to become the subsidiaries, joint ventures or associates' company to M/s. Sangam Health Care Products Limited during the year 2025-26.

44. Policies:

The SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 mandated the formulation of certain policies for all listed companies. All the policies are available on our website www.sangamhealthcare.co.in

45. Secretarial Standards:

The Company has devised proper systems to ensure compliance with the provisions of all applicable Secretarial Standards issued by the Institute of Company Secretaries of India and such systems are adequate and operating effectively. During the year under review, the Company was in compliance with the Secretarial Standards (SS) i.e., SS-1 and SS- 2, relating to "Meetings of the Board of Directors" and "General Meetings", respectively.

46. Insurance:

The properties and assets of your Company are adequately insured.

47. Particulars of Loans, Guarantees or Investments:

The company has not given loans, Guarantees or made any investments attracting the provisions of Section 186 of the Companies Act, 2013 during the financial year under review.

48. Internal Financial Control Systems:

Your Company has well laid out policies on financial reporting, asset management, adherence to Management policies and also on promoting compliance of ethical and well-defined standards. The Company follows an exhaustive budgetary control and standard costing system. Moreover, the management team regularly meets to monitor goals and results and scrutinizes reasons for deviations in order to take necessary corrective steps. The Audit Committee which meets at regular intervals also reviews the internal control systems with the Management and the internal auditors.

The internal audit is conducted at the Company and covers all key areas. All audit observations and follow up actions are discussed with the Management as also the Statutory Auditors and the Audit Committee reviews them regularly.

49. Related Party Transactions:

The company does not have any transactions with related parties as falls under the scope of Section 188(1) of the Act read with relevant rules.

50. Policy on director's appointment and remuneration:

In adherence to the provisions of Section 134(3)(e) and 178(1) & (3) of the Companies Act, 2013, the Board of Directors upon recommendation of the Nomination and Remuneration Committee approved a policy on Director's appointment and remuneration, including, criteria for determining qualifications, positive attributes, independence of a Director and other matters. The said Policy extract is covered in Corporate Governance Report which forms part of this Report and is also uploaded on the Company's website at www.sangamhealthcare.co.in

51. Particulars of Employees and related Disclosure:

Disclosure pertaining to remuneration and other details as required under section 197 of the Companies Act, 2013 read with rule 5(1) of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014 is given in **Annexure–IV** to this Report.

The Statement containing the particulars of employees as required under section 197(12) of the Companies Act, 2013 read with rule 5(2) and other applicable rules (if any) of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014, is provided in a separate annexure forming part of this report. Further, the report and the accounts are being sent to the members excluding

During the year none of the employees is drawing a remuneration of Rs.1,02,00,000/- and above per annum or Rs.8,50,000/- per month and above in aggregate per month, the limits specified under the Section 197(12) of the Companies Act,2013 read with Rules 5(2) and 5(3) of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014.

52. Employee stock option scheme:

The Company does not have an employee stock option Scheme.

53. Declaration by the company:

The Company has issued a certificate to its Directors, confirming that it has not made any default under Section 164(2) of the Companies Act, 2013, as on March 31, 2026.

54. **Non-executive directors' compensation and disclosures:**

None of the Independent / Non-Executive Directors has any pecuniary relationship or transactions with the Company which in the Judgment of the Board may affect the independence of the Directors.

No compensation was paid to the Independent and Non-Executive Directors.

55. **Implementation of Corporate Action:**

During the year under review, the Company has complied with the specified time limit for implementation of Corporate Actions.

56. **Shares transferred to investor education and protection fund:**

No shares were transferred to the Investor Education and Protection Fund during the year under review.

57. **Ratio of remuneration to each director:**

Under section 197(12) of the Companies Act, 2013, and Rule 5(1) (2) & (3) of the Companies (Appointment & Remuneration) Rules, 2014 read with Schedule V of the Companies Act, 2013.

The Board of Directors has not withdrawn Salary during the financial year 2025-26 Hence the ratio of remuneration is Nil for each director.

58. **Industry based disclosures as mandated by the respective laws governing the company:**

The Company is not a NBFC, Housing Companies etc., and hence Industry based disclosures is not required.

59. **Corporate insolvency resolution process initiated under the insolvency and bankruptcy code, 2016.**

No corporate insolvency resolution processes were initiated against the Company under the Insolvency and Bankruptcy Code, 2016, during the year under review.

60. **Designated person for furnishing information and extending co-operation to ROC in respect of beneficial interest in shares of the company:**

The Company has appointed Mr. Bala Gopal Addepalli, Chief Executive Officer, as designated person, for furnishing information and extending co-operation to ROC in respect of beneficial interest in shares of the Company to ensure compliance with MCA notification on this matter.

61. Statement on Maternity Benefit Compliance:

The provisions of the Maternity Benefit Act, 1961 were not applicable to the Company for the financial year 2025-26, as no female employees were employed during that period.

62. Policies:

The SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 mandated the formulation of certain policies for all listed companies. All the policies are available on our website (https:// www.sangamhealthcare.co.in). The policies are reviewed periodically by the Board and updated based on need and new compliance requirement.

Name of the policy	**Brief Description**	**Website link**
Board Diversity Policy	At Sangam healthcare Products Limited, we believe that a truly diverse board will leverage differences in thought, perspective, knowledge, skill, regional and industry experience, cultural and geographical background, age, ethnicity, race and gender, which will help us, retain our competitive advantage. The Board has adopted the Board Diversity Policy which sets out the approach to diversity of the Board of Directors.	www.sangamhealthcare.co.in.
Nomination and Remuneration Policy	This policy formulates the criteria for determining qualifications, competencies, positive attributes and independence for the appointment of a director (executive / non-executive) and also the criteria for determining the remuneration of the Directors, key managerial personnel and other employees.	www.sangamhealthcare.co.in.
Related Party Transaction Policy	The policy regulates all transactions between the Company and its related parties	www.sangamhealthcare.co.in.

63. Statutory compliance:

The Company has complied with the required provisions relating to statutory compliance with regard to the affairs of the Company in all respects.

64. Code of conduct for the prevention of insider trading:

Pursuant to the provisions of SEBI (Prohibition of Insider Trading) Regulations, 2015 as amended from time to time, the Company has formulated a Code of Conduct for

Prevention of Insider Trading ("Insider Trading Code") and a Code of Practices and Procedures for fair disclosure of Unpublished Price Sensitive Information ("UPSI").

The Code of Practices and Procedures for fair disclosure of UPSI is available on the website of the Company at https://www.sangamhealthcare.co.in.

65. Details of difference between valuation amount on one time settlement and valuation while availing loan from banks and financial institutions:

During the year under review, there has been no one time settlement of loans taken from banks and financial institutions.

66. Suspension of Trading:

The Company is under suspension on BSE due to penal reasons. However, the company under the new management lead by Mr. Bhagat Reddy Dundumulla, Managing Director of the Company has been working aggressively towards revoking the company from suspension. The Board assures that all due efforts are being made to revoke the company from suspension and so shall be done soon.

67. CEO/CFO Certification:

As required Regulation 17(8) read with Schedule II of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the CEO/CFO certification is attached with the annual report as **Annexure V**.

68. Prevention of sexual harassment at workplace:

The Company has always believed in providing a safe and harassment free workplace for every individual working in its premises through various policies and practices. The Company always endeavors to create and provide an environment that is free from discrimination and harassment including sexual harassment.

The Company has adopted a policy on Prevention of Sexual Harassment at Workplace which aims at prevention of harassment of employees and lays down the guidelines for identification, reporting and prevention of undesired behavior. An Internal Complaints Committee ("ICC") has been set up by the senior management (with women employees constituting the majority). The ICC is responsible for redressal of complaints related to sexual harassment and follows the guidelines provided in the Policy.

During the financial year ended March 31, 2026, no complaints pertaining to sexual harassment have been received.

69. Disclosure pursuant to Part A of Schedule V of SEBI LODR

Disclosure pursuant to Part-A of Schedule V read with Regulation 34(3) of SEBI is attached as Annexure-IV of this report.

70. Green Initiatives:

In commitment to keep in line with the Green Initiative and going beyond it to create new green initiatives, electronic copy of the Notice of 32nd Annual General Meeting of the Company are sent to all Members whose email addresses are registered with the Company/Depository Participant(s). For members who have not registered their e-mail addresses, physical copies are sent through the permitted mode.

71. Event Based Disclosures

During the year under review, the Company has not taken up any of the following activities:

1. Issue of sweat equity share: NA
2. Issue of shares with differential rights: NA
3. Issue of shares under employee's stock option scheme: NA
4. Disclosure on purchase by Company or giving of loans by it for purchase of its shares: NA
5. Buy back shares: NA
6. Disclosure about revision: NA

72. Acknowledgement:

Your Directors place on record their appreciation for the overwhelming co-operation and assistance received from the investors, customers, business associates, bankers, vendors, as well as regulatory and governmental authorities. Your Directors also thanks the employees at all levels, who through their dedication, co-operation, support and smart work have enabled the company to achieve a moderate growth and is determined to poise a rapid and remarkable growth in the year to come.

For and on behalf of the Board of Directors
Sangam Health Care Products Limited

	Sd/-	Sd/-
Place: Secunderabad	D. Bhagat Reddy	Padma Ghanakota
Date: 13.08.2025	Managing Director	Director
	DIN: 07087331	DIN: 07078176

Particulars Of Employee

(As per Sub-section (12) of section 197 of the Act and rules made thereof as amended from time to time)

A. Statement of particulars as per Rule 5 of the Companies (Appointment and Remuneration of Managerial personnel) Rules, 2014.

The remuneration and perquisites provided to the employees and Management are at par with the industry levels. The remunerations paid to Whole-time Directors and Senior Executives are reviewed and recommended by the Nomination and Remuneration Committee.

i. The ratio of the remuneration of each Director to the median remuneration of the employees of the Company for the financial year:

S No.	Name of the Director(s)	Designation	Ratio of remuneration to MRE*	Amount
Sitting Fees				
Remuneration				
1.	Mr. T. Abhilash	Company Secretary & Compliance Officer	--	1,50,000

*MRE: Median Remuneration of Employees

Note:

a) *S No. 1 to 4 are related to sitting fees paid to Non-Executive Director*

a) *S No. 5 & 6 Remuneration includes monthly salary, perquisites and annual/performance pay*

b) ***"Median"** means:*

i. *the numerical value separating the higher half of a population from the lower half and the median of a finite list of numbers may be found by arranging all the observations from lowest value to highest value and picking the middle one;*

ii. *if there is an even number of observations, the median shall be the average of the two middle values.*

ii. The percentage increase in remuneration of each Director, Chief Financial Officer, Chief Executive Officer, Company Secretary or Manager in the financial year:

S No.	Name of the Director(s)	Designation	Remuneration		% Increase/ (Decrease) in Remuneration
			FY 2025-26	FY 2024-25	
Sitting Fees Nil					**Nil**
Remuneration					
1.	Mr. T. Abhilash	Company Secretary &	1,50,000	--	Nil

		Compliance Officer			

iii.The percentage increase in the median remuneration of employees in the financial year: -1.46 **%**

S No.	**Particulars**	**Remuneration**		**% Increase/ (Decrease)**
		FY 2025-26	**FY 2024-25**	
1.	*Median Remuneration of all the employees per annum	Nil	Nil	

**Employees who have served for whole of the respective financial years have been considered.*

iv. The number of permanent employees on the rolls of company: 54 Employees.

v.Average percentile increase already made in the salaries of employees other than the managerial personnel in the last financial year and its comparison with the percentile increase in the managerial remuneration and justification thereof and point out if there are any exceptional circumstances for increase in the managerial remuneration:

a) The average percentile increase already made in the salaries of employees excluding key managerial personnel is Nil%.

b) There was no increase in the remuneration of the Key Managerial Personnel.

S No.	Particulars	Details (in %)	Justification (in case of increase in point no.2)
1.	Average percentage increase in the remuneration of all Employees* (Other than Key Managerial Personnel)	Nil	On account of event based Compensation revisions.
2.	Average Percentage increase in the Remuneration of Key Managerial Personnel T. Abhilash - Company Secretary & Compliance Officer	Nil Nil	On account of event based Compensation revisions.

vi.Affirmation that the remuneration is as per the remuneration policy of the company: Yes

Annexure-1(b)

vii.The Names of the top ten employees in terms of remuneration drawn and the name of every employee:

S No	Names of the Employees	Remuneration drawn (in Rs.)	Designation	Nature of employment, whether contractual or otherwise	Qualifications and experience of the employees	Date of commencement of employment and age of such employee	The last employment held by such employee before joining the company	% of equity shares held by the employee in the company	Whether any such employee is a relative of any director/ manager of the company and if so, name of such director or manager
01	T. Abhilash	150000	Company Secretary	Permanent	Company Secretary	01.11.2024	--	0	No

For and on behalf of the Board of directors
Sangam Health Care Products Limited

Place: Secunderabad
Date: 13.08.2026

Sd/-
D. Bhagat Reddy
Managing Director
DIN: 07087331

Sd/-
Padma Ghanakota
Director
DIN: 07078176

CORPORATE GOVERNANCE REPORT

In accordance with Regulation 34 (3) read with Schedule V of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 the report containing the details of Corporate Governance systems and processes at Sangam Health Care Products Limited as follows:

1. Company's philosophy on code of governance:

The Company's philosophy on Corporate Governance is backed by Principles of Concern, Commitment, Ethics, Excellence and Learning in all its acts and relationships with Stakeholders, Clients, Associates and Community at large. This philosophy revolves around fair and transparent governance and disclosure practices in line with the principles of Good Corporate Governance. The Corporate Governance Structure in the Company assigns responsibilities and entrusts authority among different participants in the organization viz. the Board of Directors, the Senior Management, Employees, etc. The Company believes that good Corporate Governance is a continuous process and strives to improve the Corporate Governance practices to meet shareholder's expectations.

2. Board Diversity:

The Company recognizes and embraces the importance of a diverse board in its success. We believe that a truly diverse board will leverage differences in thought, perspective, knowledge, skill, regional and industry experience, cultural and geographical background, age, ethnicity, race and gender, which will help us, retain our competitive advantage. The Board has adopted the Board Diversity Policy which sets out the approach to diversity of the Board of Directors.

3. Governance Structure:

Board of Directors: Provides strategic direction, formulates and ensures long-term business strategy, enhances shareholder value, and safeguards stakeholder interests.

Board Committees: Leverage specialized expertise to provide insightful recommendations, ensure effective oversight, and guide strategic direction across key operational areas.

Management: Implements policies, procedures, and oversees day-to-day operations, driving effective execution

4. **Code of conduct for the prevention of insider trading:**

The Board of Directors has adopted the Insider Trading Policy in accordance with the requirements of the SEBI (Prohibition of Insider Trading) Regulation, 2015. The insider trading Policy of the Company lays down guidelines and procedures to be followed, and disclosures to be made while dealing with shares of the Company. The policy has been formulated to regulate, monitor and ensure reporting of deals by employees and to maintain the highest ethical standards of dealing in Company securities.

The Insider Trading Policy of the Company covering code of practices and procedures for fair disclosure of unpublished price sensitive information and code of conduct for the prevention of insider trading, is available on our website www.sangamhealthcare.co.in.

5. **Composition of the board:**

The composition of the Board of Directors of the company is an appropriate combination of executive and non-executive Directors with right element of independence. As on date of this report, the Board comprised of four Directors, two promoter Directors including one woman Director. In addition, there are two independent Directors on the Board. The non-executive Directors are appointed or re-appointed based on the recommendation of the Nomination & Remuneration Committee which considers their overall experience, expertise and industry knowledge.

6. **Attendance and directorships held:**

As mandated by the SEBI (LODR) Regulations, 2015, none of the Directors are members of more than ten Board-level committees nor are they chairman of more than five committees in which they are members. Further all the Directors have confirmed that they do not serve as an independent director in more than seven listed companies or where they are whole-time directors in any listed company, then they do not serve as independent director in more than three listed companies.

The names and categories of the Directors on the Board, their attendance at Board meeting during the year and at last Annual General Meeting, as also the number of Directorships and Committee memberships held by them in other companies are shown in **Table 1.**

Table 1

Name of Director	**Relationship with another Director**	**Category**	**No. of Meetings Held**	**No. of Meetings Attended**	**Whether Attended Last AGM**	**No. of Outside Directorship of Public Companies**	**No. of Committee Memberships**	**No. of Committee Chairmanships**
Padma Ghanakot	Spouse of A. Bala	NID & NED	04	04	Yes	--	--	--

a	Gopal							
Rajesh Kakkera	None	ID & NED	04	04	Yes	--	--	3
M. Madhava rao	None	ID & NED	04	04	Yes	--	3	--
Mr. D. Bhagat Reddy	None	MD	04	04	Yes	--	--	--
Mr. A. Sai Balaji Krishna Teja	None	NID & NED	04	04	Yes	--	--	--
Mr. Addagarl a Tarun	None	ID & NED	04	04	Yes	--	3	--

The name of other listed entities where directors of the company are directors and the category of directorship are shown in **Table 2.**

Table 2		
Name of Director	**Name of listed entities in which the concerned Director is a Director**	**Category of Directorship**
Mr. D. Bhagat Reddy	--	--
Mr Padma Ghanakota	--	--
M. Madhavarao	--	--
Padma Ghanakota	--	--
Mr. A. Sai Balaji Krishna Teja	--	--
Mr. Addagarla Tarun	--	--

P – Promoter**, ID-** Independent, **NID-** Non-Independent Director**, ED-** Executive Director**, NED-** Non- Executive Director

Details of Skills/Expertise/Competence matrix of the Board of Directors:

Skills Description	**A. Bala Gopal**	**Padma Ghanakota**	**Rajesh Kakkera**	**M. Madhavarao**
Leadership Innate leadership skills including the ability to represent the organization and set appropriate Board and organization culture. Demonstrated strengths in talent	Yes	Yes	Yes	Yes

development, succession planning and bringing change and long term future growth.				
Strategic Planning and Analysis Ability to critically identify and assess strategic opportunities and threats and develop effective strategies in the context of long-term objectives and the organizations' relevant policies and priorities.	Yes	Yes	Yes	Yes
Technology Reasonable knowledge and experience in technology with an ability to foresee technological trends and changes, apply new technology and bring about innovations in business strategies.	Yes	Yes	Yes	Yes
Governance Understanding of the various governance and compliance requirements under various applicable laws, supporting a strong Board base and management accountability, transparency, and protection of shareholder interests.	Yes	Yes	Yes	Yes
Financial Wide ranging knowledge and financial skills, oversight for risk management and internal controls and proficiency in financial management and financial reporting processes.	Yes	Yes	Yes	Yes
Diversity An appropriate mix of varied cultures, ethnicity, geography, gender, age, philosophies, life experiences and other diversity perspectives that expand the Board's understanding of the needs of diverse stakeholders and a better ability to respond to changes.	Yes	Yes	Yes	Yes
Marketing and Communications Ability to analyze the market and technological impacts, developing	Yes	Yes	Yes	Yes

strategies for brand awareness and brand building and enhancing market share.				

7. Familiarization program for independent directors:

The Board members are provided with necessary documents, reports, internal policies and site visits to enable them to familiarize with the Company's operations, its procedures and practices. Periodic presentations are made at the Board and Board Committee Meetings, on business and performance updates of the Company business, strategy and risks involved.

Detailed presentations on the Company's business segments were made at the meetings of the Directors held during the year. Details of the same are available on www.sangamhealthcare.co.in.

8. Appointment/re-appointment of directors:

Details of Director seeking appointment/ reappointment at the forthcoming Annual General Meeting as required under Regulation 36 of the Securities and Exchange Board of India (Listing Obligation and Disclosure Requirement) Regulations, 2015 (“Listing Regulations”) is annexed to the Notice convening the Annual General Meeting and forming part of this Annual Report.

9. Information supplied to the board:

The Board has complete access to all information of the Company and is regularly provided advanced detailed information as a part of the agenda papers or is tabled therein. In addition, detailed quarterly performance report by the Managing Director is presented in the quarterly Board meeting, encompassing all facets of the Company’s operations during the quarter, including update of key projects, outlook and matters relating to environment, health & safety, corporate social responsibility etc. The following information is provided to the Board as a part of the agenda papers:

- Annual and Quarterly financial statements for the Company and the Accounting Policy.
- Minutes of the meetings of the Audit Committee and other Committees of the Board.
- Annual business plan
- Information on recruitment and remuneration of senior officers just below the level of Board, including the appointment or removal of Chief Financial Officer and Company Secretary, whenever required
- Expansion projects and its status monitoring.
- Fatal or serious accidents, injuries or any material environmental problems, if any

- Any material default in financial obligations to and by the Company, or substantial non-payment for goods sold by the Company, if any
- Significant labour problems and their proposed solutions, whenever necessary.
- Any significant development in human resources / industrial relations including long-term wage agreement, major voluntary retirement scheme, etc.
- Quarterly details of foreign exchange exposures and the steps taken by the management to limit the risks of adverse exchange rate movement, if material Quarterly disclosure of all the investments made.
- Material non-compliance of any regulatory, statutory nature or listing requirements and shareholders service, such as non-payment of dividend, delay in share transfer and others, if any
- Quarterly review of compliance status under various laws applicable to the Company.
- Substantial non-payment of goods sold by the Company except disputes.
- Related Party Transactions, if they are not at arm's length and in the ordinary course of business.
- Half-yearly summary of bank guarantees issued.

All other matters required to be placed before the Board for its review / information / approval under the statutes, including SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

10. Committees of the board:

The Company has four Board-level Committees - Audit Committee, Stakeholder Relationship Committee and Nomination & Remuneration Committee

All decisions pertaining to the constitution of Committees, appointment of members and fixing of terms of service for Committee members are taken by the Board of Directors. Details on the role and composition of these Committees, including the number of meetings held during the financial year and the related attendance are provided in this report.

11. Performance evaluation of board, committees and directors:

Pursuant to provisions of Regulation 17(10) of the SEBI Listing Regulations and the provisions of the Act, an annual Board effectiveness evaluation was conducted for FY 2025-26 on February 13, 2026, involving the following:

i. Evaluation of IDs, in their absence, by the entire Board was undertaken, based on their performance and fulfilment of the independence criteria prescribed under the Act and SEBI Listing Regulations; and

ii. Evaluation of the Board of Directors, its Committees and individual Directors, including the role of the Board Chairman.

An IDs’ meeting, in accordance with the provisions of Section 149(8) read with Schedule IV of the Act and Regulation 25(3) and 25(4) of the SEBI Listing Regulations, was convened on February 13, 2026, mainly to review the performance of Independent Directors and the Chairman & Managing Director as also the Board as a whole. All IDs were present at the said meeting.

(i) **Board:** Composition, responsibilities, stakeholder value and responsibility, Board development, diversity, governance, leadership, directions, strategic input, etc.

(ii) **Executive Directors:** Skill, knowledge, performance, compliances, ethical standards, risk mitigation, sustainability, strategy formulation and execution, financial planning & performance, managing human relations, appropriate succession plan, external relations including CSR, community involvement and image building, etc.

(iii) **Independent Directors:** Participation, managing relationship, ethics and integrity, Objectivity, brining independent judgement, time devotion, protecting interest of minority shareholders, domain knowledge contribution, etc.

(iv) **Chairman:** Managing relationships, commitment, leadership effectiveness, promotion of training and development of directors etc.

(v) **Committees:** Terms of reference, participation of members, responsibility delegated, functions and duties, objectives alignment with company strategy, composition of committee, committee meetings and procedures, management relations.

Performance evaluation was done on the scale of 1 to 5, 1 being very poor and 5 being outstanding. The outcome of performance evaluation is given below:

Categories	**Rating (out of 5)**
Board as a whole	4.5
Individual Directors	
D. Bhagat Reddy	4.6
Padma Ghanakota	4.6
A. Sai Balaji Krishna Teja	4.75
Rajesh Kakkera	4.89
M. Madhavarao	5
Addagarla Tarun	4.79
Audit Committee	4.74
Stakeholder Relationship Committee	4.75
Nomination & Remuneration Committee	4.79

Disclosures as prescribed under SEBI circular dated May 10, 2018 are given below:

Observations of Board evaluation carried out for the year	No observations.
Previous year's observations and actions taken	Since no observations were received, no actions were taken.
Proposed actions based on current year observations	Since no observations were received, no actions were taken.

12. Declaration by independent directors:

All the Independent Directors have confirmed that they meet the criteria of independence as mentioned under Regulation 16(1)(b) of the SEBI (Listing Obligations and Disclosure Requirements), 2015 read with Section 149(6) of the Act.

13. Audit Committee:

Terms of reference of Audit committee covers all the matters prescribed under Regulation 18 of the Listing Regulations and Section 177 of the Act, 2013.

The Audit Committee acts as an interface between the Statutory and Internal Auditors, the Management, and the Board. It assists the Board in fulfilling its responsibilities of monitoring financial reporting processes; reviewing the Company's established systems and processes for internal financial controls and governance; and reviews the Company's statutory and internal audit processes.

A. Brief Description of Terms of Reference: -

Overview of the Company's financial reporting process and disclosure of its financial information to ensure that the financial statements reflect a true and fair position and that sufficient and credible information is disclosed.

(1) oversight of the listed entity's financial reporting process and the disclosure of its financial information to ensure that the financial statement is correct, sufficient and credible;
(2) recommendation for appointment, remuneration and terms of appointment of auditors of the listed entity;
(3) approval of payment to statutory auditors for any other services rendered by the statutory auditors;
(4) Review and monitor the auditor's independence and performance, and effectiveness of audit process.

(5) reviewing, with the management, the annual financial statements and auditor's report thereon before submission to the board for approval, with particular reference to:

a. matters required to be included in the director’s responsibility statement to be included in the board’s report in terms of clause (c) of sub-section (3) of Section 134 of the Companies Act, 2013;
b. changes, if any, in accounting policies and practices and reasons for the same;
c. major accounting entries involving estimates based on the exercise of judgment by management;
d. significant adjustments made in the financial statements arising out of audit findings;
e. compliance with listing and other legal requirements relating to financial statements;
f. disclosure of any related party transactions;
g. modified opinion(s) in the draft audit report;
h. reviewing, with the management, the quarterly financial statements before submission to the board for approval; \

(6) To review the financial statements, in particular, the investments made by the unlisted subsidiary Company.

(7) reviewing, with the management, the statement of uses / application of funds raised through an issue (public issue, rights issue, preferential issue, etc.), the statement of funds utilized for purposes other than those stated in the offer document / prospectus / notice and the report submitted by the monitoring agency monitoring the utilisation of proceeds of a public issue or rights issue or preferential issue or qualified institutions placement], and making appropriate recommendations to the board to take up steps in this matter;

(8) To formulate the scope, functioning, periodicity and methodology for conducting the internal audit in consultation with the Internal Auditor.

(9) Reviewing, with the management, performance of statutory and internal auditors, and adequacy of the internal control systems.

(10) Reviewing the adequacy of internal audit function, if any, including the structure of the internal audit department, staffing and seniority of the official heading the department, reporting structure coverage and frequency of internal audit.

(11) Discussion with internal auditors any significant findings and follow up there on.

(12) Reviewing the findings of any internal investigations by the internal auditors into matters where there is suspected fraud or irregularity or a failure of internal control systems of a material nature and reporting the matter to the Board.

(13) Discussion with statutory auditors before the audit commences, about the nature and scope of audit as well as post-audit discussion to ascertain any area of concern.

(14) To look into the reasons for substantial defaults in the payment to the depositors, debenture holders, shareholders (in case of non-payment of declared dividends) and creditors.

(15) To review the functioning of the Whistle Blower mechanism.

(16) Approval of appointment of CFO (i.e., the whole-time Finance Director or any other person heading the finance function or discharging that function) after assessing the qualifications, experience and background, etc. of the candidate.

(17) Valuation of undertakings or assets of the Company, wherever it is necessary.

(18) Scrutiny of inter-corporate loans and investments.

(19) Evaluation of internal financial controls and risk management systems.

(20) Approval or any subsequent modification of transactions of the Company with related parties

(21) To appoint a person having such qualifications and experience and registered as a valuer in such manner, on such terms and conditions as may be prescribed and appointed by the audit Committee for valuation, if required to be made, in respect of any property, stocks, shares, debentures, securities or goodwill or any other assets or net worth of a Company or its liabilities.

(22) To ensure proper system for storage, retrieval, display or printout of the electronic records as deemed appropriate and such records shall not be disposed of or rendered unusable, unless permitted by law provided that the back-up of the books of account and other books and papers of the Company maintained in electronic mode, including at a place outside India, if any, shall be kept in servers physically located in India on a periodic basis.

(23) Reviewing the utilization of loans and/ or advances from/investment by the holding company in the subsidiary exceeding rupees 100 crore or 10% of the asset size of the subsidiary, whichever is lower including existing loans/advances / investments existing as on the date of coming into force of this provision.

(24) Reviewing the compliances under SEBI (Prohibition of Insider Trading) Regulations, 2015, at least once in a financial year and verify that the systems for internal control are adequate and are operating effectively.

(25) To consider and comment on rationale, cost-benefits and impact of schemes involving merger, demerger, amalgamation etc., on the listed entity and its shareholders.

(26) Carrying out any other function as is mentioned in the terms of reference of the Committee.

B. The audit committee shall have powers, which should include the following:

a. To investigate any activity within its terms of reference.
b. To seek information from any employee.
c. To obtain outside legal or other professional advice.
d. To secure attendance of outsiders with relevant expertise, if it considered necessary.

C. The Audit Committee Shall Mandatorily Review The Following Information:

1. management discussion and analysis of financial condition and results of operations;
2. management letters / letters of internal control weaknesses issued by the statutory auditors;
3. internal audit reports relating to internal control weaknesses; and
4. the appointment, removal and terms of remuneration of the chief internal auditor shall be subject to review by the audit committee.
5. statement of deviations:

(a)quarterly statement of deviation(s) including report of monitoring agency, if applicable, submitted to stock exchange(s) in terms of Regulation 32(1).

(b)annual statement of funds utilized for purposes other than those stated in the offer document/prospectus/notice in terms of Regulation 32(7).

D. Internal audit:

The Company has adequate internal control and Internal Audit system commensurate with its size and nature of its business. The Internal Audit Plan is approved by the Audit Committee and the Internal Auditors directly present their report to the Audit Committee for their consideration.

E. Composition, meetings & attendance:

There were four (4) Audit Committee Meetings held during the year on, 30.05.2025, 14.08.2025, 13.11.2025, and 13.02.2026.

Name	Designation	Category	No of Meetings held	No of Meetings attended
Mr. Rajesh kakkera	Chairman	NED(I)	4	4
Mr. M. Madhavarao	Member	NED(I)	4	4
Mr. Addagarla Tarun	Member	NED(I)	4	4

NED (I): Non Executive Independent Director

All the recommendations of the Audit Committee have been accepted by the Board of Directors.

During the year, the Audit Committee inter alia reviewed key audit findings covering Operational, Financial and Compliance areas, Risk Mitigation Plan covering key risks affecting the Company which were presented to the Committee. The Chairman of the Audit Committee briefed the Board members on the significant discussions which took place at Audit Committee Meetings.

The Chairman of the Audit Committee was present at the Annual General Meeting of the Company.

14. Nomination and remuneration committee:

The Nomination and Remuneration Committee ('NRC') functions in accordance with Section 178 of the Act, Regulation 19 of the Listing Regulations and its Charter adopted by the Board.

The NRC is vested with all the necessary powers, authority to identify persons who are qualified to become Directors, Key Managerial Personnel and who may be appointed in senior management in accordance with the criteria laid down, recommend to the Board their appointment and removal, and shall carry out evaluation of every Director's performance.

A. Brief description of terms of reference:

The Nomination and Remuneration Committee set up by the Board is responsible for:

a. Formulation of the criteria for determining qualifications, positive attributes and independence of a director and recommend to the Board a policy, relating to the remuneration of the directors, key managerial personnel and other employees;

b. Formulation of criteria for evaluation of performance of independent directors and the Board;

c. Devising a policy on Board diversity;

d. Identifying persons who are qualified to become directors of the Company and who may be appointed in senior management in accordance with the criteria laid down, and recommend to the Board their appointment and removal. The Company shall disclose the remuneration policy and the evaluation criteria in its annual report;

e. Analysing, monitoring and reviewing various human resource and compensation matters, including the compensation strategy;

f. Determining the Company's policy on specific remuneration packages for executive directors including pension rights and any compensation payment.

g. Recommending the remuneration, in whatever form, payable to non-executive directors and the senior management personnel and other staff (as deemed necessary);

h. Reviewing and approving compensation strategy from time to time in the context of the then current Indian market in accordance with applicable laws;

i. Determining whether to extend or continue the term of appointment of the independent director, on the basis of the report of performance evaluation of independent directors;

j. Perform such functions as are required to be performed by the compensation committee under the Securities and Exchange Board of India (Share Based Employee Benefits and Sweat Equity) Regulations, 2021;

k. Administering the employee stock option scheme/plan approved by the Board and shareholders of the Company in accordance with the terms of such scheme/plan ("ESOP Scheme") including the following:

    i. Determining the eligibility of employees to participate under the ESOP Scheme.
    ii. Determining the quantum of option to be granted under the ESOP Scheme per employee and in aggregate;
    iii. Date of grant;
    iv. Determining the exercise price of the option under the ESOP Scheme;

l. Construing and interpreting the employee stock option scheme/plan approved by the Board and shareholders of the Company in accordance with the terms of such scheme/ plan ("ESOP Scheme") and any agreements defining the rights and obligations of the Company and eligible employees under the ESOP Scheme, and prescribing, amending and/or rescinding rules and regulations relating to the administration of the ESOP Scheme;

m. Framing suitable policies, procedures and systems to ensure that there is no violation of securities laws, as amended from time to time, including:

n. the Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015, as amended; and

o. the Securities and Exchange Board of India (Prohibition of Fraudulent and Unfair Trade Practices Relating to the Securities Market) Regulations, 2003, as amended, by the Company and its employees, as applicable;

p. Performing such other activities as may be delegated by the Board of Directors and/ or are statutorily prescribed under any law to be attended by the Nomination and Remuneration Committee; and

q. Such terms of reference as may be prescribed under the Companies Act, SEBI Listing Regulations or other applicable laws or by any other regulatory authority.

The Nomination and Remuneration Committee, while formulating the above policy, should ensure that:

(i) the level and composition of remuneration be reasonable and sufficient to attract, retain and motivate directors of the quality required to run our Company successfully;

(ii) relationship of remuneration to performance is clear and meets appropriate performance benchmarks; and

(iii) remuneration to directors, key managerial personnel and senior management involves a balance between fixed and incentive pay, reflecting the short and long term performance objectives appropriate to the working of the Company and its goals.

(iv) The conditions under which option may vest in employee and may lapse in case of termination of employment for misconduct;

(v) The exercise period within which the employee should exercise the option and that option would lapse on failure to exercise the option within the exercise period;

(vi) The specified time period within which the employee shall exercise the vested option in the event of termination or resignation of an employee;

(vii) The right of an employee to exercise all the options vested in him at one time or at various points of time within the exercise period;

(viii) Re-pricing of the options which are not exercised, whether or not they have been vested if stock option rendered unattractive due to fall in the market price of the equity shares;

(ix) Re-pricing of the options which are not exercised, whether or not they have been vested if stock option rendered unattractive due to fall in the market price of the equity shares;

(x) The grant, vest and exercise of option in case of employees who are on long leave;

(xi) Allow exercise of unvested options on such terms and conditions as it may deem fit; xii. The procedure for cashless exercise of options;

(xii) Forfeiture/ cancellation of options granted;

(xiii) Formulating and implementing the procedure for making a fair and reasonable adjustment to the number of options and to the exercise price in case of corporate actions such as rights issues, bonus issues, merger, sale of division and others. In this regard following shall be taken into consideration:

- the number and the price of stock option shall be adjusted in a manner such that total value of the option to the employee remains the same after the corporate action;

- for this purpose, global best practices in this area including the procedures followed by the derivative markets in India and abroad may be considered; and the vesting period and the life of the options shall be left unaltered as far as possible to protect the rights of the employee who is granted such option

B. Composition of the committee, meetings and attendance during the year:

There was one Nomination and Remuneration Committee Meetings held during the financial year on 26.02.2026.

Name	Designation	Category	No. of Meetings held	No. of Meetings attended
Mr. Rajesh kakkera	Chairman	NED(I)	1	1
Mr. M. Madhavarao	Member	NED(I)	1	1
Mr. Addagarla Tarun	Member	NED(I)	1	1

NED (I) : Non Executive Independent Director
NED (NI) : Non Executive Non- Independent Director

Performance evaluation criteria for independent directors:

The performance evaluation criteria for Independent Directors are already mentioned under the head "Formal Annual Evaluation/Board Evaluation" in Directors' Report.

<u>Policy for selection of directors and determining directors' independence</u>

Scope:
This policy sets out the guiding principles for the Nomination & Remuneration Committee for identifying persons who are qualified to become Directors and to determine the independence of Directors, in case of their appointment as independent Directors of the Company.

Terms and References:

2.1 **"Director"** means a director appointed to the Board of a Company.

2.2 **"Nomination and Remuneration Committee** means the committee constituted in accordance with the provisions of Section 178 of the Companies Act, 2013 and Reg. 19 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

2.3 **"Independent Director"** means a director referred to in sub-section (6) of Section 149 of the Companies Act, 2013 and Regulation 16(b) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Policy:

1. The Nomination and Remuneration Committee, and the Board, shall review on annual basis, appropriate skills, knowledge and experience required of the Board as a whole and its individual members. The objective is to have a board with diverse background and experience that are relevant for the Company's operations.

2. In evaluating the suitability of individual Board member, the NR Committee may take into account factors, such as:

- General understanding of the company's business dynamics, global business and social perspective;
- Educational and professional background
- Standing in the profession;
- Personal and professional ethics, integrity and values;
- Willingness to devote sufficient time and energy in carrying out their duties and responsibilities effectively.

2.1 The proposed appointee shall also fulfil the following requirements:

- shall possess a Director Identification Number;
- shall not be disqualified under the companies Act, 2013;
- shall endeavour to attend all Board Meeting and Wherever he is appointed as a Committee Member, the Committee Meeting;
- shall abide by the code of Conduct established by the company for Directors and senior Management personnel;
- shall disclose his concern or interest in any company or companies or bodies corporate, firms, or other association of individuals including his shareholding at the first meeting of the Board in every financial year and thereafter whenever there is a change in the disclosures already made;
- Such other requirements as may be prescribed, from time to time, under the companies Act, 2013, SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 and other relevant laws.

3. Criteria of independence

3.1 The Nomination & Remuneration Committee shall assess the independence of Directors at time of appointment/ re-appointment and the Board shall assess the same annually. The Board shall re-assess determinations of independence when any new interest or relationships are disclosed by a Director.

3.2 The criteria of independence shall be in accordance with guidelines as laid down in companies Act, 2013 and Regulation 16(b) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

3.3 The independent Director shall abide by the "code for independent Directors "as specified in Schedule IV to the companies Act, 2013.

4. Other directorships/ committee memberships

4.1 The Board members are expected to have adequate time and expertise and experience to contribute to effective Board performance. Accordingly, members should voluntarily limit their directorships in other listed public limited companies in such a way that it does not interfere with their role as director of the company. The NR Committee shall take into account the nature of and the time involved in a director's service on other Boards, in evaluating the suitability of the individual Director and making its recommendations to the Board.

4.2 A Director shall not serve as director in more than 20 companies of which not more than 10 shall be public limited companies.

4.3 A Director shall not serve as an independent Director in more than 7 listed companies and not more than 3 listed companies in case he is serving as a whole-time Director in any listed company.

4.4 A Director shall not be a member in more than 10 committees or act as chairman of more than 5 committee across all companies in which he holds directorships.

For the purpose of considering the limit of the committee, Audit committee and stakeholder's relationship committee of all public limited companies, whether listed or not, shall be included and all other companies including private limited companies, foreign companies and companies under section 8 of the companies Act, 2013 shall be excluded

15. Stakeholders' relationship committee:

A. Brief description of terms of reference:

Terms of reference of the committee comprise of various matters provided under Regulation 20 of the Listing Regulations and section 178 of the Act, 2013 which inter-alia include:

(a) Redressal of all security holders' and investors' grievances such as complaints related to transfer of shares, including non-receipt of share certificates and review of cases for refusal of transfer/transmission of shares and debentures, dematerialisation and re-materialisation of shares, non-receipt of balance sheet, non-receipt of declared dividends, non-receipt of annual reports, etc., assisting with quarterly reporting of such complaints and formulating procedures in line with statutory guidelines to ensure speedy disposal of various requests received from shareholders;

(b) Reviewing of measures taken for effective exercise of voting rights by shareholders;

(c) Investigating complaints relating to allotment of shares, approval of transfer or transmission of shares, debentures or any other securities;

(d) Giving effect to all transfer/transmission of shares and debentures, dematerialisation of shares and re-materialisation of shares, split and issue of duplicate/consolidated share certificates, compliance with all the requirements related to shares, debentures and other securities from time to time.

(e) Reviewing the measures and initiatives taken by the Company for reducing the quantum of unclaimed dividends and ensuring timely receipt of dividend warrants/annual reports/statutory notices by the shareholders of the Company;

(f) Reviewing the adherence to the service standards by the Company with respect to various services rendered by the registrar and transfer agent of our Company and to recommend measures for overall improvement in the quality of investor services;

(g) Carrying out such other functions as may be specified by the Board from time to time or specified/provided under the Companies Act or SEBI Listing Regulations, or by any other regulatory authority;

(h) To approve allotment of shares, debentures or any other securities as per the authority conferred / to be conferred to the Committee by the Board of Directors from time to time;

(i) To approve requests for transfer, transposition, deletion, consolidation, sub-division, change of name, dematerialization, rematerialisation etc. of shares, debentures and other securities;

(j) To monitor and expedite the status and process of dematerialization and rematerialisation of shares, debentures and other securities of the Company; and

(k) Such terms of reference as may be prescribed under the Companies Act and SEBI Listing Regulations

B. Composition of the committee, meetings and attendance during the year:

There were Four (4) Stakeholders' relationship Committee Meetings held during the year on 30.05.2025, 14.08.2025, 13.11.2025, and 13.02.2026.

Name	**Designation**	**Category**	**No of Meetings held**	**No of Meetings attended**
Mr. M. Madhavarao	Chairman	NED(I)	4	4

Mr. Rajesh kakkera	Member	NED(I)	4	4
Mrs. Padma Ghanakota	Member	NED (NI)	4	4

NED (I) **:** Non Executive Independent Director
NED (NI) **:** Non Executive Non- Independent Director

C. Details of complaints/requests received, resolved and pending during the year 2025-26:

Opening balance	Received during the year	Resolved during the year	Closing balance
0	**0**	**0**	**0**

D. Name and designation of compliance officer:

Mrs. T. Abhilash was the company secretary and compliance officer of the company,

16. Pecuniary relationship or transactions of the non-executive directors vis-à-vis the listed company:

None of the Non-Executive Directors except Mrs. Padma Ghanakota had any pecuniary relationship or transaction with the company as she is a non-executive director and promoter of the company.

A. Criteria for making payments to non-executive directors:

Policy:

1. Remuneration to Executive Director and key managerial personnel

1.1 The Board on the recommendation of the Nomination and Remuneration (NR) committee shall review and approve the remuneration payable to the Executive Director of the company within the overall limit approved by the shareholders.

1.2 The Board on the recommendation of the NR committee shall also review and approve the remuneration payable to the key managerial personnel of the company.

1.3 The remuneration structure to the Executive Director and key managerial personnel shall include the following components:

(i) Basic pay
(ii) Perquisites and Allowances
(iii) Stock Options
(iv) Commission (Applicable in case of Executive Directors)
(v) Retrial benefits

1.4 The Annual plan and Objectives for Executive committee shall be reviewed by the NR committee and Annual performance Bonus will be approved by the committee based on the achievement against the Annual plan and Objectives.

2.Remuneration to Non – Executive Directors

2.1 The Board, on the recommendation of the NR Committee, shall review and approve the remuneration payable to the Non – Executive Directors of the Company within the overall limits approved by the shareholders.

2.2 Non – Executive Directors shall be entitled to sitting fees attending the meetings of the Board and the Committees thereof. The Non- Executive Directors shall also be entitled to profit related commission in addition to the sitting fees.

3. Remuneration to other employees

3.1. Employees shall be assigned grades according to their qualifications and work experience, competencies as well as their roles and responsibilities in the organization. Individual remuneration shall be determined within the appropriate grade and shall be based on various factors such as job profile skill sets, seniority, experience and prevailing remuneration levels for equivalent jobs.

17. Independent directors' meeting:

As per clause 7 of the schedule IV of the Companies Act (Code for Independent Directors), a separate meeting of the Independent Directors of the Company (without the attendance of Non-Independent directors) was held on 13.02.2026, to discuss:

1. Evaluation of the performance of Non-Independent Directors and the Board of Directors as whole;

2. Evaluation of the quality, content and timelines of flow of information between the management and the Board that is necessary for the Board to effectively and reasonably perform its duties.

As required under Regulation 34(3) read with Schedule V of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, the company regularly familiarizes Independent Directors with the Company, their roles, rights, responsibilities in the company, nature of the industry in which the company operates, business model of the company etc. The detail of the familiarization program is given at company's website (www.sangamhealthcare.co.in).

18. Policy for selection of directors and determining directors' independence:

1. Scope:

This policy sets out the guiding principles for the Nomination & Remuneration Committee for identifying persons who are qualified to become Directors and to determine the independence of Directors, in case of their appointment as independent Directors of the Company.

2. Terms and References:

2.1 "Director" means a director appointed to the Board of a Company.

2.2 "Nomination and Remuneration Committee means the committee constituted in accordance with the provisions of Section 178 of the Companies Act, 2013 and Regulation 19 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015.

2.3 "Independent Director" means a director referred to in sub-section (6) of Section 149 of the Companies Act, 2013 and Regulation 16 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015.

Remuneration policy for Directors, key managerial personnel and other employees:

1. Scope:

1.1 This policy sets out the guiding principles for the Nomination and Remuneration committee for recommending to the Board the remuneration of the directors, key managerial personnel and other employees of the company.

2. Terms and Reference:
In this policy the following terms shall have the following meanings:

2.1 "Director" means a director appointed to the Board of the company.

2.2 "Key Managerial Personnel" means

(i) The Chief Executive Office or the Managing Director or the Manager;
(ii) The Company Secretary;
(iii) The Whole-Time Director;
(iv) The Chief Finance Officer; and
(v) Such other office as may be prescribed under the companies Act, 2013

2.3 "Nomination and Remuneration committee" means the committee constituted by Board in accordance with the provisions of section 178 of the Companies Act, 2013 and Regulation 19 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015.

19. Non-executive directors' compensation and disclosures:

None of the Independent/Non-Executive Directors has any pecuniary relationship or transactions with the Company which in the Judgment of the Board may affect the independence of the Directors.

20. Number of shares and convertible instruments held by non-executive directors:

None of the Non-executive Director of the Company holds equity shares of the Company.

21. Disclosure of commodity price risks and commodity hedging activities:

Price and demand of the Company's finished products are inherently volatile and remain strongly influenced by global economic conditions. Any fluctuation in finished product prices or currency has direct impact on the Company's revenue and profits.

The Company considers exposure to commodity price fluctuations to be an integral part of our business and its usual policy is to sell its products at prevailing market prices. The Company has a well-defined policy framework wherein no speculative positions are taken and limited commodity hedging is done with endeavours to achieve month-average rates both in currency and metal prices. The Company follows the policy of taking forward cover for net foreign exposure, if the net is payable in foreign currency, with negligible exposure in non USD currencies All policies are periodically reviewed basis local and global economic environment.

22. Details on General Body Meetings:

A. Location, date and time of last three AGMs and special/ordinary resolutions there at as under:

Financial Year	Date	Time	Location	Special / Ordinary Resolution
2024-25	30.09.2025	09.00 AM	Survey No.182, Yellampet Village, Medchal Mandal, Medchal District, Telangana-501401	3 Ordinary Resolution
2023-24	30.09.2024	09.00 AM	Survey No.182, Yellampet Village, Medchal Mandal, Medchal District, Telangana-501401	2 Ordinary Resolution
2022-23	30.09.2023	09.00 AM	Survey No.182, Yellampet Village, Medchal Mandal, Medchal District, Telangana-501401	2 Ordinary Resolution

23. Passing of Resolutions by Postal Ballot

There were no resolutions passed by the Company through Postal Ballot during the financial year 2025-26.

24. Means of Communication:

The Company regularly intimates its financial results, audited/limited reviewed, to the Stock Exchanges, as soon as the same are taken on record/approved. These results are not distributed/ sent individually to the shareholders.

In terms of the requirements of SEBI (Listing Obligations & Disclosures Requirements), the un-audited financial results as well as audited financial results, shareholding pattern of the Company and Corporate Governance Report are electronically submitted, unless there are technical difficulties and are displayed through Corporate.

Filing and Dissemination System viz., on www.listing.bseindia.com.The un-audited financial results as well as audited financial results, shareholding pattern of the Company and Report on Corporate Governance are displayed on www.bseindia.com.

All important information and official press releases are displayed on the website for the benefit of the public at large. Analysts 'Reports/ Research Report, if any, are also uploaded on the website of the Company. The Company's website can be accessed at *www.sangamhealthcare.co.in*.

25. General shareholder information:

A. Annual General Meeting:

The 32nd Annual General Meeting of the Company will be held as per the following schedule:

Day	**Wednesday**
Date	30.09.2026
Time	09.00 A.M.
Venue	At the Registered Office of the Company

B. Venue: Financial Year and Financial Year Calendar 2026-27 (Tentative Schedule)

The financial calendar (tentative) shall be as under:

Financial Year	2026-27
First Quarterly Results	14.08.2026
Second Quarterly Results	14.11.2026
Third Quarterly Results	14.02.2027
Fourth Quarterly Results	29.05.2027
Annual General Meeting for year ending 31st March, 2026	30.09.2027

C. Dividend Payment Date: No Dividend is declared during the Financial Year 2025-26.

D. name and address of stock exchange where the companies securities were listed:

E. Listing On Stock Exchanges: The equity shares of the Company are listed on BSE Ltd. The Company has paid the listing fees for the year 2025-26 to BSE Limited.

G. Registrar and share transfer agents:

M/s. XL SOFTECH SYSTEMS LTD.
3, Sagar Society, Road No.2,
Banjara Hills, Hyderabad
Phone # 040-23545913/14/15
Email: xlfield@rediffmail.com
xlfield@gmail.com

I. Share transfer system:

Shares received for transfer by the Company or its Registrar and Share Transfer Agent in physical mode are processed and all valid transfers are approved. The share certificate(s) is/are duly transferred and dispatched within a period of 15 days from the date of receipt.

J. Distribution of shareholding as on 31st march, 2026:

Category	Number of shareholders	%	Number of shares	Amount	%
1 - 5000	343	53.85	152310	1523100	1.02
5001 - 10000	140	21.98	130100	1301000	0.88
10001 - 20000	29	4.55	47600	476000	0.32
20001 - 30000	52	8.16	128400	1284000	0.86
30001 - 40000	2	0.31	7600	76000	0.05
40001 - 50000	19	2.98	89300	893000	0.60
50001 - 100000	17	2.67	1527200	15272000	1.03
100001 & Above	35	5.49	14152690	141526900	95.24
Total:	**637**	**100.00**	**14860700**	**148607000**	**100.00**

K. Dematerialisation & liquidity of shares:

Trading in Company's shares is permitted only in dematerialized form for all investors. The ISIN allotted to the Company's scrip is INE431E01011. The Company is not having demat facility with NSDL. Investors are therefore advised to open a demat account with a Depository participant of their choice to trade in dematerialized form. Shares held in demat and Physical mode as on March 31, 2026 is as follows:

Particulars	No. of Shares	% Share Capital
NSDL	100506	0.68
CDSL	11222824	75.52
PHYSICAL	3537370	23.80
Total	**14860700**	**100**

To enable us to serve our investors better, we request shareholders whose shares are in the physical mode to dematerialize their shares and update their bank accounts with respective depository participants.

L. Plant locations:

1. Survey no.182, Yellampet Villiage, Medchal Mandal, Medchal, Malkajgiri District.

2. Survey No.189/A, Durshed Village , Karimnagar District.

M. Address for Correspondance: 205 & 206, Amarchand Sharma Complex, S.P. Road, Secunderabad- 500002 Telangana.

N. Book Closure Date: The date of Book Closure for the purpose of Annual General Meeting shall be from 24.09.2026 to 30.09.2026 (both days inclusive)

O. Electronic Connectivity: Demat ISIN Number: INE431E01011

P. Central Depository Services (India) Limited

Marathon Futurex, A-Wing,
25th floor, NM Joshi Marg,
Lower Parel, Mumbai 400013

Q. Shareholding pattern as on 31st march, 2026:

S. No	Category	No. of shares held	% of shareholding

A	**Shareholding of Promoter and Promoter group**		
1.	Indian	-	-
	Individual	10420940	70.12
2.	Foreign	-	-
	Individual	-	-
	Sub-Total A	**10421030**	**70.12**
B	**Public Shareholding**	-	-
1.	Institutions	1253000	8.43
2.	**Non Institutions** a. Bodies Corporate b. Non-Resident Indian (NRI) c. Others	**3186760** 1596750 10000 1580010	**21.44** 10.75 0.07 10.63
	Sub Total B	**3186760**	**21.44**
	Grand Total (A+B)	**14860700**	**100.00**

26. Other disclosures:

a) **disclosures on materially significant related party transactions that may have potential conflict with the interests of listed entity at large;** Not applicable

b) **Non-Compliances by the Company:**

During the last three years and during the Financial Year 2025-26, there were penalties imposed on the Company BSE, or any other statutory authority for non-compliance of any matter related to capital markets.

c) Vigil Mechanism and Whistle Blower Policy:

In Compliance with the provisions of section 177 of the Act and Regulation 22 of SEBI Listing Regulations, the Company has in place the Whistle Blower Policy and Vigil Mechanism for Directors, employees and other stakeholders which provides a platform to them for raising their voice about any breach of code of conduct, financial irregularities, illegal or unethical practices, unethical behaviour, actual or suspected fraud. Adequate safeguards are provided against victimization to those who use such mechanism and direct access to the Chairman of the Audit Committee in appropriate cases is provided. During the year under review, no employee was denied access to the Audit Committee.

The policy on Vigil Mechanism and Whistle Blower Policy has been posted on the website of the Company and can be accessed through the following link: https://www.sangamhealthcare.co.in/

d) Details of compliance with mandatory requirements on Corporate Governance under the SEBI Listing Regulations:

The Company has complied with the mandatory requirements on Corporate Governance under the SEBI Listing Regulations.

e) web link where policy on dealing with related party transactions; https://www.sangamhealthcare.co.in/

f) **disclosure of commodity price risks and commodity hedging activities.** Not Applicable

g) Details of utilisation of funds raised through preferential allotment or qualified institutions placement as specified under Regulation 32 (7A)

During the Financial Year 2025-26, the Company has not raised funds through preferential allotment and qualified institutions placement.

h) Practicing company secretary certification:

A certificate from a Company Secretary in Practice that as on March 31, 2026, none of the directors on the board of the company have been debarred or disqualified from being appointed or continuing as directors of Company by the Securities and Exchange Board of India/ Ministry of Corporate Affairs or any such statutory authority is annexed to this Report as Annexure - 2

i) Recommendation of Committee(s) of the Board of Directors

During the year, all recommendations of Committees of Board of Directors, were accepted by the Board

j) Total fee for all services paid by the listed entity and its subsidiaries on a consolidated basis, to the statutory auditor and all entities in the network firm/ network entity of which the statutory auditor is a part;

Payment to Auditors	**Amount in Rs.(INR)**
Statutory Audit fees including limited review	2,00,000
Certification & other attest services	NIL
Non–audit services	NIL
Outlays and Taxes	NIL

k) Disclosures in relation to the Sexual Harassment of Women at Workplace (Prevention, Prohibition and Redressal) Act, 2013:

The Company has established an appropriate mechanism for dealing with complaints in relation to Sexual Harassment of Women at Workplace, in accordance with its Policy on Prevention of Sexual Harassment at Workplace ('POSH') which is available on the website of the Company. There was on Complaints received during the financial year.

l) Loans and Advances in the nature of Loans to Firms/ Companies in which Directors are interested by name and amount.

The details of loans and advances in the nature of loans to firms/ companies in which Directors are interested, being disclosed in Note 12 to the Standalone Financial Statements of the Company forming part of the Annual Report.

m) Details of material subsidiaries of the listed entity; including the date and place of incorporation and the name and date of appointment of the statutory auditors of such subsidiaries. Not applicable

n) Non-compliance of any requirement of corporate governance report of sub-paras (2) to (10) of schedule-V:

The company has complied with the requirement of Corporate Governance Report of sub–paras (2) to (10) of Schedule–V of the Securities Exchange Board of India (LODR) Regulations, 2015.

o) Adoption of discretionary requirements as specified in part e of schedule ii of the securities and exchange board of india (listing obligations and disclosure requirements) regulations, 2015:

With regard to discretionary requirements, the Company has adopted clauses relating to the internal auditor directly reporting to the Audit Committee.

p) the disclosures of the compliance with corporate governance requirements specified in regulation 17 to 27 and clauses (b) to (i) of sub-regulation (2) of regulation 46 are as follows:

Regulation	Particulars of Regulations	Compliance status (Yes/No)
17	Board of Directors	Yes
18	Audit Committee	Yes
19	Nomination and Remuneration Committee	Yes
20	Stakeholders Relationship Committee	Yes
21	Risk Management Committee	Yes
22	Vigil mechanism	Yes

23	Related Party Transactions	Yes
24	Corporate Governance requirement with respect to subsidiary of listed entity	Yes
25	Obligations with respect to Independent Directors	Yes
26	Obligation with respect to Directors and senior management	Yes
27	Other Corporate Governance requirements	Yes. Regulation 46(2)(b) to (i) Functional Website

27. Disclosures with respect to demat suspense account/ unclaimed suspense account.

There are no shares which are lying in demat suspense account/ unclaimed suspense account as on March 31, 2026+.

28. Disclosure of certain types of agreements binding listed entities:

There are no agreements that require disclosure under clause 5A of paragraph A of Part A of Schedule III of the Listing Regulations.

29. Insider Trading:

In terms of the SEBI (Prohibition of Insider Trading) Regulations 2015 (“PIT Regulations”), the Company has a comprehensive Code of Conduct for regulating, monitoring and reporting of trading by Insiders. The said Code lays down guidelines which provide for the procedure to be followed and disclosures whilst dealing with shares of the Company. Further, in terms of the PIT Regulations, the Company has in place a Code of Practices and Procedures of Fair Disclosures of Unpublished Price Sensitive Information.

30. Board Procedures:

The Board meets at least once in a quarter to review financial results and operations of the Company. In addition to the above, the Board also meets as and when necessary to address specific issues concerning the businesses of your Company

The Board Meetings are governed by a structured Agenda. The agenda along with detailed explanatory notes and supporting material are circulated in advance before each meeting to all the Directors for facilitating effective discussion and decision making. The Board has access to any information within your Company which includes the information as specified in Schedule II of the SEBI Listing Regulations.

31. Independent Directors' Meeting:

In accordance with the provisions of Schedule IV (Code for Independent Directors) of the Companies Act, 2013 and Regulation 25 of the SEBI Listing Regulations, a meeting of the Independent Directors of the Company was held on February 13, 2026 without the presence of Non-Independent Directors and Company's Management.

The Company Secretary was an invitee to the said meeting and acted as a facilitator to the Independent Directors.

32. Mandatory requirements:

To the extent applicable, during the year under review the Company has complied all the mandatory requirements of the SEBI Listing Regulations.

33. Disclosure of Accounting Treatment:

The Company has complied with the appropriate accounting policies and has ensured that they have been applied consistently. There have been no deviations from the Indian Accounting Standards prescribed under section 133 of the Companies Act, 2013 read with relevant rules.

34. Non- mandatory requirements:

The Company has adopted the following non-mandatory requirements on Corporate Governance:-

35. Audit qualifications:

There was no audit qualification on your Company's financial statements, during the year under review.

36. Code of Conduct:

The Board of Directors has laid down a Code of Conduct, which is applicable to all Directors and Senior Management Personnel of the Company. The Code has also been posted on the website of the Company

All Board Members and Senior Management Personnel have affirmed with the compliance of Code of Conduct for the Financial Year 2025-26.

An annual declaration signed by the Chairman & Managing Director of the Company affirming compliance to the Code by the Board of Directors and the Senior Management is annexed to this Report as Annexure - 10. The Code of Conduct is available on website of the Company and can be accessed through the following link: https://www.sangamhealthcare.co.in/.

37. CEO/ CFO Certification

In terms of regulation 17(8) of the Listing Regulations, the CFO made a certification to the Board of Directors which has been reviewed by the Audit Committee and taken on record by the Board and enclosed as Annexure-9 to this Annual Report.

For and on behalf of the Board of Directors
Sangam Health Care Products Limited

	Sd/-	Sd/-
Place: Secunderabad	D. Bhagat Reddy	Padma Ghanakota
Date: 13.08.2026	Managing Director	Director
	DIN: 07087331	DIN: 07078176

Declaration Code of Conduct as required by schedule V of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015

I, D. Bhagat Reddy, Managing Director of the Company hereby declare that all the members of Board of Directors and Senior Management Personnel have affirmed compliance with Code of Conduct, as applicable to them, in respect of the financial year 2025-26.

For and on behalf of the Board of Director
Sangam Health Care Products Limited

Sd/-
D. Bhagat Reddy
Managing Director
DIN: 07087331

Place: Secunderabad
Date: 13.08.2026

CEO/CFO Certification Pursuant to regulation 17 (8) of SEBI (Listing Obligations & Disclosure Requirements), Regulations, 2015

To
The Board of Directors
Sangam Health Care Products Limited

We, Bhagat Reddy Dundumulla, Managing Director and Vijay Rayapa Reddy Tumma, Chief Financial Officer of Sangam Health Care Products Limited ("Company") to the best of our knowledge and belief certify that:

We have reviewed standalone as well as consolidated financial statements and the cash flow statement of the Company for the quarter/year ended 31st March, 2025 and to the best of their knowledge and belief:

a. these statements do not contain any materially untrue statement or omit any material fact or contain statements that might be misleading;

b. these statements together present a true and fair view of the listed entity's affairs and are in compliance with existing accounting standards, applicable laws and regulations.

c. There are, to the best of our knowledge and belief, no transactions entered into by the Company during the year which are fraudulent, illegal or violative of the Company code of conduct.

d. We accept responsibility for establishing and maintaining internal controls for financial reporting and that they have evaluated the effectiveness of internal control systems of the Company pertaining to financial reporting and we have disclosed to the auditors and the audit committee, deficiencies in the design or operation of such internal controls, if any, of which we are aware and the steps we have taken or propose to take to rectify these deficiencies.

e. We have indicated to the auditors and the Audit committee

f. There have not been any significant changes in internal control over financial reporting during the year;

g. There have not been any significant changes in accounting policies during the year and that the same have been disclosed in the notes to the financial statements; and

h. There have not been any instances of significant fraud of which we have become aware and the involvement therein, if any, of the management or an employee having a significant role in the Company's internal control system over financial reporting.

	Sd/-	Sd/-
Place: Secunderabad	Bhagat Reddy Dundumulla	S Vijayagowri Satyabhavani
Date: 13.08.2026	Chairperson & MD	Chief Financial Officer (CFO)

Annexure-10

DECLARATION REGARDING COMPLIANCE BY BOARD MEMBERS AND SENIOR MANAGEMENT PERSONNEL WITH THE COMPANY'S CODE OF CONDUCT

This is to confirm that the Company has obtained from all the Members of the Board and Senior Management Personnel affirmation that they have complied with the Code of Conduct for Directors and Senior Management Personnel as required under Regulation 26(3) of the Listing Regulations for the FY 2025-26.

For and on behalf of the Board of
Sangam Health Care Products Limited

Sd/-
Bhagat Reddy Dundumulla
Managing Director
DIN: 07087331

Place: Hyderabad
Date: 13.08.2026

Certificate of Non-Disqualification of Directors

[Pursuant to Regulation 34(3) and Schedule V Para C clause (10)(i) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015]

To,
The Board of Directors
Sangam Health Care Products Limited
Survey No.182, Yellampet Village,
Medchal Mandal, Medchal District,
Telangana, 501401

I have examined the relevant registers, records, forms, returns and disclosures received from Sangam Health Care Products Limited having CIN L24230TG1993PLC016731 and having registered office at Survey No.182, Yellampet Village, Medchal Mandal, Medchal District, Telangana, 501401 (hereinafter referred to as 'the Company'), produced before me by the Company for the purpose of issuing this Certificate, in accordance with Regulation 34(3) read with Schedule V Para-C Sub clause 10 (i) of the Securities Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

In my opinion and to the best of my information and according to the verifications (including Directors Identification Number (DIN) status at the portal www.mca.gov.in) as considered necessary and explanations furnished to me by the Company & its officers, I hereby certify that none of the Directors on the Board of the Company as stated below for the Financial Year ending on March 31st, 2026 have been debarred or disqualified from being appointed or continuing as Directors of companies by the Securities and Exchange Board of India, Ministry of Corporate Affairs, or any such other Statutory Authority.

S. No	**DIN No**	**Name of the Director**	**Designation**
1.	07087331	Mr. D. Bhagat Reddy	Managing Director
2.	07078176	Mrs. Padma Ghanakota	Non-Executive Director
3.	07003946	Mr. A. Sai Balaji Krishna Teja	Non-Executive Director
4.	07931218	Mr. Rajesh Kakkera	Independent Director
5.	07931672	Mr. M. Madhavarao	Independent Director
6.	07003887	Mr. Addagarla Tarun	Independent Director

Ensuring the eligibility of for the appointment/continuity of every Director on the Board is the responsibility of the management of the Company. Our responsibility is to express an opinion on these based on our verification. This certificate is neither an assurance as to the future viability of the Company nor of the efficiency or effectiveness with which the management has conducted the affairs of the Company.

For Chakravarthy & Associates
Practicing Company Secretaries

Sd/-
CS N Phani Chakravarty
Practicing Company Secretary
M. No. 32380 & C.P. No. 22563
Peer Review No: 6621/2025

Date: 13.08.2026
Place: Hyderabad
UDIN: A032380H001430414

COMPLIANCE CERTIFICATE ON CORPORATE GOVERNANCE

To
The Members of
Sangam Health Care Products Limited
Hyderabad

We have examined the compliance of conditions of Corporate Governance by Sangam Health Care Products Limited (‘the Company’), for the Financial Year ended 31st March 2026, as stipulated in regulations 17 to 27 and clauses (b) to (i) of regulation 46(2) and para C, D and E of Schedule V of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (the Listing Regulations).

We have conducted our examination on the basis of the relevant records and documents maintained by the Company and furnished to us for the purpose of the review and the information and explanations given to us by the Company during the course of such review.

The compliance of conditions of Corporate Governance is the responsibility of the management. My examination was limited to a review of procedures and implementation thereof, adopted by the Company for ensuring the compliance with the conditions of Corporate Governance. It is neither an audit nor an expression of opinion on financial statements of the Company.

In our opinion and to the best of our information and according to the explanations given to us and the representations made by the Directors and the Management of the Company, we certify that the Company has in all material respect complied with the conditions of Corporate Governance as stipulated in the above-mentioned SEBI Listing Regulations, as applicable.

I further state that such compliance is neither an assurance as to the future viability of the Company nor the efficiency or effectiveness with which the management has conducted the affairs of the Company.

For Chakravarthy & Associates
Practicing Company Secretaries

Sd/-
CS N Phani Chakravarty
Practicing Company Secretary
M. No. 32380 & C.P. No. 22563
Peer Review No: 6621/2025

Date: 13.08.2026
Place: Hyderabad
UDIN: A032380H001430326

MANAGEMENT'S DISCUSSION AND ANALYSIS REPORT

1. Overview:

Sangam Health Care Products Limited is a small-cap manufacturer of medical disposables and surgical products under the "SAFTI" brand, with significant distribution across India's hospitals and clinics. The portfolio includes syringes, infusion sets, sterile needles, catheters, cannulas, and specialized Ayurvedic and nutraceutical products—serving both institutional and retail customers. Expansion of product range is ongoing, with new launches targeted to higher-margin segments and hospitals.

2. Economy – review and out look:

The year gone by was a challenging one for the Indian Pharmaceutical Industry as it faced couple of challenges during the year impacting its growth. National Pharmaceutical Pricing Authority (NPPA) announced reduction in the prices of more drugs in the beginning of the financial year affecting the pricing of such drugs adversely. As a result of this, portfolio of products under the National List of Essential Medicines (NLEM) de-grew in value terms though it registered value growth during the year.

3. Opportunities & threats:

The pharmaceutical industry is highly competitive and the challenges are from both the Indian manufacturers who have similar production facilities as well as those abroad. Human resources with similar skills, talent and experiences in the industry are mobile between competing companies. Price pressures from foreign players are expected to stay. Going forward, there is a risk of inability to maintain current margins on its products. Price sensitivities get tested in a crowded market where price tends to sag while volume business gets done. Competing pharmaceutical companies have several similar bio-equivalent products in the same market manufactured at facilities that have been approved by the highest regulatory authorities. All of them stay focused in the same markets resulting in price elasticity being tested and margins eroding.

4. Segment wise / product wise performance:

The Company manufactures IV sets, Disposable Syringes and Disposable Needles. The Annual Capacity of IV sets is 40 millions, Disposables Syringes is 264 Millions and Disposable Needles is 135 Millions per Annum. As the Company has completed the de-bottlenecking of the IV sets, Capacity is increased to 40 millions from July 07 onwards.

5. Outlook:

Healthcare should be extended to the people at an affordable cost and the industry needs to set its priorities straight by treating healthcare activity as a service activity rather than a business activity.

Our Company has emerged as one of the leaders in the Medical Disposables market and it’s continuous efforts for a strong presence in the domestic market. There has been growing awareness among the end users about the threats posed while using Low Quality Infusion sets produced and marketed by the Unorganized Sector. There were conscious efforts from the government which helped the cause more. The share of unorganized sector is falling drastically and there was a corresponding spurt in the demand for quality products in addition to the normal increase in demand.

The Company is making all efforts to meet the increase in demand for our products.

6. Risks:

There is no visible silver lining in the job market yet. With government extending price controls over the medical devices and proposing generic prescriptions, healthcare industry foresee millions of employees losing jobs in the next two years.

7. Internal Control Systems:

The Company has sound and adequate internal control systems commensurate with its size and nature of business. We constantly upgrade our systems for incremental improvements, because we firmly believe that ‘change is the only permanent thing’. The Audit Committee of the Board periodically reviews these systems. These systems ensure protection of assets and proper recording of transactions and timely reporting.

8. Financial Performance:

The financial performance of the company has been discussed in detail in Auditors report attached to it.

9. Human Resources:

Sangam is a professionally managed company with high competent and committed industry professionals forming a tight-knit team of dedicated colleagues. The corporate promises to focus on performing and delivering on patient safety.

The knowledge, expertise and skills of the team form a strong foundation of the Company's progress, and hence considerable strategic emphasis is laid at people development and leadership. The overall target is to enhance business growth by enabling engagement and performance. This is achieved by having the right people supported by leadership of able management working together towards organizational goals. Appreciation for the support and co-operation that the company received from the customers, auditors, consultants and all other associated with the company.

The company always looked upon them as partners in its progress and has happily shared the rewards of growth. It will be the company's endeavour to build and nurture strong links with trade based on mutuality, respect and co-operation.

10. Strategic initiatives:

Capacity & Expansion

- Expansion of product range targeting hospitals and healthcare facilities, with focus on essential and safety devices.

- Investments in automation and process streamlining yielded improvements in operational efficiency.

- No change in the nature of business during the year; the company remained focused on its core products.

Technology & Specializations

- Investments in digital health, telemedicine, hospital automation, and AI-driven diagnostics are improving patient outcomes and operational efficiency.

- Specializations—oncology (now 26% of revenue for some chains), orthopedics, and gastroenterology—drive premium pricing and higher margins.

Partnerships & Medical Tourism

- Increasing medical tourism with cost advantage relative to Western markets; infrastructure investments attract Middle East/African patients.

- Joint ventures with pharma and diagnostic firms enhance integrated health offerings.

Risks & Mitigation

- Infrastructure Shortage: 2 billion sq. ft gap in hospital space; mitigated through capex and public-private partnerships.

- Regulatory changes (pricing, insurance) may pressure margins; companies adapt through scale, efficiency, and specialty focus.

- Out-of-pocket expenses remain high due to slow insurance adoption, a systemic sector risk.

11. Details of any change in return or net worth as compared to the immediately previous financial year:

Ratios		
Particulars	**2025-26**	**2024-25**
Key Profitability Ratios		
Operating Profit Margin	2.49%	2.33%
Net Profit Margin	0.44%	3.61
Pat / Net Worth (ROE) (Rs. in Lacs)	--	44.97
key capital structure ratios		
Net Debt / Equity Ratio	(1.57)	(1.57)
Current Ratio	0.79	0.69
Debt Service Coverage Ratio	257	292.45
Interest Coverage Ratio	--	5.51
Debtors Turnover Ratio	--	6.41
Stock Turnover Ratio	--	4.37

FORM MR-3
Secretarial Audit Report
(Pursuant to section 204(1) of the Companies Act, 2013 and
Rule 9 of the Companies (Appointment and Remuneration Personnel) Rules, 2014
for the financial year ended 31st March, 2026

To
The Members of
M/s. Sangam Health Care Products Limited

We have conducted the secretarial audit of the compliance of applicable statutory provisions and the adherence to good corporate practices by M/s. Sangam Health Care Products Limited (hereinafter called “the Company”). Audit was conducted in a manner that provided us a reasonable basis for evaluating the corporate conducts/statutory compliances and expressing my opinion thereon.

Management’s Responsibility for Secretarial Compliances:

The Company’s Management is responsible for preparation and maintenance of secretarial records and for devising proper systems to ensure compliance with the provisions of applicable laws and regulations.

Auditor’s Responsibility:

My responsibility is to express an opinion on the secretarial records, standards and procedures followed by the Company with respect to secretarial compliances.

I believe that audit evidence and information obtained from the Company’s management is adequate and appropriate for me to provide a basis for my opinion.

Based on our verification of the Company’s Books, Papers, Minute Books, Forms and Returns filed and other Records maintained by the Company and also the information provided by the Company, its officers, agents and authorized representatives during the conduct of secretarial audit, we hereby report that in our opinion, the company has, during the financial year commencing from 1st April, 2025 and ended 31st March, 2026, complied with the statutory provisions listed hereunder and also that the Company has proper Board process and compliance mechanism in place to the extent, in the manner and subject to the reporting made hereinafter:

1. I have examined the books, papers, minute books, forms and returns filed and other records maintained by M/s. Sangam Health Care Products Limited (“The Company”) for the financial year ended on 31st March, 2026, according to the provisions of:

   a. The Companies Act, 2013 (the Act) and the rules made there under;

b. The Securities Contracts (Regulation) Act, 1956 ('SCRA') and the Rules made there under;

c. The Depositories Act, 1996 and the Regulations and Bye-laws framed there under.

d. Foreign Exchange Management Act, 1999 and the Rules and Regulations made there under to the extent of Foreign Direct Investment (FDI) and Overseas Direct Investment and External Commercial Borrowings;

2. The following Regulations and Guidelines prescribed under the Securities and Exchange Board of India Act, 1992 ('SEBI Act') is furnished hereunder for the financial year 2024-25: -

a. The Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011; **including the provisions with regard to disclosures and maintenance of records required under the said Regulations;**

b. The Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015 and Amended Regulations 2018;

c. The Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018 - **Not Applicable as there was no reportable event during the financial year under review;**

d. Securities and Exchange Board of India (Share Based Employee Benefits and Sweat Equity) Regulations, 2021; **Not Applicable as the Company has not issued any Employee Stock Options during the year under review.**

e. The Securities and Exchange Board of India (Issue and Listing of Non-Convertible Securities) Regulations, 2021: **Not Applicable as the Company has not issued any debt securities during the year under review.**

f. The Securities and Exchange Board of India (Registrars to an issue and Share Transfer Agents) Regulations, 1993, regarding the Companies Act and dealing with client; **Not Applicable as the Company is not registered as Registrar to an Issue and Share Transfer Agent during the year under review.**

g. Securities and Exchange Board of India (Delisting of Equity Shares) Regulations, 2021; **Not Applicable as the company has not delisted/ proposed to delist its equity shares during the year under review.**

h. The Securities and Exchange Board of India (Buyback of Securities) Regulations, 2018. **Not Applicable as the Company has not bought back/ proposed to buy-back any of its securities during the year under review.**

i. The Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

3. As per the information and explanations provided by the Company, its officers, agents and authorized representatives during the conduct of secretarial audit, we report that

a. As per the information and explanations provided by the company, its officers, agents and authorized representatives during the conduct of Secretarial Audit, we report that the Company has not made any GDRs/ADRs or any Commercial Instrument under the financial year under report.

b. The provisions of the Foreign Exchange Management Act, 1999 and the Rules and Regulations made there under to the extent of:

- External Commercial Borrowings were not attracted to the Company under the financial year under report;

- Foreign Direct Investment (FDI) was compiled by the company under the financial year under report;

- Overseas Direct Investment by Residents in Joint Venture/Wholly Owned Subsidiary abroad was not attracted to the company under the financial year under report.

4. I have also examined compliance with the applicable clauses of the following:

a. Secretarial Standards issued by The Institute of Company Secretaries of India on Meetings of the Board of Directors and General Meetings.

b. Securities and Exchange Board of India Act, 1992 & Circulars, Master Circulars and Regulations issued by SEBI and applicable to the Company.

c. Listing Agreements entered into by the Company with BSE Limited.

5. Compliances/ processes/ systems under other specified applicable Laws (as applicable to the industry) to the Company being submitted to the Board of Directors by the Company Secretary as required under section 205 of the Act and same not being verified by us:

6. I have not examined compliance by the Company with applicable financial laws, like direct and indirect tax laws, since the same have been subject to review by statutory financial auditor and other designated professionals during the period under review the Company has complied with the provisions of the Act, Rules, Regulations, Guidelines, Standards, etc. mentioned above subject to the following observations:

Observations/ Non-Compliances/ Adverse Remarks/ Qualifications in respect of the Companies Act, 2013 and SEBI Act, Regulations, Rules, Guidelines, Notifications, Circulars made there under are as follows:

- The Company failed to Comply the provisions of Regulation 47(1) of the SEBI (LODR) Regulation 2015 in relation to paper ad publication for the Approved financial results.

- The company has not provided Declarations from Independent Directors received by the company u/r 25 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 read with sec. 149 and schedule IV of the Companies Act, 2013 for audit verification.

- The company has not provided Disclosures (DIR-8 and MBP-1) received from director's u/s 164 and 184 of Companies Act, 2013 for audit verification.

- The company has not provided Board Meeting & Committee Meeting Agenda and Board Meeting Minutes & Audit Committee Minutes & Nomination Remuneration Committee Minutes & Stake Holder Committee Minutes for Audit verification.

- The company has not maintained the statutory registers as per the provision of the companies act, 2013.

- Mr. Rajesh Kakkera, Mr. M. Madhavarao and Mr. Addagarla Tarun an Independent directors (ID) have not registered/renew ID data bank maintained by Institute of Corporate Affairs (IICA) with in stipulated period.

- Regulation 17 (10) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 and pursuant to Section 134 (3) (p) of the Companies Act, 2013, the Company had not carried out annual evaluation of the performance of the Board, its Committees and of individual directors.

- Acknowledgement for sending the notices of the Meeting of the Board and Committees is not maintained by the company.

- The company has not maintained the attendance register for Board and committee meeting.

- Certain event-based E Forms have not been filed by the company in time which were required to be filed with ROC during the audit period.

  During the period under review, the Company remained continuously suspended from trading by BSE Limited due to certain non-compliances with regulations, lapses in corporate governance, and delays in submission of certain reports.

7. We have not examined compliance by the Company with applicable financial laws, like direct and indirect tax laws, since the same have been subject to review by statutory financial auditor and other designated professionals.

   I, further report that there are adequate systems and processes in the company commensurate with the size and operations of the company to monitor and ensure compliance with applicable laws, rules, regulations and guidelines

For Chakravarthy & Associates
Practicing Company Secretaries

Sd/-
CS N Phani Chakravarty
Practicing Company Secretary
M. No. 32380 & C.P. No. 22563
Peer Review No: 6621/2025

Date: 13.08.2026
Place: Hyderabad
UDIN: A032380H001430370

Annexure- A to Secretarial Audit Report

To
The Members of
M/s. **Sangam Health Care Products Limited**

Our report of even date is to be read along with this letter.

1. Maintenance of secretarial records is the responsibility of the management of the company. Our responsibility is to express an opinion on these secretarial records based on our audit.

2. I have followed the audit practices and processes as were appropriate to obtain reasonable assurance about the correctness of the secretarial records. The verification was done on test basis to ensure that correct facts are reflected in secretarial records. We believe that the processes and practices we followed provide a reasonable basis for our opinion.

3. I have relied on the reports given by the concerned professionals in verifying the correctness and appropriateness of financial records and books of accounts of the company.

4. Where ever required, we have obtained the Management representation about the compliance of laws, rules and regulations and happening of events etc.

5. The compliance of provisions of Corporate and other applicable laws, rules, regulations, standards is the responsibility of management. Our examination was limited to the verification of procedures on test basis.

6. The secretarial Audit report is neither an assurance as to future viability of the company nor of the efficacy or effectiveness with which the management has conducted the affairs of the company.

For Chakravarthy & Associates
Practicing Company Secretaries

Sd/-
CS N Phani Chakravarty
Practicing Company Secretary
M. No. 32380 & C.P. No. 22563
Peer Review No: 6621/2025

Date: 13.08.2026
Place: Hyderabad
UDIN: A032380H001430370

INDEPENDENT AUDITORS' REPORT

To

The Members

SANGAM HEALTH CARE PRODUCTS LIMITED

Report on the Audit of the Standalone Financial Statements

Opinion

We have audited the accompanying standalone financial statements of **Sangam Health Care Products Limited**, which comprise the Balance Sheet as at 31st March, 2026, the Statement of Profit and Loss (including Other Comprehensive Income), the Statement of Changes in Equity and the Statement of Cash Flows for the year ended 31st March,2026, and a summary of the significant accounting policies and other explanatory information (hereinafter referred to as "the standalone financial statements").

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid standalone financial statements give the information required by the **Companies Act, 2013** ("the Act") in the manner so required and give a true and fair view in conformity with the Indian Accounting Standards prescribed under section 133 of the Act read with the **Companies (Indian Accounting Standards) Rules, 2015**, as amended, ("Ind AS") and other accounting principles generally accepted in India, of the state of affairs of the Company as at March 31, 2026, the Profit and total comprehensive income, changes in equity and its cash flows for the year ended on that date.

Basis for opinion

We conducted our audit of the standalone financial statements in accordance with the Standards on Auditing specified under section 143(10) of the Act (SAs). Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the Standalone Financial Statements section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India (ICAI) together with the independence requirements that are relevant to our audit of the financial statements under the provisions of the Act and the Rules made thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the ICAI's Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the financial statements.

Key audit matters

Key audit matters are those matters that, in our professional judgment, were of most significance in our audit of the financial statements of the current period. These matters were addressed in the context of our audit of the financial statements as a whole, and in forming our opinion thereon, we do not provide a separate opinion on these matters.

Information Other than the Standalone Financial Statements and Auditor's Report Thereon

The Company's Board of Directors is responsible for the preparation of the other information. The other information comprises the information included in the Management Discussion and Analysis, Board's Report including Annexures to Board's Report, Business Responsibility Report, Corporate Governance and Shareholder's Information, but does not include the standalone financial statements and our auditor's report thereon.

Our opinion on the standalone financial statements does not cover the other information and we do not express any form of assurance conclusion thereon.

In connection with our audit of the standalone financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the standalone financial statements or our knowledge obtained during the course of our audit or otherwise appears to be materially misstated.

If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

Management's Responsibility for the Standalone Financial Statements

The Company's Board of Directors is responsible for the matters stated in section 134(5) of the Act with respect to the preparation of these standalone financial statements that give a true and fair view of the financial position, financial performance, total comprehensive income, changes in equity and cash flows of the Company in accordance with the Ind AS and other accounting principles generally accepted in India. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the standalone financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the standalone financial statements, management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors are responsible for overseeing the Company's financial reporting process.

Auditor’s Responsibilities for the Audit of the Standalone Financial Statements

Our objectives are to obtain reasonable assurance about whether the standalone financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor’s report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these standalone financial statements.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the standalone financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal controls.

- Obtain an understanding of internal financial controls relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under section 143(3)(i) of the Act, we are also responsible for expressing our opinion on whether the Company has adequate internal financial controls system in place and the operating effectiveness of such controls.

- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
- Conclude on the appropriateness of management’s use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company’s ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor’s report to the related disclosures in the standalone financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor’s However, future events or conditions may cause the Company to cease to continue as a going concern.

- Evaluate the overall presentation, structure and content of the standalone financial statements, including the disclosures, and whether the standalone financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

  Materiality is the magnitude of misstatements in the standalone financial statements that, individually or in aggregate, makes it probable that the economic decisions of a reasonably knowledgeable user of the financial statements may be influenced. We consider quantitative materiality and qualitative factors in (i) planning the scope of our audit work and in evaluating the results of our work; and (ii) to evaluate the effect of any identified misstatements in the financial statements.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

From the matters communicated with those charged with governance, we determine those matters that were of most significance in the audit of the standalone financial statements of the current period and are therefore the key audit matters. We describe these matters in our auditor's report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.

Report on Other Legal and Regulatory Requirements

1. As required by the Companies (Auditor's Report) Order, 2020 ("the Order") issued by the Central Government in terms of Section 143(11) of the Act, we give in "Annexure- A" a statement on the matters specified in paragraphs 3 and 4 of the order.

2. As required by Section 143(3) of the Act, based on our audit we report that:

   a) We have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purposes of our audit.
   b) In our opinion, proper books of account as required by law have been kept by the Company so far as it appears from our examination of those books.

   c) The Balance Sheet, the Statement of Profit and Loss including Other Comprehensive Income, Statement of Changes in Equity and the Statement of Cash Flow dealt with by this Report are in agreement with the relevant books of account.

   d) In our opinion, the aforesaid standalone financial statements comply with the Ind AS specified under Section 133 of the Act.

   e) On the basis of the written representations received from the directors as on March 31, 2026 taken on record by the Board of Directors, none of the directors is disqualified as on March 31, 2026 from being appointed as a director in terms of Section 164 (2) of the Act.

f) With respect to the adequacy of the internal financial controls over financial reporting of the Company and the operating effectiveness of such controls, refer to our separate Report in “Annexure- B”.

g) With respect to the other matters to be included in the Auditor’s Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules, 2014, in our opinion and to the best of our information and according to the explanations given to us:

i. The Company does not have any pending litigations on its financial position in its standalone financial Statements.

ii. The Company has made provision, as required under the applicable law or accounting standards, for material foreseeable losses, if any, on long-term contracts including derivative contracts.

iii. There has been no delay in transferring amounts, required to be transferred, to the Investor Education and Protection Fund by the company.

iv. A) The management has represented that, to the best of its knowledge and belief, no funds (which are material either individually or in the aggregate) have been advanced or loaned or invested (either from borrowed funds or share premium or any other sources or kind of funds) by the Company to or in any other person or entity, including foreign entity (“Intermediaries”), with the understanding, whether recorded in writing or otherwise, that the Intermediary shall, whether, directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Company (“Ultimate Beneficiaries”) or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries.

B) The management has represented that, to the best of its knowledge and belief, no funds (which are material either individually or in the aggregate) have been received by the company from any person or entity, including foreign entity with the understanding, whether recorded in writing or otherwise, that the company shall, whether directly or indirectly, lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Funding party(“Ultimate Beneficiaries”) or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries.

v. The company has neither declared nor paid any dividend during the year as per Section 123 of the Act.

vi. Based on our examination, which included test checks, the Company has used Focus accounting software’s for maintaining its books of account for the financial year ended March 31, 2026, which has a feature of recording audit trail (edit log) facility and the same has operated throughout the year for all relevant transactions recorded in the software’s. Further, during the course of our audit we did not come across any instance of the audit trail feature being tampered with.

vii. As proviso to Rule 3(1) of the Companies (Accounts) Rules, 2014 is applicable from April 1, 2023, reporting under Rule 11(g) of the Companies (Audit and Auditors) Rules, 2014 on preservation of audit trail as per the statutory requirements for record retention is not applicable for the financial year ended March 31, 2026.

For M M REDDY & CO.,

Chartered Accountants
Firm Reg No. 010371S

.

M Madhusudhana Reddy

Date: 29-05-2026

Partner

Place: Hyderabad

Membership No: 213077

UDIN: 26213077QQOHYR5458

Annexure ‘A’ to the Independent Auditor’s Report

(Referred to in paragraph 2 under ‘Report on Other Legal and Regulatory Requirements’ section of our report to the Members of **Sangam Health Care Products Limited** of even date)

i. In respect of the Company’s fixed assets:

a. The Company has maintained proper records showing full particulars, including quantitative details and situation of fixed assets.
b. The Company has a program of verification to cover all the items of fixed assets in a phased manner which, in our opinion, is reasonable having regard to the size of the Company and the nature of its assets. Pursuant to the program, certain fixed assets were physically verified by the management during the year. According to the information and explanations given to us, no material discrepancies were noticed on such verification.
c. According to the information and explanations given to us, the records examined by us and based on the examination of the conveyance deeds/ registered sale deed provided to us, we report that, the title deeds, comprising all the immovable properties of land and buildings which are freehold, are held in the name of the Company as at the balance sheet date.

ii. The Management has conducted physical verification of inventory at reasonable intervals during the year and no material discrepancies were noticed on such physical Verification.

iii. According the information and explanations given to us, the Company has not granted any loans, secured or unsecured to companies, firms, Limited Liability Partnerships, or other parties, covered in the register maintained under section 189 of the Companies Act, 2013, Accordingly, the provisions of clause 3(iii) (a), (b) and (c) of the order are not applicable to the company and hence not commented upon.

iv. In our opinion and according to the information and explanations given to us, the Company has complied with the provisions of Sections 185 and 186 of the Act in respect of grant of loans, making investments and providing guarantees and securities, as applicable. There were no loans granted during the year under Section 185 of the Act.

v. The Company has not accepted deposits during the year and does not have any unclaimed deposits as at March 31, 2026 and therefore, the provisions of the clause 3 (v) of the Order are not applicable to the Company.

vi. The maintenance of cost records has not been specified by the Central Government under section 148(1) of the Companies Act, 2013 for the business activities carried out by the company. Thus reporting under clause 3(vi) of the order is not applicable to the Company.

vii. According to the information and explanations given to us, in respect of statutory dues:

a. The Company has not been regular in depositing undisputed statutory dues, including Provident Fund, Employees' State Insurance, Goods and Service Tax, Customs Duty, Cess and other material statutory dues applicable to it with the appropriate authorities Except the dues mentioned below:

Sl. No	Type of Dues	Amt in lakhs
1	TDS Payable	48.46
2	Professional tax payable	7.20
3	PF and ESI	2.32
	TOTAL	**57.98**

b. Details of dues of Income Tax, Sales Tax, Service Tax, Excise Duty and Value Added Tax which have not been deposited as at March 31, 2026 on account of dispute. According to the information and explanation given to us, there are no such dues.

viii. According to the information and explanations given to us, there are no transactions which are not accounted in the books of account which have been surrendered or disclosed as income during the year in Income-tax Assessment of the Company. Accordingly, the provisions stated under clause 3(viii) of the Order are not applicable to the Company.

ix. In our Opinion and according to the information and explanations provided by the Management, the company has not defaulted in repayment of loans or borrowings to a financial Institution, bank or Government or dues to debenture holders.

x. The Company has not raised moneys by way of initial public offer or further public offer (including debt instruments) or term loans and hence reporting under clause 3 (ix) of the Order is not applicable to the Company.

xi. In our opinion and according to the information and explanations given to us, no fraud by the Company or no material fraud on the Company by its officers or employees has been noticed or reported during the year.

xii. The Company is not a Nidhi Company and hence reporting under clause 3 (xii)(a) to (c) of the Order is not applicable to the Company.

xiii. In our opinion and according to the information and explanations given to us, the Company is in compliance with Section 177 and 188 of the Companies Act, 2013 where applicable, for all transactions with the related parties and the details of related party transactions have been disclosed in the financial statements as required by the applicable accounting standards.

xiv. According to the information and explanations given to us and based on our examination the company does not have an internal audit system and commensurate with the size and nature of the business.

xv. According to the information and explanations given to us and based on our examination of the records of the Company, the Company has not entered into non-cash transactions with directors or persons connected with him. Accordingly, paragraph 3(xv) of the Companies (Auditor's Report) Order, 2020 is not applicable.

xvi. The Company is not required to be registered under section 45-IA of the Reserve Bank of India Act, 1934.

xvii. According to the information and explanations given to us and based on our examination of the records of the Company, the Company has not incurred any cash losses in the financial year and in the immediately preceding financial year.

xviii. There has been no instance of any resignation of the statutory auditors occurred during the year. Accordingly, the provisions stated under clause 3(xviii) of the Order are not applicable to the Company

xix. According to the information and explanations given to us and based on our examination of the records of the Company, the company is able to pay off the existing liabilities for next one year and material uncertainty doesn’t exist as on date of audit report.

xx. CSR is not applicable to this company.

xxi. According to the information and explanations given to us and based on our examination of the records of the Company, the company don’t have subsidiaries. Therefore, clause 3(xxi) of the Order are not applicable to the Company.

For M M REDDY & CO.,

Chartered Accountants
Firm Reg No. 010371S

M. Madhusudhana Reddy
Partner
Membership No: 213077
UDIN: 26213077QQOHYR5458

Date: 29-05-2026
Place: Hyderabad

Annexure "B" to the Independent Auditor's Report

(Referred to in paragraph 1(f) under 'Report on Other Legal and Regulatory Requirements' section of our report to the Members of **Sangam Health Care Products Limited** of even date)

Report on the Internal Financial Controls Over Financial Reporting under Clause (i) of Sub-section 3 of Section 143 of the Companies Act, 2013 ("the Act")

We have audited the internal financial controls over financial reporting of **Sangam Health Care Products Limited** ("the Company") as of March 31, 2026 in conjunction with our audit of the standalone Ind AS financial statements of the Company for the year ended on that date.

Management's Responsibility for Internal Financial Controls

The Management of the Company is responsible for establishing and maintaining internal financial controls based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting issued by the Institute of Chartered Accountants of India. These responsibilities include the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the orderly and efficient conduct of its business, including adherence to respective company's policies, the safeguarding of its assets, the prevention and detection of frauds and errors, the accuracy and completeness of the accounting records, and the timely preparation of reliable financial information, as required under the Companies Act, 2013.

Auditor's Responsibility

Our responsibility is to express an opinion on the internal financial controls over financial reporting of the Company based on our audit. We conducted our audit in accordance with the (the "Guidance Note") issued by the Institute of Chartered Accountants of India and the Standards on Auditing prescribed under Section 143(10) of the Companies Act, 2013, to the extent applicable to an audit of internal financial controls. Those Standards and the Guidance Note require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether adequate internal financial controls over financial reporting was established and maintained and if such controls operated effectively in all material respects.

Our audit involves performing procedures to obtain audit evidence about the adequacy of the internal financial controls system over financial reporting and their operating effectiveness. Our audit of internal financial controls over financial reporting included obtaining an understanding of internal financial controls over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. The procedures selected depend on the auditor's judgement, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error.

We believe that the audit evidence we have obtained, is sufficient and appropriate to provide a basis for our audit opinion on the internal financial controls system over financial reporting of the Company.

Meaning of Internal Financial Controls Over Financial Reporting

A company's internal financial control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company's internal financial control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company's assets that could have a material effect on the financial statements.

Limitations of Internal Financial Controls Over Financial Reporting

Because of the inherent limitations of internal financial controls over financial reporting, including the possibility of collusion or improper management override of controls, material misstatements due to error or fraud may occur and not be detected. Also, projections of any evaluation of the internal financial controls over financial reporting to future periods are subject to the risk that the internal financial control over financial reporting may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

Opinion

In our opinion, to the best of our information and according to the explanations given to us, the Company has, in all material respects, an adequate internal financial controls system over financial reporting and such internal financial controls over financial reporting were operating effectively as at March 31, 2026, based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting issued by the Institute of Chartered Accountants of India.

For M M REDDY & CO.,

Chartered Accountants
Firm Reg No. 010371S

M. Madhusudhana Reddy
Partner
Membership No: 213077
UDIN: 26213077QQOHYR5458

Date: 29-05-2026
Place: Hyderabad

Corporate Information:

Sangam Health Care Products Limited ("the Company") is a listed entity incorporated in India in the year 1993. The Registered office of the company is located at Sy No: 182, Yellampet village, Medchal Mandal, Hyderabad, Telangana-501401, India. The Company is engaged manufacturing and trading of medical disposables/ surgical products.

1. Disclosure of Significant Accounting Policies:

a) Compliance with Indian Accounting Standards (Ind AS)

The Standalone financial statements have been prepared in accordance with Indian Accounting Standards (Ind AS) as per the Companies (Indian Accounting Standards) Rules, 2015 notified under section 133 of the Companies Act, 2013.

The standalone financial statements have been prepared on the historical cost basis except for certain instruments which are measured at fair values at the end of each reporting period, as explained in the accounting policies below.

Accordingly, the Company has prepared these Standalone Financial Statements which comprise the Balance Sheet as at 31 March, 2025, the Statement of Profit and Loss for the year ended 31 March 2025, the Statement of Cash Flows for the year ended 31 March 2025 and the Statement of Changes in Equity for the year ended as on that date, and accounting policies and other explanatory information (together hereinafter referred to as 'Standalone Financial Statements' or 'financial statements').

These financial statements are approved by the Board of Directors on 30-07-2026.

b) Basis of Preparation of financial statements

The separate financial statements have been prepared in accordance with Indian Accounting Standards (Ind AS) under historical cost convention on accrual basis except the assets and liabilities which have been measured at Fair Values.

- Financial instruments – measured at fair value;
- Assets held for sale – measured at fair value less cost of sale;
- Plan assets under defined benefit plans – measured at fair value
- Employee share-based payments – measured at fair value
- Biological assets – Not applicable
- In addition, the carrying values of recognized assets and liabilities, designated as hedged items in fair value hedges that would otherwise be carried at cost, are adjusted to record changes in the fair values attributable to the risks that are being hedged in effective hedge relationship.

Current and Non-Current Classification:

The Company presents assets and liabilities in the balance sheet based on current / non-current classification.

An asset is classified as current when it satisfies any of the following criteria:

- Expected to be realized, or is intended to be sold or consumed, the Company's normal operating cycle.
- held primarily for the purpose of trading;
- It is expected to be realized within twelve months after the reporting date; or
- It is cash or cash equivalent unless restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period.

All other assets are classified as non-current.

A liability is classified as current when it satisfies any of the following criteria:

- It is expected to be settled in the Company's normal operating cycle;
- It is held primarily for the purpose of being traded
- It is due to be settled within 12 months after the reporting date; or the Company does not have an unconditional right to defer settlement of the liability for at least 12 months after the reporting date.
- Terms of a liability that could, at the option of the counterparty, result in its settlement by the issue of equity instruments do not affect its classification

All other liabilities are classified as non-current liabilities.

c) Use of estimates and judgment

The preparation of the financial statements in conformity with Ind AS, management has made judgments, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets, liabilities, income and expenses. Actual results may differ from these estimates.

This note provides an overview of the areas where there is a higher degree of judgment or complexity. Detailed information about each of these estimates and judgments is included in relevant notes together with information about the basis of calculation.

The areas involving critical estimates or judgments are:

S.no	Name of the estimate	Note No	Remarks
1	Fair value of unlisted equity securities	Not applicable	No unlisted equity shares are held by the company during the current financial year
2	Goodwill impairment	Not applicable	No amount provided during the current Financial year
4	Useful life of intangible asset	Not Applicable	Intangible assets are stated at cost less accumulated amortization and impairment. Intangible assets are amortized over their respective useful life on straight line basis, from the

			date they are available for use.
5	Defined benefit obligation	Note No.2.16	Long term provision for gratuity.
7	Measurement of contingent liabilities and contingent purchase consideration in a business combination	Note No.2.23	Contingent transactions are recognized based on happening contingent event. No contingent liabilities for the report
8	Current tax expense and current tax payable	Note No.2.27	As per the Ind AS.12
9	Deferred tax assets for carried forward tax losses	Note No.2.27	As per the Ind AS.12
10	Impairment of financial assets	Note No.2.3	As per Ind AS 16

d. Recent Accounting Pronouncements

The Ministry of Corporate Affairs (MCA) has issued the Companies (Indian Accounting Standards) (Amendment) Rules, 2024:

a) Ind AS 117 – Insurance Contracts, which replaces the interim Ind AS 104 and introduces comprehensive requirements on measurement and disclosures aligned with IFRS 17.

b) Amendments are made to Ind AS 101, 103, 105, 107, 109, 115, 116 which are necessary to align them with the newly issued to reflect the issuance of Ind AS 117, including scope adjustments, transition provisions and disclosure enhancements.

These changes are effective for accounting periods beginning on or after 1 April 2025.

The Company has assessed their impact and concluded that, they have no material effect on the financial statements.

2. Significant accounting policies:

A summary of the significant accounting policies applied in the preparation of the financial statements is as given below. These accounting policies have been applied consistently to all the periods presented in the financial statements.

1.1. Ind AS 105: Non-Current Assets held for Sale or Discontinued Operations:

This standard specifies accounting for assets held for sale, and the presentation and disclosure for discontinued operations:

(a) Assets that meet the criteria to be classified as held for sale to be measuredat the lower of carrying amount and fair value less cost to sell, and depreciation on such assets to cease; and

(b) Assets that meet the criteria to be classified as held for sale to be presented separately in the balance sheet and the results of discontinued operations to be presented separately in the statement of profit and loss.

S.no	Particulars of Disclosures	As at 31st March 2026 (Rs.)	As at 31st March 2025 (Rs.)
1	A Description of Non-Current Asset (Disposal group)	-	-
2	a description of the facts and circumstances of the sale, or leading to the expected disposal, and the expected manner and timing of that disposal	-	-

3	the gain or loss recognized in accordance with paragraphs 20–22 and, if not separately presented in the statement of profit and loss, the caption in the statement of profit and loss that includes that gain or loss	-	-

2.2 Ind AS 106: Exploration for Evolution of Mineral resources:

This standard specifies the financial reporting for the exploration for evaluation of mineral resources. In particular, this standard requires:

a. Limited improvements to existing accounting practices for exploration and evaluation of expenditures
b. Entities that recognize exploration and evaluation of assets to assess such assets for impairment in accordance with this standard and measure any impairment.

Disclosures that identify and explain the amounts in the entity's financial statements arising from the exploration for the evaluation of mineral resources and help users of those financial statements understand the amount, timing and certainty of future cash flows from any exploration and evaluation of assets recognized.

This Ind AS 106 not applicable, the company is in the business of engaged manufacturing and trading of medical products. Hence this Ind AS does not have any financial impact on the financial statements of the company.

2.3 Ind AS-16: Property, Plant and Equipment:

Property, Plant and Equipment are stated at cost less accumulated depreciation. Cost of an item of property, plant and equipment comprises its purchase price, including import duties and non-refundable purchase taxes, after deducting trade discounts and rebates, any directly attributable cost of bringing the item to its working condition for its intended use and estimated costs of dismantling and removing the item and restoring the site on which it is located.

The cost of a self-constructed item of property, plant and equipment comprises the cost of materials and direct labor, any other costs directly attributable to bringing the item to working condition for its intended use, and estimated costs of dismantling and removing the item and restoring the site on which it is located.

Property, plant and equipment which are significant to the total cost of that item of Property Plant and Equipment and having different useful life are accounted for as separately.

Gains or losses arising from de recognition of property, plant and equipment are measured as the difference between the net disposal proceeds and carrying amount of the asset is recognized in the statement of profit or loss when the asset is de recognized.

Depreciation on Property Plant and Equipment is provided on Straight line method. Depreciation is provided based on useful life as prescribed under part C of the schedule II of the Companies act, 2013.

S.no	Asset	Use full life in Years
1	Plant and Machinery	3-60
2	Electrical Installations	2-40
3	Lab Equipment	3-60
4	Computers	3-10
5	Office Equipment	2-20
6	Furniture & Fixtures	3-15
7	Vehicles	5-20

Depreciation on additions (disposals) is provided on a pro-rata basis i.e. from (up to) the date on which asset is ready for use (disposed of).

Impairment

Property Plant and Equipment are evaluated for recoverability whenever events or changes in circumstances indicate that their carrying amount may not be recoverable. An impairment loss is recognised for the amount by which the asset's carrying amount exceeds its recoverable amount. The recoverable amount is the higher of an asset's fair value less cost of disposal and value in use. For the purposes of assessing impairment, assets are grouped at the lowest levels for which there are separately identifiable cash inflows which are largely independent of the cash inflows from other assets or groups of assets (cash-generating units).

2.4 Impairment Assets (Ind AS 36)

The Company's non-financial assets, other than deferred tax assets are reviewed at each reporting date to determine whether there is any indication of impairment. If any such indication exists, then the asset's recoverable amount is estimated.

For impairment testing, assets that do not generate independent cash inflows are grouped together into cash-generating units (CGUs). Each CGU represents the smallest group of assets that generates cash inflows that are largely independent of the cash inflows of other assets or CGUs.

The recoverable amount of a CGU (or an individual asset) is the higher of its value in use and its fair value less costs to sell. Value in use is based on the estimated future cash flows, discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the CGU (or the asset).

An impairment loss is recognized if the carrying amount of an asset or CGU exceeds its estimated recoverable amount. Impairment losses are recognized in the statement of profit and loss. Impairment loss recognized in respect of a CGU is allocated first to reduce the carrying amount of any goodwill allocated to the CGU, and then to reduce the carrying amounts of the other assets of the CGU (or group of CGUs) on a pro rata basis.

The books of accounts of the company doesn't carry any impairment of assets during the reporting period, hence this accounting standard does not have financial impact on the financial statements of the company.

2.5 Intangible assets (Ind AS 38):

Intangible assets are stated at cost less accumulated amortization and impairment. Intangible assets are amortized over their estimated useful life on straight line basis.

Subsequent costs are included in assets carrying amount or recognized or recognized as a separate asset, as appropriate, only when it is probable that future economic benefits associated with the item will flow to the entity and the cost can be measured reliably.

The residual Values, useful lives and methods of depreciation of Property Plant and Equipment are reviewed at each Financial year end and adjusted prospectively, if appropriate.

Gains or losses arising from de recognition of Intangible asset are measured as the difference between the net disposal proceeds and carrying amount of the asset is recognized in the statement of profit or loss when the asset is de recognized.

The books of accounts of the company doesn't carry any intangible assets during the reporting period, hence this accounting standard does not have financial impact on the financial statements of the company.

2.6 Cash Flow Statement (Ind AS 7):

Cash flows are reported using the indirect method under Ind AS 7, whereby profit/(loss) before extraordinary items and tax is adjusted for the effects of transactions of non-cash nature and any deferrals or accruals of past or future cash receipts or payments. The cash flows from operating, investing and financing activities of the Company are segregated based on the available information.

Cash comprises cash on hand and demand deposits with banks. Cash equivalents are short-term balances (with an original maturity of three months or less from the date of acquisition), highly liquid investments that are readily convertible into known amounts of cash and which are subject to insignificant risk of changes in value.

a). Non-cash items: Nil

b). Changes in Liability Arising from Financing Activity:

(Amt in Rs. Lakhs)

Particulars	01-Apr-25	Cash Flow		31-Mar-26
		Receipts	Payments	

Current Borrowings	21.45	-	21.45*	-
Non-current Borrowings	2176.72	21.45	4.83	2193.34
Total	**2198.17**	**21.45**	**26.28**	**2193.34**

*The current borrowings of Rs. 21.45 Lakhs have been converted to Non-Current Borrowings.

2.7 Operating Cycle:

The Company has adopted its normal operating cycle as twelve months based on the nature of products and the time between the acquisition of assets for processing and their realization, for the purpose of current / non-current classification of assets and liabilities.

2.8 Capital Work in Progress

Capital Work in Progress (CWIP) includes Civil Works in Progress, Plant & Equipment under erection and Preoperative Expenditure pending allocation on the assets to be acquired/commissioned, capitalized. It also includes payments made to towards technical know-how fee and for other General Administrative Expenses incurred for bringing the asset into existence.

2.9 Investments:

Investments are classified as Non-Current and Current investments.

Investments, which are readily realisable and are intended to be held for not more than one year from the date on which such investments are made, are classified as current investments. All other investments are classified as non-current investments.

Current investments are carried at lower of cost and fair value. Non-Current Investments are carried at cost less provision for other than temporary diminution, if any, in value of such investments.

2.10 Effects of changes in Foreign Rates (Ind AS 21):

Foreign currency transactions are recorded at the exchange rates prevailing on the dates when the relevant transactions took place. Exchange difference arising on settled foreign currency transactions during the year and translation of assets and liabilities at the yearend are recognized in the trade statement of profit and loss.

In respect of Forward contracts entered into to hedge risks associated with foreign currency fluctuation on its assets and liabilities, the premium or discount at the inception of the contract is amortized as income or expense over the period of contract. Any profit or loss arising on the cancellation or nonperiod in which such cancellation or renewal is made.

The company has not entered any foreign exchange transactions during the reporting period, hence this accounting standard does not have financial impact on the financial statements.

2.11 Borrowing Costs (Ind AS 23):

Borrowing costs directly attributable to the acquisition, construction or production of qualifying assets, which are assets that necessarily take a substantial period of time to get ready for their intended use or sale, are added to the cost of those assets, until such time as the assets are substantially ready for the intended use or sale.

Investment income earned on temporary investment of specific borrowings pending their expenditure on qualifying assets is recognized in statement of profit and loss.

Discounts or premiums and expenses on the issue of debt securities are amortized over the term of related securities are included within borrowing costs. Premiums payable on early redemptions of debt securities, in lieu of future costs, are recognized as borrowing costs.

All other borrowing costs are recognized as expenses in the period in which it is incurred.

2.12 Revenue Recognition (Ind AS 18):

Revenue is recognized to the extent that it is probable that the economic benefits will flow to the Company and the revenue can be reliably measured**.** The following specific recognition criteria must also be met before revenue is recognized:

a) Sales Revenue is recognized on dispatch to customers as per the terms of the order. Gross sales are net of returns and applicable trade discounts and excluding GST billed to the customers.

b) Subsidy from Government is recognized when such subsidy has been earned

by the company and it is reasonably certain that the ultimate collection will be made.

c) Interest income is recognized on a time proportion basis taking into account the amount outstanding and the applicable interest rate. Interest income is included under the head “other income” in the statement of profit and loss.

d) All other incomes are recognized based on the communications held with the parties and based on the certainty of the incomes.

2.13 Accounting for Government Grants and Disclosure of Government Assistance (Ind AS 20):

Government grants:

Government grants are not recognized until there is reasonable assurance that the Company will comply with the conditions attached to them and that the grants will be received.

Government grants are recognized in the Statement of Profit and Loss on a systematic basis over the years in which the Company recognizes as expenses the related costs for which the grants are intended to compensate or when performance obligations are me.

Government grants, whose primary condition is that the Company should purchase, construct or otherwise acquire non-current assets and nonmonetary grants are recognized and disclosed as 'deferred income' under non-current liability in the Balance Sheet and transferred to the Statement of Profit and Loss on a systematic and rational basis over the useful lives of the related assets.

The benefit of a government loan at a below-market rate of interest and effect of this favorable interest is treated as a government grant. The loan or assistance is initially recognized at fair value and the government grant is measured as the difference between proceeds received and the fair value of the loan based on prevailing market interest rates and recognized to the income statement immediately on fulfillment of the performance obligations. The loan is subsequently measured as per the accounting policy applicable to financial liabilities.

2.14 Inventories (Ind AS 2):

Inventories are assets:

a. Held for sale in the ordinary course of business;

b. In the process of production for such sale;

c. In the form of materials or supplies to be consumed in the production process or in the rendering of services

Net Realisable value is the estimated selling price in the ordinary course of business less the estimated costs of completion and the estimated costs necessary to make the sale.

Fair value is the price that would be received to sell an asset or paid to transfer a

liability in an orderly transaction between market participants at the measurement date.

Inventories at the year-end are valued as under:

Raw Materials, Packing Material, Components, Consumables and Stores & Spares	At Cost.
Work In Progress and Finished goods	At lower of net realizable value and Cost of Materials plus Cost of Conversion and other costs incurred in bringing them to the present location and condition.

- Cost of Material excludes duties and taxes which are subsequently recoverable.
- Stocks at Depots are inclusive of duty, wherever applicable, paid at the time

  of dispatch from Factories.

- Based on the information provided the difference between physical verification and valuation of the of inventories are charged to the profit and loss account.

2.15 Trade Receivables – Doubtful debts:

A Trade receivable represents the company's right to an amount of consideration that is unconditional.

Provision is made in the Accounts for Debts/Advances which is in the opinion of Management are considered doubtful of Recovery.

2.16 Retirement and other Employee Benefits (Ind AS 19):

Retirement benefit in the form of provident fund is a defined contribution scheme. The Company has no obligation, other than contribution payable to the provident fund. The Company recognizes contribution payable to the provident fund scheme as expenditure, when an employee renders related service.

The Company has entered into contracts with third-party service providers for the supply of labour for various operational requirements. These labourers are under the employment and control of the respective contractors and are not employees of the Company.

As per the terms of the contracts and in accordance with the provisions of the Payment of Gratuity Act, 1972, the obligation to pay gratuity to such contract labourers lies with the respective contractors, who are the principal employers for such laborers.

The Company ensures that appropriate clauses are included in all labour supply agreements, requiring contractors to comply with applicable labour laws, including the Payment of Gratuity Act, 1972. Based on this arrangement and legal opinion obtained, the Company does not have any direct obligation towards the gratuity liabilities of such contract labourers.
Accordingly, no provision has been made in the books of accounts for gratuity payable in respect of contract labourers.

Accumulated leave, which is expected to be utilized within the next 12 months, is treated as short term employee benefit. The Company measures the expected cost of such absences as the additional amount that it expects to pay as a result of the unused entitlement that has accumulated at the reporting date.

It has been noted that the Company follows a compensation policy under which all employee benefits, including leave, are structured within the total Cost to Company (CTC). The Company does not permit leave encashment either during the period of service or upon separation, and unavailed leave lapses as per the Company's leave policy. Accordingly, no separate provision for leave encashment has been made in the financial statements.

2.17 Ind AS 116- Leases

The Company assesses whether a contract is or contains a lease at the inception of the contract. A contract is classified as a lease if it conveys the right to control the use of an identified asset for a period of time in exchange for consideration.

a) As a Lessee

The Company applies the single lease accounting model for all leases, except for:
Short-term leases (lease term of 12 months or less), and
Leases of low-value assets (such as small office equipment)

For these exempted leases, the Company recognises lease payments as an expense on a straight-line basis over the lease term.

For all other leases, the Company recognises a right-of-use (ROU) asset and a corresponding lease liability at the lease commencement date.

The ROU asset is initially measured at cost and subsequently depreciated on a straight-line basis over the shorter of the lease term or useful life of the asset. It is also adjusted for impairment losses, if any.

The lease liability is initially measured at the present value of future lease payments, discounted using the Company’s incremental borrowing rate. Subsequently, it is measured at amortized cost using the effective interest method.

Lease liabilities are re-measured when there is a change in future lease payments arising from a change in an index or rate or a reassessment of the lease term. The corresponding adjustment is made to the carrying amount of the ROU asset.

b) Lease Term

The lease term includes the non-cancellable period of the lease and any periods covered by an option to extend or terminate the lease, if the Company is reasonably certain to exercise or not exercise those options.

c) Disclosure

The Company has applied the exemption available under Ind AS 116 for leases of low-value assets and leases with lease terms of 12 months or less.

The Company has evaluated all its contracts in accordance with Ind AS 116 – Leases and has concluded that there are no lease contracts that meet the recognition criteria under the standard.

All existing arrangements either:

Do not convey the right to control the use of an identified asset, or Qualify as short-term leases or low-value leases, for which the recognition exemption has been applied.

Accordingly, the Company has not recognized any right-of-use assets or lease liabilities in its financial statements during the year. Payments under such lease arrangements have been accounted for as lease expenses on a straight-line basis over the lease term.

2.18 Insurance Claims:

Insurance Claims are accounted for on the basis of claims admitted/excepted to be admitted and to the extent that the amount recoverable can be measured reliably and it is reasonable to expect ultimate collection.

2.19 Earnings per Share (Ind AS 33):

Basic earnings per share are calculated by dividing the net profit or loss for the period attributable to equity shareholders by the weighted average number of equity shares outstanding during the period. Partly paid equity shares are treated as a fraction of an equity share to the extent that they are entitled to participate in dividends relative to a fully paid equity share during the reporting period. The weighted average number of equity shares outstanding during the period is adjusted for events such as bonus issue, bonus element in a rights issue, share split, and reverse share split (consolidation of shares) that have changed the number of equity shares outstanding, without a corresponding change in resources.

For the purpose of calculating diluted earnings per share, the net profit or loss for the period attributable to equity shareholders and the weighted average number of shares outstanding during the period are adjusted for the effects of all dilutive potential equity shares.

The EPS and Diluted EPS of the company are provided in Note no: 26.

2.20 Provisions, Contingent Liabilities and Contingent Assets (Ind AS 37):

Provisions are recognized in the balance sheet when the company has a present obligation (legal or constructive) as a result of a past event, which is expected to result in an outflow of resources embodying economic benefits which can be reliably estimated. Each provision is based on the best estimate of the expenditure required to settle the present obligation at the balance sheet. Where the time value of money is material, provisions are made on a discounted basis.

Disclosure for Contingent liabilities is made when there is a possible obligation or present obligation arising from past events, the existence of which will be confirmed only by the occurrence or non-occurrence of one or more uncertain future events not wholly within the control of the company or a present obligation that arises from the past events where it is either not probable that an outflow of resources embodying in economic benefits will be required to settle or a reliable estimate of amount cannot be made.

Disclosure for Contingent assets are made when there is possible asset that arises from past events and whose existence will be confirmed only by the occurrence or non-occurrence of one or more uncertain future events not wholly within the control of the entity. However Contingent assets are neither recognized nor disclosed in the financial statements.

2.21 Prior Period and Extraordinary and Exceptional Items:

(i) All Identifiable items of Income and Expenditure pertaining to prior period are accounted through ‘’Prior Period Items’’.

(ii) Extraordinary items are income or expenses that arise from events or transactions that are clearly distinct from the ordinary activities of the enterprise and, therefore, are not expected to recur frequently or regularly. The nature and the amount of each extraordinary item be separately disclosed in the statement of profit and loss in a manner that its impact on current profit or loss can be perceived.

(iii) Exceptional items are generally non-recurring items of income and expenses within profit or loss from ordinary activities, which are of such, nature or incidence.

There are no such items in the company.

2.22 Financial Instruments (Ind AS 107 Financial Instruments: (Disclosures)

I. Financial assets:

A. Initial recognition and measurement

All financial assets and liabilities are initially recognized at fair value. Transaction costs that are directly attributable to the acquisition or issue of financial assets and financial liabilities, which are not at fair value through profit or loss, are adjusted to the fair value on initial recognition.

B. Subsequent Measurement

a) Financial assets measured at amortized cost (AC)

A financial asset is measured at amortized cost if it is held within a business model whose objective is to hold the asset in order to collect contractual cash flows and the contractual terms of the financial asset give rise on specified dates to cash flows that are solely payments of principal and interest on the principal amount outstanding.

b) Financial assets at fair value through other comprehensive income (FVTOCI)

A financial asset is measured at FVTOCI if it is held within a business model whose

Objective is achieved by both collecting contractual cash flows and selling financial assets and the contractual terms of the financial asset give rise on specified dates to cash flows that are solely payments of principal and interest on the principal amount outstanding.

d) Financial assets measured at fair value through profit or loss (FVTPL)

A Financial asset which is not classified in any of above categories are measured at FVTPL e.g. investments in mutual funds. Financial assets are reclassified subsequent to their recognition, if the Company changes its business model for managing those financial assets. Changes in business model are made and applied prospectively from the reclassification date which is the first day of immediately next reporting period following the changes in business model in accordance with principles laid down under Ind AS 109 –Financial Instruments.

II. Financial Liabilities

A. Initial recognition

All financial liabilities are recognized at fair value and in case of borrowings, net of directly attributable cost. Fees of recurring nature are directly recognized in the Statement of Profit and Loss as finance cost.

B. Subsequent measurement

Financial liabilities are carried at amortized cost using the effective interest method. For trade and other payables maturing within one year from the balance sheet date, the carrying amounts approximate fair value due to the short maturity of these instruments

2.23 Contingent Liabilities not provided for and commitments:

(in Rupees)

Nature of Contingent Liability	March 31, 2026	March 31, 2025
i. Unexpired guarantees issued on behalf of the company by Banks for which the Company has provided counter guarantee	NIL	NIL
ii. Bills discounted with banks which have not matured	Nil	Nil
iii. Corporate Guarantees issued by Company on behalf of others to Commercial Banks & Financial Institutions	Nil	Nil
iv. Collateral Securities offered to Banks for the limit Sanctioned to others	Nil	Nil
v. Legal Undertakings given to Customs Authorities for clearing the imports	Nil	Nil
vi. Claims against the company not acknowledged as debts		
a. Excise	NIL	NIL
b. Sales Tax	NIL	NIL

c. Service Tax	Nil	Nil
d. Income Tax	NIL	NIL
e. Civil Proceedings	NIL	NIL
f. Company Law Matters	Unascertainable	Unascertainable
g. Criminal Proceedings	Unascertainable	Unascertainable
h. Others	Nil	Nil
vii. Estimated amounts of contracts remaining to be executed on Capital Account and not provided for	Nil	Nil

2.24 Operating Segments (Ind AS 108)

Operating segment is a component of an entity:

a. That engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same entity).
b. Whose operating results are regularly reviewed by the entity's chief operating decision maker to make decision about resources to be allocated to the segments and assess its performance, and
c. For which discrete financial information is available.

The Company is engaged in engaged manufacturing and trading of medical products. As there are no separate reportable segments, Segment Reporting as per Ind AS -108, "Operating Segments" is not applicable.

2.25 Events After the Reporting Period (Ind AS 10)

Events after the reporting period are those events, favorable and unfavorable, that occur between the end of the reporting and the date when the financial statements are approved by the Board of Directors in case of a company, and, by the corresponding approving authority in case of any other entity for issue. Two types of events can be identified:

- Those that provide evidence of conditions that existed at the end of reporting period (adjusting events after the reporting period);
- Those that are indicative of conditions that arose after the reporting period (non-adjusting events after the reporting period).

An entity shall adjust the amounts recognized in its financial statements to reflect adjusting events after the reporting period.

There are no such events are identified during the reporting period. Hence Ind AS 10 Events After the Reporting Period is not applicable.

2.26 Construction Contracts (Ind AS 11)

Construction contract is a contract specifically negotiated for the construction of an asset or a combination of assets that are closely interrelated or interdependent in terms of their design, technology, and function or their ultimate purpose or use.The company is engaged manufacturing and trading of medical products, hence Ind AS 11 "Construction Contract" is not applicable.

2.27 Income Taxes (Ind AS 12)

The Tax Expense for the period comprises of current and deferred tax.

- **Current Tax:**

  Current Tax Assets and Liabilities are measured at the amount expected to be recovered from or paid to the Income tax authorities, based on tax rates and laws that are enacted at the Balance Sheet date.

- **Deferred Tax:**

  Deferred tax liabilities are recognized for all timing differences. Deferred tax assets are recognized for deductible timing differences only to the extent that there is reasonable certainty that sufficient future taxable income will be available against which such deferred tax assets can be realized. In situations where the Company has unabsorbed depreciation or carry forward tax losses, all deferred tax assets are recognized only if there is virtual certainty supported by convincing evidence that they can be realized against future taxable profits.

  At each reporting date, the Company re-assesses unrecognized deferred tax assets. It recognizes unrecognized deferred tax asset to the extent that it has become reasonably certain or virtually certain, as the case may be, that sufficient future taxable income will be available against which such deferred tax assets can be realized.

  The carrying amount of deferred tax assets are reviewed at each reporting date. The Company writes-down the carrying amount of deferred tax asset to the extent that it is no longer reasonably certain or virtually certain, as the case may be, that sufficient future taxable income will be available against which deferred tax asset can be realized. Any such write-down is reversed to the extent that it becomes reasonably certain or virtually certain, as the case may be, that sufficient future taxable income will be available.

Deferred Tax Liability / (Asset)

(**Amt in Rs. Lakhs**)

Particulars	For FY 2025-26	For FY 2024-25
Opening Balance	**(43.17)**	(19.85)
Adj/Credit during the year	10.00	(23.32)
Closing balance	**(33.18)**	**(43.17)**

2.28 Related party (Ind AS 24)

Disclosures are made on related party relationships, transactions and outstanding balances, including commitments. Related parties are identified by the Company in accordance with the requirements of Ind AS 24 and are disclosed in the Notes to Financial Statements.

Related party transactions are reflected in the notes to accounts forming part of financial statements.

SANGAM HEALTH CARE PRODUCTS LIMITED
NOTES TO ACCOUNTS

22. Related Party Disclosures (Ind AS 24)

Related Party disclosures required as per Accounting Standard (Ind AS-24) on "Related Party disclosures "issued by the Institute of Chartered Accountants of India, are as below:

a) Names of related parties and the Description of Relationship:

Sl. No	Name	Relationship
(i)	Subsidiaries	NIL
(ii)	**Key Management Personnel** Satish Kumar Varre Bala Gopal Reddy Addepalli Padma Ghanakota Rajesh Kakkera Madhavarao Mandlapu Bhagath Reddy Dundumulla	CFO CEO Director Independent Director Independent Director Director
(iii)	**Directors interested companies/ firms:** Sri Siri constructions	G. Padma & A. Bala Gopal– Directors interested entity.

b) Related Party Transactions

A. Balagopal (Unsecured Loan)

(Rs.in Lakhs)

Particulars	For FY 2025-26	For FY 2024-25
Opening Balance	561.18	614.65
Loan taken	12.82	-
Loan given	-	-
Repaid during the year		53.46
Closing Balance	**574.01**	**561.18**

G. Padma (Loans & Advances “Asset”)

(Rs. in Lakhs)

Particulars	**For FY 2025-26**	**For FY 2024-25**
Opening Balance	30.35	29.15
Loan taken	-	-
Loan given	1.37	1.20
Received during the year	-	-
Closing Balance	**31.72**	**30.35**

Sri Siri Constructions (Unsecured Loans)

(Rs. in Lakhs)

Particulars	**For FY 2025-26**	**For FY 2024-25**
Opening Balance	1,297.64	1,165.21
Loan taken	-	132.43
Loan given	-	-
Repaid during the year	17.66	-
Closing Balance	**1,279.99**	**1,297.64**

23. Consolidated and Separate Financial Statement (Ind AS 27)

The company has no subsidiary companies for the current reporting period**.** Hence consolidate and separate financial statement are not applicable.

24. Investments in Associates (Ind AS 28)

The company has not made any investments in any of its associates during the reporting period**.** This accounting standard has no financial impact on the financial statements for the current reporting period.

25. Interest in Joint Ventures (Ind AS 31)

The company has no interest in any Joint ventures. This accounting standard has no financial impact on the financial statements for the current reporting period.

26. Earnings Per Share (Ind AS 33):

a) Basic Earnings Per Share for (continued operations) there are no discontinued operations hence, EPS is presented for continued operations only.

(Amt in Rs. Lakhs)

Particulars	**March 31, 2026**	**March 31, 2025**
Profit After Tax (Rs.)- (A)	5.33	43.18
Weighted Average	148.61	148.61

No. of Shares (Basic)- (B)		
EPS (Basic) = (A)/(B)	0.04	0.29

b). Diluted earnings per share (continued operations) there are no discontinued operations hence, EPS is presented for continued operations only.

(Amt in Rs. Lakhs)

Particulars	**March 31, 2026**	**March 31, 2025**
Profit After Tax (Rs.)- (A)	5.33	43.18
Weighted Average No. of Shares (Diluted) -(B)	148.61	148.61
EPS (Diluted) = (A)/(B)	0.04	0.29

27. Derivative instruments and un-hedged foreign currency exposure:

a) There are no outstanding derivative contracts as at March 31, 2026 and March 31, 2025.

b) Particulars of Un-hedged foreign currency exposure is: Nil

28. Confirmation of Balances:

Confirmation letters have been issued by the company to Trade Receivables, Trade Payables, Advances to suppliers and others advances requesting that the confirming party responds to the company only if the confirming party disagrees with the balances provided in the request and however the company has not received any letters on disagreements.

29. Net Current Assets:

(Rs. In Lakhs)

Sl. no	**Particulars**	**As at 31st March 2025**	**Incr/ (Decr)**	**As at 31st March 2026**

	Current Assets:			
1	Inventories	130.89	29.52	101.36
2	Trade Receivables **	361.92	9.54	352.39
3	Cash and Cash equivalent	20.74	(5.56)	15.17
4	Current Tax Asset	-	-	-
5	Other Current Asset	42.32	(22.7)	65.02
	Total Current Assets (A)	**555.97**	**(22.03)**	**533.94**
	Current Liabilities:			
1	Borrowings	21.45	(21.45)	-
2	Trade Payables **	658.22	(42.95)	615.27
3	Other Current Liabilities	117.34	12.77	130.11
4	Current Tax Liability	3.82	(3.82)	-
	Total Current liabilities (B)	**800.83**	**(55.45)**	**745.38**
	Current Assets-	**(254.95)**		**(191.44)**
	Current Liabilities (A-B)		**(77.48)**	

** In the current year Assets and liabilities were regrouped and reclassified from current to Non-current wherever necessary.

30. Revenue from Operations:

(Rs. in Lakhs)

S. no	**Particulars**	**As at 31st March 2026**	**As at 31st March 2025**
1	Sale of goods:		

	Sale of Manufactured Products	1,123.33	1,245.96
	Stock in trade	-	-
	Total	1,123.33	1245.96
2	Revenue from Sale of Service	-	-
3	Other Operating Revenues	-	-

31. Revenue Reconciliation:

(Rs. in Lakhs)

Sl. no	**Particulars**	**As at 31st March 2026**	**As at 31st March 2025**
1	Sale of Products”		
	Domestic	1,128.26	1,252.47
	Exports	-	-

	Gross Revenue	**1,128.26**	**1252.47**
	Less: Discount	-	-
	Less: Returns	4.93	6.51
	Less: price Concession	-	-
	Less Incentives and Performance bonus	-	-
	Less: Goods and service Tax	-	-
	Net Revenues recognized from contracts with customers	**1,123.33**	**1,245.96**

32. Other Income:

(Rs. In Lakhs)

S.no	**Particulars**	**As at 31st March 2026**	**As at 31st March 2025**
1	Discounts Received	-	-
2	Interest Received from FD	-	-
3	Other Income	2.10	2.11

33. Details of Loans given, Investments made, and Guarantee given covered Under Section 186(4) of the Companies Act, 2013.

The company has not extended any Corporate Guarantees in respect of loans availed by any company/firm as at March 31, 2025.

34. Auditors' Remuneration:

(Rs. In lakhs)

Particulars	**March 31, 2026**	**March 31, 2025**
Fees towards Statutory Audit	2.34	2.00

*The fees are exclusive of GST

35. Dues to Micro Small and Medium Enterprises:

Disclosure required as per section 22 of the Micro, Small and Medium Enterprise Development Act, 2006 (MSMED Act.) as at 31.03.2026.

Sl. No	**Description**	**March 31, 2026**
1	Principal amount due to suppliers under MSMED	NIL
2	Interest accrued and due to suppliers covered under MSMED on the above amount, unpaid	NIL
3	Payment made to suppliers (with Interest) beyond the appointed day during the year.	NIL
4	Payment made to suppliers (other than interest) beyond the appointed day during the previous year	NIL
5	Interest paid to suppliers covered under MSMED	NIL
6	Interest due & Payable to suppliers covered under	NIL

	MSMED Act., towards payments already made.	

The information has been given in respect of such vendors to the extent they could be identified as micro and small enterprises on the basis of information available with company.

As per the information provided / submitted by the Company, there are no dues to Micro, Small and Medium Enterprises covered under ('MSMED' Act, 2006).

36. Non – Payment of Statutory dues:

The Company has certain delays in depositing statutory dues with the appropriate authorities. Although the amount is not material to the financial statements, this matter was of significance due to its regulatory implications and the nature of the obligation. The amount has been deducted but not paid to the regulatory authorities. The dues are given below:

Sl. No	**Name of the Dues**	**Amount (Rs. In Lakhs)**
1.	TDS Payable	48.46
2.	Professional tax payable	7.20
3	Provident Fund & ESI Payable	2.32
	TOTAL	**57.98**

37. Financial Risk Management

In course of its business, the company is exposed to certain financial risk such as market risk (Including currency risk and other price risks), credit risk and liquidity risk that could have significant influence on the company's business and operational/financial performance. The Board of directors reviews and approves risk management framework and policies for managing these risks and monitor suitable mitigating actions taken by the management to minimize potential adverse effects and achieve greater predictability to earnings.

38. Credit Risk

Credit risk refers to the risk that the counterparty will default on its contractual obligations resulting in financial loss to the company. The company has adopted a policy of only dealing with creditworthy counterparties and obtaining sufficient collateral, where appropriate, a means of mitigating the risk of financial loss from defaults.

39. Liquidity risk

Liquidity risk refers to the risk that the company cannot meet its financial obligations. The objective of liquidity risk management is to maintain sufficient liquidity and ensure that funds are available for use as pre requirements. The Company's exposure to liquidity risk is minimal as the promoters of the company is infusing the funds based on the requirements.

39. Amounts have been rounded off to nearest Rupee.

Schedules 2 to 39 form part of Balance Sheet and have been authenticated.

As per our report of even date
For **M M REDDY & CO.,**
Chartered Accountants
Firm Reg. No. 010371S

For and on behalf of the Board of

SANGAM HEALTH CARE PRODUCTS LIMITED

A. Balagopal	Padma Ghanakota
Managing Director	Director
DIN: 01712903	DIN: 07078176

M. Madhusudhana Reddy
Partner
Membership No. 213077

UDIN: 26213077QQOHYR5458

Place: Hyderabad
Date: 29-05-2026

SANGAM HEALTH CARE PRODUCTS LIMITED
CIN NO- L24230TG1993PLC016731
Statement of Financial Position as at March 31, 2026

(Amt in Lakhs)

	Particulars	Note No.	As at March 31, 2026	As at March 31, 2025
I	**ASSETS**			
1	**Non-current assets**			
	(a) Property, plant and equipment	3	30.18	17.63
	(b) Capital work in progress		-	-
	(c) Other intangible Assets		-	-
	(d) Financial assets		-	-
	(i) Investments		-	-
	(ii) Trade receivables		-	-
	(iii) Loans		-	-
	(vi) other Fiancial assets		-	-
	(e) Deferred Tax Asset (Net)	9	33.18	43.17
	(f) Other non-current asset	4	524.83	517.69
	Total non-current assets (A)		**588.18**	**578.50**
2	**Current assets**			
	(a) Inventories	5	101.36	130.89
	(a) Financial assets			
	(i) Investments			
	(ii) Trade receivables	6	352.39	361.92
	(iii) Cash and cash equivalents	7	15.17	20.74
	(iv) Bank Balances other than (iii) above			
	(iv) other financial assets			
	(b) Current Tax Asset (Net)			-
	(c) Other current assets	8	65.02	42.42
	Total current assets (B)		**533.95**	**555.97**
	Total assets (A+B+C)		**1,122.13**	**1,134.47**
II	**EQUITY AND LIABILITIES**			
1	**Equity**			
	(a) Equity share capital	10	1,486.07	1,486.07
	(b) Other equity	11	(3,471.01)	(3,492.13)
	Total equity (A)		**(1,984.94)**	**(2,006.06)**
2	**Liabilities**			
(i)	**Non-current liabilities**			
	(a) Financial Liabilities			
	(i) Borrowings	12	2,193.34	2,176.72
	(ii) Trade Payables	13	126.97	126.97
	(iii) Other Financial Liabilties			
	(b) Long term provisions			
	(c) Deferred tax Liabilities(Net)			-
	(d) Other non Current Liabilities	14	36.00	36.00
	Total non-current liabilities (B)		**2,356.31**	**2,339.69**
(ii)	**Current liabilities**			
	(a) Financial liabilities			
	(i) Borrowings	15	-	21.45
	(ii) Trade payables	13	615.27	658.22
	(iii) Other financial liabilities			
	(b) Short term provisions			
	(c) Other current liabilities	16	130.11	117.34
	(d) Current Tax Liabilities (net)		5.38	3.82
	Total current liabilities (C)		**750.76**	**800.83**
	Total liabilities (D+B+C)		**3,107.07**	**3,140.52**
	Total equity and liabilities (A+D)		**1,122.13**	**1,134.47**
	The notes are an integral part of the financial statements	**1-2**		

As per our Report of even date
For M M REDDY & CO.,
Chartered Accountants
Firm Reg No:010371S

CA. M. Madhusudhana Reddy
Partner
Membership No: 213077
UDIN: 26213077QQOHYR5458

Place: Hyderabad
Date : 29-05-2026

For and on behalf of the Board of Directors
SANGAM HEALTH CARE PRODUCTS LIMITED

A.Balagopal
Managing Director
DIN:01712903

Padma Ghanakota
Director
DIN:07078176

SANGAM HEALTH CARE PRODUCTS LIMITED
CIN NO- L24230TG1993PLC016731
Statement of Profit and Loss and Other Comprehensive Income for the Period ended March 31, 2026
(Amt in Lakhs)

		Note No.	For the year ended March 31, 2026	For the year ended March 31, 2025
	Continuing Operations			
I	Revenue from operations	17	1,123.33	1,245.96
II	Other income		2.10	2.11
III	Net gain on de-recognition of financial assets at amortised cost			-
IV	Net gain on reclassification of financial assets			-
V	**Total income**		**1,125.43**	**1,248.07**
VI	**Expenses**			
	(a) Cost of material Consumed	18	591.59	663.91
	(b) Purchase of Stock in Trade		-	-
	(c) Changes in stock of finished goods, work- in progress and stock-in-trade		-	-
	(d) Employee benefits	19	228.68	193.94
	(e) Finance cost	20	0.91	1.49
	(f) Depreciation expense	3	5.63	121.84
	(g) Impairment expenses/losses		-	-
	(i) Other expenses	21	277.90	241.43
	Total expenses (VI)		**1,104.72**	**1,222.60**
VII	**Profit/(loss) before Share of profit/(loss) of associates / joint ventures, exceptional items and tax (V - VI)**		**20.71**	**25.47**
VIII	Share of profit/(loss) of associates		-	-
	Share of profit/(loss) of joint ventures		-	-
IX	**Profit/(Loss) before exceptional items and tax**		**20.71**	**25.47**
X	**Exceptional items**		-	-
XI	**Profit before Tax**		**20.71**	**25.47**
XII	**Tax expense :**			
	a. Current tax		5.38	3.82
	b. Deferred tax		10.00	(23.32)
XIII	**Profit/(loss) for the year from continuing operations (XI-XII)**		**5.33**	**44.97**
	Discontinued Operations			
XIV	Profit/(loss) from discontinued operations		-	-
XV	Tax Expense of discontinued operations		-	-
XVI	**Profit/(loss) from discontinued operations (XIV +XV)**		-	-
XVII	**XVII Profit/(loss) for the year (XIII+XVI)**		**5.33**	**44.97**
XIX	**Other comprehensive income**			
IX.	**Total comprehensive income for the year (V+ VI)**		**5.33**	**44.97**
X.	**Earning per equity share (for Continuing Opertations)**			
	(i) Basic		0.04	0.30
	(ii) Diluted.		0.04	0.30
XI.	**Earnings per equity share (for discontinued operation):**			
	(i) Basic		-	-
	(ii) Diluted.		-	-
XII.	**Earnings per equity share (for Continued and discontinued operation):**			
	(i) Basic		0.04	0.30
	(ii) Diluted.		0.04	0.30
	The notes are an integral part of the financial statements	**1-2**		

As per our Report of even date
For **M M REDDY & CO.,**
Chartered Accountants
Firm Reg No:010371S

CA. M. Madhusudhana Reddy
Partner
Membership No: 213077
UDIN: 26213077QQOHYR5458

Place: Hyderabad
Date: 29-05-2026

For and on behalf of the Board of Directors
SANGAM HEALTH CARE PRODUCTS LIMITED

A.Balagopal
Managing Director
DIN:01712903

Padma Ghanakota
Director
DIN:07078176

SANGAM HEALTH CARE PRODUCTS LIMITED
CIN:L24230TG1993PLC016731
Cash Flow Statement for the year ended 31st March, 2026

(Amt in Lakhs)

Particulars	31.03.2026	31.03.2025
A. CASH FROM OPERATING ACTIVITIES		
(Loss)/Profit before tax and extraordinary items	20.71	25.47
Adjustment for:		
Income tax expense recognised in profit or loss	(3.82)	-
Finance costs recognised in profit or loss	0.91	1.49
Investment income recognised in profit or loss	-	-
Gain on disposal of property, plant and equipment	-	-
Reversal of impairment loss on trade receivables	-	-
Depreciation and amortisation of non-current assets	5.63	121.84
Impairment of non-current assets	-	
Net foreign exchange (gain)/loss	-	-
Expense recognised in respect of equity-settled share-based payments	-	-
Expense recognised in respect of shares issued in exchange for goods/services	-	-
Amortisation of financial guarantee contracts	-	-
Operating Profit before Working Capital Changes	**23.44**	**148.79**
Movement for Working Capital:		
(Increase)/decrease trade receivables	9.54	(335.26)
(Increase)/decrease in inventories	29.52	41.91
(Increase)/decrease in other assets	(29.74)	(301.57)
(Increase)/decrease in Deferred Tax	-	-
Increase/(decrease) in Trade payables	(42.95)	170.65
Increase/(decrease) in provisions	-	-
(Decrease)/increase in deferred revenue	-	-
(Decrease)/increase in other liabilities	12.77	(0.49)
Cash generated from operations	**2.58**	**(275.97)**
- Income taxes paid	-	-
Net Cash flow before extraordinary items	2.58	(275.97)
-Extraordinary & Prior period items	-	-
NET CASH FROM OPERATING ACTIVITIES	**2.58**	**(275.97)**

B. CASH FLOW FROM INVESTING ACTIVITIES:

Particulars	31.03.2026	31.03.2025
B. CASH FLOW FROM INVESTING ACTIVITIES:		
Payments to acquire financial assets	(2.39)	-
Proceeds on sale of financial assets	-	-
Interest received	-	-
Royalties and other investment income received	-	-
Dividends received from associates	-	-
Net cash inflow on disposal of subsidiary	-	-
Net cash inflow on disposal of associate	-	-
NET CASH FROM INVESTING ACTIVITIES	**(2.39)**	**-**

C. CASH FLOW FROM FINANCING ACTIVITIES

Particulars	31.03.2026	31.03.2025
CASH FLOW FROM FINANCING ACTIVITIES		
Proceeds from issue of equity instruments of the Company		-
Payment for debt issue costs Proceeds from borrowings		-
Repayment of borrowings	(4.83)	264.77
Proceeds from government loans	-	-
Interest paid	(0.91)	(1.49)
Long Term Provisions	-	-
NET CASH FROM FINANCING ACTIVITIES	**(5.75)**	**263.28**
NET INCREASE IN CASH & CASH EQUIVALENTS	**(5.56)**	**(12.69)**
Cash and cash equivalents at the beginning of the year	20.74	33.43
Effects of exchange rate changes on the balance of cash held in foreign currencies	**-**	**-**
Cash and cash equivalents at the end of the year	**15.17**	**20.74**
Reconciliation of cash and cash equivalents as per the cash flow Statement		
Cash and cash equivalents (Note no.7.3)	15.17	20.74
Balance as per statement of cash flows	**15.17**	**20.74**

As per our Report of even date
For M M REDDY & CO.,
Chartered Accountants
Firm Reg No:010371S

CA. M. Madhusudhana Reddy
Partner
Membership No: 213077
UDIN: 26213077QQOHYR5458

Place: Hyderabad
Date : 29-05-2026

For and on behalf of the Board of Directors
SANGAM HEALTH CARE PRODUCTS LIMITED

A. Balagopal
Managing Director
DIN:01712903

Padma Ghanakota
Director
DIN:07078176

SANGAM HEALTH CARE PRODUCTS LIMITED							
Depeciation schedule as per companies Act,2013 for the year 2025-26							**(Amt in lakhs)**
Particular	**Plant & Machinery**	**Lab Equipments**	**Computers**	**Office Equipment**	**Furniture & Fixtures**	**Vehicles**	**Total**
Cost/Deemed Cost:							
As at March 2024	**2,723.63**	**80.86**	**18.95**	**16.95**	**25.86**	**87.39**	**2,953.64**
Additions	-	-	-	-	-	-	-
Deletions	-	-	-	-	-	-	-
As at March 2025	**2,723.63**	**80.86**	**18.95**	**16.95**	**25.86**	**87.39**	**2,953.64**
Additions	-	-	2.39	-	-	-	**2.39**
Deletions	-	-	-	-	-	-	
As at March 2026	**2,723.63**	**80.86**	**21.34**	**16.95**	**25.86**	**87.39**	**2,956.03**
Depreciation/Impairment							-
As at March 2024	**2,622.59**	**78.21**	**18.85**	**14.47**	**25.68**	**54.36**	**2,814.17**
Depreciation for the year	116.82	0.24	0.04	0.13	-	4.61	121.84
Disposals	-	-	-	-	-	-	-
Impairment	-	-	-	-	-	-	-
As at March 2025	**2,739.41**	**78.46**	**18.89**	**14.60**	**25.68**	**58.97**	**2,936.01**
Depreciation for the year	-	0.24	0.47	0.13	0.18	4.61	5.63
Disposals/ Adjustemnts	15.78	-	-	-	-	-	15.78
Impairment	-	-	-	-	-	-	-
As at March 2026	**2,723.63**	**78.70**	**19.35**	**14.73**	**25.86**	**63.57**	**2,925.85**
Net Book Value							
As at March 2026	-	2.16	1.99	2.22	-	23.82	30.18
As at March 2025	(15.78)	2.40	0.06	2.35	0.18	28.42	17.63
As at March 2024	101.04	2.65	0.10	2.48	0.18	33.03	139.47

SANGAM HEALTH CARE PRODUCTS LIMITED

Note.4 **Other Assets : Current and Non Current Assets** **(Amt in Lakhs)**

Particulars	As at 31st March, 2026	As at 31st March, 2025
(A) Other Non-Current Assets		
Loans & Advances	280.12	273.22
Capital Advances :		-
Advances to plant & Machinery	143.49	143.49
Security Deposits:		-
Government Authorities - Electricity Dept	33.59	33.59
Other Advances:		
Advances to Old staff	2.34	2.34
TDS receivable	1.88	1.65
Interest Receivable		
MAT Credit Entitlement	63.39	63.39
Total of Other Non-current Assets	**524.83**	**517.69**

Note 5 **Inventories**

Particulars	As at 31st March, 2026	As at 31st March, 2025
Raw Material	44.48	12.28
Packing Material	41.86	22.32
Work In Process	2.51	7.30
Finished Goods	3.39	75.40
Consumbles & Stores and Spares	9.13	13.58
Total Inventories	**101.36**	**130.89**

Note 6 **Trade Receivables**

Particulars	As at 31st March, 2026	As at 31st March, 2025
Unsecured considered good		
- From Others	352.39	361.92
Total Trade Receivables	**352.39**	**361.92**

Note: Amount which has been netted off in previous years reclassified as Creditors & Debtors

Note 7 **Cash and Cash Equivalents**

Particulars	As at 31st March, 2026	As at 31st March, 2025
Cash and Cash Equivalents	8.64	8.63
Bank Balances other than Cash and Cash Equivalents	6.53	12.10
Total Cash and Cash Equivalents	**15.17**	**20.74**

Cash and Cash Equivalents

Particulars	As at 31st March, 2026	As at 31st March, 2025
Bank and Cash Balances		
On Current Accounts:		
Kotak Bank-KNR-6912456133	-	-
Karur Vysya Bank Ltd A/C.No.1404135000006078	-	-
Kotak Bank-356	-	-
Kotak Bank-295	0.08	11.26
SBI-CURRENT A/C.62263238738(Commerical Branch)		
HDFC BANK	6.39	0.79
Andhra Bank		
Syndicate Bank	0.05	0.05
Fixed Deposits with maturity less than 3 months		
Cheques/dafts on hand		
Cash on hand	8.64	8.63
Total Cash and Cash Equivalents	**15.17**	**20.74**

Note 8 **Other Current Assets**

Particulars	As at 31st March, 2026	As at 31st March, 2025
Capital Advances:		
Advances to Plant and Machinery	-	-
Advances other than capital advances:		
MAT Credit Entitlement		-
Other Advances	61.15	38.54
Other Advances:		
GST Input		
TDS receivable	-	-
Interest Receivable	3.87	3.88
Total of Other current Assets	**65.02**	**42.42**

Note 9 **Income Taxes**

Particulars	As at 31st March, 2026	As at 31st March, 2025
a) Current Tax Asset		
Opening Balance	-	-
Add: Taxes paid/TDS Receivable	-	-
Less: Current tax payable for the year	-	-
	-	-
b) Differred tax Liabilty		19.85
on Written down value of fixed assets		-
Add/Less : Provided for the Current Year		(23.32)
Total		**(3.47)**

SANGAM HEALTH CARE PRODUCTS LIMITED

Note 12 Borrowings

Particulars	As at 31st March, 2026		As at 31st March, 2025	
	Non Current	Current	Non Current	Current
From banks	-	-	-	-
Interest-free sales Tax deferal loan from state Govt.	-	-	-	-
Unsecured Loans				
From Individuals other than banks	2,171.89	-	2,176.72	-
Interest-free sales Tax deferral loan from state Govt.	21.45	-	-	21.45
Total Borrowings	**2,193.34**	**-**	**2,176.72**	**21.45**

Notes: 1. The Unsecured Loans were obtained from promoters, Directors & other related parties. No repayment terms has been stipulated & these amounts to be repayable on demand.

2. Unsecured Loans from Individuals other than banks has been reclassified.

Particualrs	As at 31st March, 2026	As at 31st March, 2025
Long Term		
Bonds	-	-
Debentures	-	-
Rupee term loans from Banks:	-	-
Interest-free sales Tax deferal loan from state Govt.	-	-
Short Term		
Interest-free sales Tax deferal loan from state Govt.	-	-

Notes 14 Other non Current Liabilities

Particulars	As at 31st March, 2026	As at 31st March, 2025
Advances from Customers	36.00	36.00
Total	**36.00**	**36.00**

Notes 15 Short Term Borrowings	As at 31st March, 2026	As at 31st March, 2025
Term loans		
Interest-free sales Tax deferal loan from state government		21.45
Unsecured Loans		-
Total	**-**	**21.45**

Note 13 Trade payables

	As at 31st March, 2026		As at 31st March, 2025	
	Non Current	Current	Non Current	Current
Trade payables				
Dues to other than Micro, Small and Medium Enterprises	126.97	615.27	126.97	658.22
Sub total	**126.97**	**615.27**	**126.97**	**658.22**

Note: Dues to micro and small enterprises - As per Micro, Small and Medium Enterprises Development Act, 2006 ('MSMED' Act) This information has not been determined by the company.

Note 16 Other Current Liabilities

	As at 31st March, 2026	As at 31st March, 2025
a).Revenue Received in Advance		
Advances From customers		-
b).Other Payables		
Statutory Dues Payable		
Provident fund & ESI contribution payable	2.32	9.03
Interest Payable on statutory dues	42.69	42.69
TDS & TCS payable	48.46	43.82
Salaries and Wages & settlements payable	22.83	7.99
Directors Remuneration Payable		-
Bonus payable	3.31	3.31
Electricity Charges Payable		-
Other Expenses Payable		-
Deposits	1.30	1.30
Other Advance payable		-
Professional Tax Payable	7.20	7.20
Audit fee payable	2.00	2.00
GST payable		-
Total	**130.11**	**117.34**

SANGAM HEALTH CARE PRODUCTS LIMITED

Notes annexed to and forming part of the Financial Statements

Note 10: Equity share capital

a. Equity share capital **(Amt in Lakhs)**

	As at March 31, 2026		As at March 31, 2025	
	No. of Shares	Amount in Rs.	No. of Shares	Amount in Rs.
Authorised				
Equity shares of Rs. 10 each	1,500.00	15,000.00	1,500.00	15,000.00
Issued	-	-	-	-
Equity shares of Rs. 10 each	148.61	1,486.07	148.61	1,486.07
Subscribed and Paid-up	-	-	-	-
Equity shares of Rs. 10 each fully paid-up	148.61	1,486.07	148.61	1,486.07
Total	**148.61**	**1,486.07**	**148.61**	**1,486.07**

b. Reconciliation of the number of equity shares outstanding and the amount of share capital

	As at March 31, 2026		As at March 31, 2025	
	No. of Shares	Amount	No. of Shares	Amount
Equity Shares				
Issued and Subscribed:				
Shares outstanding at the beginning of the year	148.61	1,486.07	148.61	1,486.07
Add: Issued During the year for cash	-	-	-	-
Add:Shares issued at ESOP trust	-	-	-	-
Shares outstanding at the end of the year	**148.61**	**1,486.07**	**148.61**	**1,486.07**

c. Terms / rights attached to equity Shares

The company has one class of equity shares having a par value of Rs.10 per share. Each shareholder is eligible for one vote per share held. In the event of liquidation, the equity shareholders are eligible to receive the remaining assets of the company after distribution of all preferential amounts, in proportion to their shareholdings.

d. Shares reserved for issue underwriter options Nil

e. Detail of Rights Issues Nil

f. details of shares held by Holding/Ultimatley Holding Company Nil

g. Details of shares issued for consideration other than cash Nil

h. Shares in the company held by each shareholder holding more than 5 percent

Name of the Shareholder	As at March 31, 2026		As at March 31, 2025	
	No. of Shares held	% of Holding	No. of Shares held	% of Holding
M/s. Boin Medica Co Ltd	1,240,260	8.35%	1,240,260	8.35%
Addepalli Balagopal	3,001,000	20.19%	3,001,000	20.19%
D.V.S.Sharma	2,500,000	16.82%	2,500,000	16.82%
G.Ramana	2,255,140	15.18%	2,255,140	15.18%
G.Padma	2,000,000	13.46%	2,000,000	13.46%

*Includes 10 Equity shares of Rs. 10 each fully paid up held by nominee.

i. Dividend Declaration Details

Particualrs	As at March 31, 2026	As at March 31, 2025
Cash Dividend Declared for the Year 31st March 2026	-	-
Interim Dividend for the year ended on 31st March 2026		
Total	-	-
Proposed Dividend on Equity Shares	-	-
Final Dividend for the year ended 31st March 2026	-	-
Total	-	-

Note 11 Other equity

	As at March 31, 2026	As at March 31, 2025
Capital Reserve:		
Balance at the beginning of the year	770.01	770.01
Add: Addition During the Year	-	-
Balance at the end of the year	**770.01**	**770.01**
Securities Premium:		
Balance at the beginning of the year	-	-
Add: Securities Premium on shares issued during the year	-	-
Balance at the end of the year	-	-
Retained earnings		
Balance at the beginning of the year	(4,262.14)	(4,307.10)
Add: Addition During the Year	5.33	44.97
Adjustments made during the year	15.78	-
Balance at the end of the year	**(4,241.02)**	**(4,262.14)**
Total Other Equity	**(3,471.01)**	**(3,492.13)**

Note 11.1 Other Reserves

	As at March 31, 2026	As at March 31, 2025
Debentures Redemption Reserves:		
Balance at the beginng of the year	-	-
Add: Addition during the Year	-	-
Balance at the end of the year	-	-
Capital Redemption Reserves:		
Balance at the beginng of the year	-	-
Add: Addition during the Year	-	-
Balance at the end of the year	-	-
Investment Fluctuation Reserves:		
Balance at the beginng of the year	-	-
Add: Addition during the Year	-	-
Balance at the end of the year	-	-
Total Other Reserves	-	-

SANGAM HEALTH CARE PRODUCTS LIMITED

Notes annexed to and forming part of the Financial Statements

Note 17: Revenue from operations

Particulars	For the Year ended Mar 2026	For the Year ended Mar 2025
A.Revenue from contracts with customers disaggregated based on nature of product or services		
Revenue from Sale of Products		
a). Sale of Manufactured Goods	1,123.33	1,245.96
b).Stock in Trade	-	-
Net Revenue	**1,123.33**	**1,245.96**
Revenue from Sale Service		
a). Software servieces	-	-
b). Other Services	-	-
Sub total	**-**	**-**
Other Operating Revenues		
a). Export Incentives	-	-
b).Royalty Received		
From subsidiaries and associates	-	-
From others	-	-
c). Scrap Sale	-	-
d). Others	-	-
Sub total	**-**	**-**
Total Revenue from Operations	**1,123.33**	**1,245.96**

Particulars	For the Year ended Mar 2026	For the Year ended Mar 2025
B Disaggregated revenue information		
Revenue from contracts with customers disaggregated based on geography		
a). Domestic	1,128.26	1,252.47
b).Export	-	-
	1,128.26	**1,252.47**
C)Reconciliation of Gross Revenue from Contracts With Customers		
Gross Revenue	**1,128.26**	**1,252.47**
Less: Discount	-	-
Less: Returns	4.93	6.51
Less: Price Concession	-	-
Less: Incentives and performance bonus	-	-
Less: Goods and Service Tax	-	-
Net Revenue recognised from Contracts with Customers	**1,123.33**	**1,245.96**

Note 18 Cost of Material Consumed

Particulars	For the Year ended Mar 2026	For the Year ended Mar 2025
A. Raw Material Consumed		
Raw materials at the beginning of the year	12.28	75.52
Add: Purchases During the year	423.31	482.03
Less: Raw materials at the end of the year	44.48	12.28
Total cost of raw material consumed	**391.10**	**545.27**
B). Packing Material		
Packing materials at the beginning of the year	22.32	23.19
Add : Purchases During the year	87.49	80.10
Less: Packing materials at the end of the year	41.86	22.32
Total cost of packing materials consumed (B)	**67.96**	**80.97**
Total cost of Materials consumed (B)	459.06	626.24

Note 18 Changes in inventories of finished goods, work-in-progress and stock-in-trade

Particulars	For the Year ended Mar 2026	For the Year ended Mar 2025
Opening Balance		
Finished Goods	75.40	58.23
Work in Progress	7.30	7.46
Stock in Trade (Including Goods in Transit)	-	-
Spares and Consumables	13.58	8.40
Total Opening Balnces	**96.29**	**74.09**
Purchases Made		
Consumables	**51.27**	**59.87**
Closing Balance		
Finished Goods	3.39	75.40
Work in Progress	2.51	7.30
Stock in Trade (Including Goods in Transit)	-	-
Spares and Consumables	9.13	13.58
Total Closing Balance	15.03	96.29
Total Changes in inventories of finished goods, work-in-progress and stock-in-trade	**132.53**	**37.67**

Note 19 Employee Benefits

Particulars	For the Year ended Mar 2026	For the Year ended Mar 2025
Salaries, Wages, Bonus etc.	203.68	162.45
Director Remuneration	24.00	24.25
Contribution to P.F, E.S.I and Other Statutory Funds	-	-
Employee share based payment expenses	-	-
Gratuity	-	-
Leave compensation	-	-
Post-employment pension benefits	-	-
Post-employment medical benefits	-	-
Staff welfare expenses	1.00	7.24
Total Employee benefits	**228.68**	**193.94**

Note: The Company has not provided for gratuity liability for its employees in the financial statements. The gratuity obligation has neither been actuarially valued nor recognized, which is not in compliance with Ind AS 19.

Note 20 Finance Cost

Particulars	For the Year ended Mar 2026	For the Year ended Mar 2025
Interest and finance charges on financial liabilities carried at amortised cost		
a). Interest on Bank Borrowings	0.85	1.38
b). Interest on Bill Discounting		
c). Other Interest Expenses (Bank Charges)	0.06	0.10
Less: Amount Capitalised		-
Total Interest on financial liabilities carried at amortised cost	**0.91**	**1.49**
Intest on Trade payables (as per MSME Act)	-	-
Interest on delayed payment of statutory dues	-	-
Unwinding of discount on provision	-	-

Exchange difference regarded as adjustment to borrowing costs	-	-
Dividend on redeemable preference shares (including dividend distribution tax)	-	-
Total Finance Cost	**0.91**	**1.49**

Note 21 : Other expenses

Particulars	For the Year ended Mar 2026	For the Year ended Mar 2025
Audit Fees	2.34	2.00
Power and Fuel	61.63	70.63
Factory & office Maintenance	10.69	9.54
Insurance	0.04	0.42
Rates and Taxes	0.07	4.18
Security Charges	6.47	7.65
Travelling & Conveyance Expenses	0.20	16.97
Printing & Stationery	0.50	0.63
Factory rent	71.64	66.96
Telephone Expense	2.24	2.29
Other General Expenses	0.06	0.03
Marketing Expenses	46.94	7.86
Carriage Inward	9.03	9.02
Consultancy and Legal Charges	-	3.45
Freight	0.30	3.14
GST	11.08	36.66
License Taxes and Fees	54.69	-
Total	**277.90**	**241.43**

18.6.1 Payment to Auditors

Particualrs	For the Year ended Mar 2026	For the Year ended Mar 2025
As An Auditor		
- Audit Fees	2.34	2.00
- Tax Audit	-	-
- Limited Review	-	-
In Other Capacity		
- Taxation Matters	-	-
- Company Law matters	-	-
- Certification matters	-	-
- Reimbursement of Expenses	-	-
Total Payment to Auditor	**2.34**	**2.00**

18.6.2 Corporate Social Responsibility(CSR) Not Applicable to this period

Particualrs	For the Year ended Mar 2026	For the Year ended Mar 2025
Amount required to be spent as per Section 135 of the Companies Act, 2013	-	-
Amount spent during the year	-	-
	-	-

Form No. MGT-11

PROXY FORM

[Pursuant to section 105(6) of the Companies Act, 2013 and rule 19(3) of the Companies (Management and Administration) Rules, 2014]

CIN : L24230TG1993PLC016731
Name of the company : Sangam Health Care Products Limited
Registered office : Survey No.182, Yellampet Village, Medchal Mandal, Medchal District, Telangana – 501401
Name of the member(s):
Registered Address :
E-mail Id :
Folio No./Client Id :
DP ID :

I / We, being the Member(s) of Sangam Health Care Products Limited, hereby appoint

Name:
Address:____
E-mail ID:
Signature or failing him

as my/our proxy to attend and vote (on a poll) for me/us and on my/our behalf at the 32nd Annual General Meeting of the Company, to be held on Wednesday, the 30th day of September, 2026 at 9.00 A.M. at Survey No.182, Yellampet Village, Medchal Mandal, Medchal District, Telangana – 501401 and at any adjourned meeting thereof in respect of such resolutions as are indicated below:

Resolution No:

1. To receive, consider and adopt the Audited Balance Sheet as at 31st March 2026, the Statement of Profit & Loss and Cash Flow Statement for the year ended on that date together with the Notes attached thereto, along with the Reports of Auditors and Directors thereon.

2. To appoint a director in place of Mr. A. Sai Balaji Krishna Teja (DIN: 07003946), Non-Executive Director who retires by rotation and, being eligible, offers himself for re-appointment."

3. Continuation of Directorship of Mrs. Padma Ghanakota (DIN: 07078176) as a Non-Executive and Non-Independent Director of the Company.

4. Re appointment of Mr. Bhagat Reddy Dundumulla as Managing Director of the Company:

Affix Revenue Stamp

Signed this …..............… day of… 2026
Signature of shareholder

Signature of Proxy holder(s)

Note: This form of proxy in order to be effective should be duly completed and deposited at the Registered Office of the Company, not less than 48 hours before the commencement of the Meeting.

SANGAM HEALTH CARE PRODUCTS LIMITED

Survey No.182, Yellampet Village, Medchal
Mandal, Medchal District, Telangana – 501401

Attendance Slip

(Please present this slip at the Meeting venue)

I hereby record my presence for the 32nd Annual General Meeting of the Company, to be held on Wednesday, the 30th day of September, 2026 at 9.00 A.M. at Survey No.182, Yellampet Village, Medchal Mandal, Medchal District, Telangana – 501401 and at any adjourned meeting thereof.

Shareholders/Proxy’s Signature

Shareholders/Proxy’s full name (In block letters)
Folio No./ Client ID
No. of shares held

Note: Shareholders attending the meeting in person or by proxy are required to complete the attendance slip and hand it over at the entrance of the meeting hall.

Route Map

Mahyco,Kallakal
Priyadarshini Veg Restaurant, Kallakal
Janatha Family Dhaba
SANGAM HEALTH CARE PRODUCTS...
DRS Warehousing (South) Pvt. Ltd
DRS DILIP ROAD LINE
44